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 SUMMARY 
The constitutively active oncogenic fusion tyrosine kinase Bcr-Abl is the 
product of a reciprocal chromosomal translocation (t(9;22), ʻPhiladelphia 
Chromosomeʼ). The constitutive tyrosine kinase activity is central to Bcr-Ablʼs 
ability to cause chronic myeloid leukemia (CML) and is the target of tyrosine 
kinase inhibitors like imatinib (Gleevec®, Novartis). Despite the success of 
imatinib, many patients either develop resistance to the drugs and eventually 
relapse or they do not respond, when the treatment is initiated in advanced 
stages of the disease. However, the actual molecular setup of the endogenous 
drug target Bcr-Abl is still unknown. We have therefore charted the protein-
protein interaction network of Bcr-Abl by a systematic two-pronged proteomics 
approach:  
Using a monoclonal antibody we have first purified endogenous Bcr-Abl 
protein complexes from the CML cell line K562 and characterized a set of 
eighteen most tightly associated interactors by mass spectrometry. Nine 
interactors were subsequently subjected to tandem affinity purification/mass 
spectrometry analysis to obtain a molecular interaction network.  The resulting 
network revealed a high degree of interconnection of seven 'core' components 
around Bcr-Abl (Ship2, c-Cbl, p85, Sts-1, Shc1, Grb2 and Crk-I), as well as their 
links to the AP2 adaptor protein complex and different signaling pathways. 
Quantitative analysis of these Bcr-Abl ʻcoreʼ complex components showed that 
the absolute protein copy numbers range within one order of magnitude 
consistent with a stoichiometric complex of around 200,000 to 300,000 copies 
per cell and revealed the highest interaction stoichiometry for the 5-inositol 
phosphatase Ship2. Quantitative proteomics analysis showed that tyrosine 
kinase inhibitors disrupt this complex, while certain components still appear to 
interact with Bcr-Abl in a phospho-tyrosine-independent manner.  
The results of this study therefore motivate us to propose that Bcr-Abl 
and other drug targets, rather than being considered as single polypeptides, can 
be considered as complex protein assemblies that are disrupted or re-modeled 
upon drug action.
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 ZUSAMMENFASSUNG 
Die konstitutiv aktive onkogene Fusions-Tyrosin-Kinase Bcr-Abl 
resultiert aus einer reziproken chromosomalen Translokation (t(9;22), 
‚Philadelphia Chromosomʼ). Die konstitutive Tyrosin-Kinaseaktivität von Bcr-Abl 
ist Auslöser der Chronisch Myeloischen Leukämie (CML) und das Ziel von 
Tyrosin-Kinaseinhibitoren wie Imatinib (Gleevec®, Novartis). Trotz des Erfolges 
von Imatinib entwickeln Patienten Resistenzen und werden rückfällig oder 
sprechen nicht auf die Therapie an, wenn diese erst in fortgeschrittenen 
Krankheitsstadien initiiert wird. Dennoch ist die genaue Beschaffenheit des 
endogenen Arzneistoffziels Bcr-Abl noch unbekannt. Daher haben wir das 
Protein-Interaktionsnetzwerk um Bcr-Abl mit einer doppelten proteomischen 
Herangehensweise systematisch kartiert: 
Anhand eines monoklonalen Antikörpers haben wir zunächst endogene 
Bcr-Abl - Proteinkomplexe aus der CML-Zelllinie K562 gewonnen und 
massenspektrometrisch die achtzehn engsten Interaktoren charakterisiert. Nach 
‚Tandem-Affinitätsreinigungʼ von neun dieser Kandidaten und 
massenspektrometrischer Analyse haben wir ein Interaktionsnetzwerk erstellt, 
das eine intensive Vernetzung der sieben ‚Kernkomponentenʼ (Ship2, c-Cbl, 
p85, Sts-1, Shc1, Grb2 und Crk-I) mit Bcr-Abl und deren Verknüpfung mit dem 
AP2-Adapterproteinkomplex und verschiedenen Signaltransduktionswegen 
offenbarte. Quantitative Analysen dieser sieben Komponenten zeigten, dass 
sich deren absolute Kopienzahl innerhalb einer Größenordnung bewegt und auf 
200,000 - 300,000 stöchiometrische Komplexe pro Zelle schließen lässt, wobei 
die 5-Inositol-Phosphatase Ship2 die höchste Interaktionsstöchiometrie 
aufweist. Massenspektrometrische Quantifizierungen zeigten, dass Tyrosin-
Kinaseinhibitoren den Bcr-Abl-ʼKernkomplexʼ zerstören, einige Komponenten 
aber in Phospho-Tyrosin-unabhängiger Weise mit Bcr-Abl verbunden bleiben. 
Wir kommen daher zu der Hypothese, dass Bcr-Abl und auch andere 
Arzneistoffziele nicht nur als einzelne Polypeptide, sondern vielmehr als 
komplexe Proteinverbände zu betrachten sind, die durch Arzneistoffe zerstört 
oder verändert werden.
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1 INTRODUCTION  
1.1 Chronic myeloid leukemia (CML) 
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder 
of a pluripotent hematopoietic stem cell that was first described in 1845 
(Bennett 1845; Craigie 1845; Virchow 1845). In patients, CML displays three 
major characteristic clinical phases (Figure 1.1). In most patients, CML is 
manifested as a longer chronic phase (CP) disease that is identifiable by an 
initial leukocytosis with an increased count of peripheral blood myeloid 
progenitor cells often remaining undiscovered for years, as mature granulocytes 
are still produced (Melo and Barnes 2007). However, most patients are 
diagnosed at chronic phase, where the first symptoms include splenomegaly, 
fatigue and weight loss (Melo and Barnes 2007). Upon disease progression, 
patients enter an intermediate stage of CML development, the so-called 
accelerated phase (AP), usually characterized by aggravating splenomegaly 
and leukocytosis, increasing numbers of blast cells and additional cytogenetic 
abnormalities that lead to therapy failure (Figure 1.1) (Melo and Barnes 2007). 
Finally patients succumb to the blast crisis (BC) phase, where the 
haematopoietic differentiation process is fully arrested while immature blasts 
continue accumulating in the bone marrow and the blood circulation to 20% or 
more in the peripheral blood or bone marrow (Melo and Barnes 2007). 
Secondary cytogenetic and molecular changes associated with progression into 
BC usually directly or indirectly affect p53 and/or Rb gene activity, which further 
drive proliferation of blast crisis cells in addition to secondary effects such as 
differentiation arrest (Figure 1.1) (Calabretta and Perrotti 2004). Most cancerous 
malignancies are the consequence of a sequel of mutagenic events (Hanahan 
and Weinberg 2000). However, as CML was the first human cancer that was 
found associated with only a single consistent and causative chromosomal 
abnormality, the Philadelphia (Ph) chromosome (Nowell and Hungerford, 1960), 
diagnosis of CML was significantly improved and it has become one of the most 
comprehensively studied human malignancies and a breakthrough story in 
cancer biology (Deininger, Goldman et al. 2000; Melo and Barnes 2007).  
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Figure 1.1 Multi-step disease progression and major disease stages in chronic 
myeloid leukemia (CML) 
During chronic phase (CP) of CML leukemic stem cells differentiate into progenitor cells 
and lead to the accumulation of mature granulocytes. As tumour-suppressors (TS) are 
still functional in these granulocytes, they undergo either senescence or apoptosis. 
However, acquisition of a series of additional genomic alterations during the 
accelerated phase (AP) of the disease leads to differentiation arrest and excessive 
proliferation of immature blasts finally leading to blast crisis (BC)(Figure taken from 
(Melo and Barnes 2007)). 
 
CML and a subset of acute lymphocytic leukaemia (ALL) are caused by 
the expression of the fusion protein Bcr-Abl (Advani and Pendergast 2002; 
Druker, Sawyers, Capdeville et al. 2001; Goldman and Melo 2003; Sattler and 
Griffin 2003) and serve as a paradigmatic example for the development of 
target tyrosine kinase inhibitor cancer treatment. Prior to the advent of targeted 
molecular Bcr-Abl therapy, most CML treatments aimed at the destruction of 
actively proliferating cells. Typical cytostatic chemotherapeutic agents were 
busulfan and hydroxyurea, which were effective in the generation of 
hematological responses in chronic phase CML patients. However, due to the 
lack of specificity of these therapies, they were unable to selectively clear Ph+ - 
positive cells or to inhibit Bcr-Abl activity, therefore never achieved cytogenetic 
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remissions and could at most delay the onset of blast crisis (Sawyers 1999). 
Therapy with Interferon-α (IFN-α), however, lead to both complete 
hematological (CHR) and cytogenetic (CCR) responses in chronic phase 
patients who consequently showed excellent long-term prognosis and survived 
for more than ten years upon IFN-α treatment (Kantarjian, O'Brien et al. 2003). 
Combination therapy with IFN-α and cytosine arabinoside (Ara-C), however, 
showed even better efficacy and was therefore established as standard therapy 
before the advent of imatinib (Ezaki 2000; Ferrajoli, Liberati et al. 1995). For all 
these therapies, early diagnosis and therapy are crucial as diagnosis of CML at 
accelerated or blast crisis stage is almost inevitably associated with poor 
survival prognosis, as more and more cytogenetic abnormalities, such as 
trisomy 8 (Jennings and Mills 1998), are likely to be acquired during the course 
of the disease (Mitelman 1993). Until today, the only curative CML therapies 
consist in the combination of chemotherapy with irradiation therapy followed by 
bone marrow transplantation (BMT), if compatible healthy bone marrow cells 
are available (Druker, Sawyers, Capdeville et al. 2001). 
With the discovery of the constitutively active oncogenic fusion tyrosine 
kinase Bcr-Abl as the cause of CML (Bartram, de Klein et al. 1983; Ben-Neriah, 
Daley et al. 1986; de Klein, van Kessel et al. 1982; Konopka, Watanabe et al. 
1984) almost 26 years after the discovery of the Philadelphia chromosome and 
its link to CML (Nowell and Hungerford 1960), the first successful targeted 
cancer drug imatinib mesylate initiated a new era of CML treatment with CCR 
rates of > 90% in chronic phase CML patients (Buchdunger, Zimmermann et al. 
1996; Druker, Tamura et al. 1996). This key discovery was followed by detailed 
structural and functional characterization of the Abl kinase domain in complex 
with imatinib (Nagar, Bornmann et al. 2002) and elucidation of the mechanism 
of action of imatinib. However, treatment with imatinib mesylate and the 
following second (Lombardo, Lee et al. 2004; Shah, Tran et al. 2004; Weisberg, 
Manley et al. 2005) and third generation (Golas, Arndt et al. 2003; Yokota, 
Kimura et al. 2007) inhibitors turned out not to be the curative end of the story, 
as drug resistances and disease relapses persist. 
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1.2 Expression of Bcr-Abl from the Philadelphia chromosome is 
sufficient to cause CML 
Bcr-Abl is a constitutively active tyrosine kinase and its expression is 
the result of a reciprocal chromosomal translocation event between 
chromosomes 22 and 9 (t9;22; Philadelphia Chromosome) (Rowley 1973) that 
leads to the fusion of the breakpoint cluster region (BCR) gene and the Abelson 
tyrosine kinase (ABL1) and sequences from the first exon of the ABL1 tyrosine 
kinase are replaced by sequences from the BCR (breakpoint cluster region) 
gene, thereby generating a de-regulated, constitutively activated tyrosine kinase 
(Figure 1.2) (de Klein, van Kessel et al. 1982), (Wong and Witte 2004). Despite 
of evidence for remaining functional autoinhibitory mechanisms of c-Abl in Bcr-
Abl, such as SH3 domain binding to P242 (c-Abl-1b) within the SH2-CD linker 
(Barilá and Superti-Furga 1998; Smith, Yacobi et al. 2003), fusion-dependent 
aberrations such as loss of the c-Abl N-terminal myristate (Hantschel, Nagar et 
al. 2003) as well as oligomerisation via the amino-terminal Bcr-coiled-coil 
domain (Figure 1.2) (McWhirter, Galasso et al. 1993; Tauchi, Miyazawa et al. 
1997; Taylor and Keating 2005; Zhao, Ghaffari et al. 2002) lead to an open and 
active enzyme conformation, intermolecular autophosphorylation of the Bcr-Abl 
catalytic domain on Y412 within the activation loop and consequently on Y245 
within the SH2-CD linker finally resulting in constitutive activity of the c-Abl 
tyrosine kinase. Depending on the particular cell type, Bcr-Abl expression either 
results in enhanced cell proliferation, morphological transformation or 
abrogation of growth factor/adhesion dependence (Daley, Van Etten et al. 1990; 
Raitano, Whang et al. 1997). Most importantly, however, expression of Bcr-Abl 
alone is sufficient for the transformation of hematopoietic stem cells leading to 
chronic myeloid leukemia (CML) in humans and a CML-like myeloproliferative 
disorder in mice (Daley, Van Etten et al. 1990; Li, Ilaria et al. 1999; Van Etten 
2007). Also, a transgenic B-ALL mouse model demonstrated that continued 
expression of tetracycline-regulatable Bcr-Abl is required for the initiation and 
maintenance of leukemia (Huettner, Zhang et al. 2000).  
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Figure 1.2 The Philadelphia chromosome translates into the oncogenic fusion 
tyrosine kinase Bcr-Abl 
(A) The reciprocal chromosomal translocation between chromosomes 9 and 22 (t9;22) 
leads to formation of the Philadelphia chromosome (Ph 22q-) (Figure adapted from 
(Druker 2008)). 
(B) Domain model representation of the consequences of the (t9;22) chromosomal 
translocation. Exon 1 of c-Abl (including the myristate of c-Abl1b) and the C-terminal 
C2- and RhoGAP-domains of Bcr are lost in the Bcr-Abl fusion protein. Phosphorylation 
sites on Bcr-Abl are shown. 
 
Two major p210 Bcr-Abl fusion protein types are found in CML, b2a2 
(e13a2) and b3a2 (e14a2) (Deininger, Goldman et al. 2000). The e1a2 p190 
Bcr-Abl fusion protein is only rarely found in CML but represents the major 
fusion type in Ph+ cases of B-cell acute lymphoblastic leukemia (ALL) (Melo, 
Gordon, Tuszynski et al. 1993; Melo, Myint et al. 1994). Besides the Bcr-Abl 
hybrid gene, also its counterpart chimeric gene Abl-Bcr was found to be 
expressed by reverse transcription polymerase chain reaction amplification of 
mRNA in Ph+ positive CML patients (31/44) (Melo, Gordon, Cross et al. 1993), 
in patients with Ph+ positive acute lymphoblastic leukemia (ALL) (Zheng, Guller 
et al. 2006) as well as in three out of five Bcr-Abl positive cell lines, where the 
K562 cell line was negative for Abl-Bcr probably due to transcriptional inactivity 
(Melo, Gordon, Cross et al. 1993). As the Abl-Bcr fusion transcript is not 
consistently expressed in Ph+ positive leukemias, its differential expression was 
hypothesized to represent a determinant of the heterogenic character of CML 
A
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(Melo, Gordon, Tuszynski et al. 1993). However, a recent study showed that 
there is no correlation between Abl-Bcr expression and response to IFN-α 
therapy in CML. 
 
1.3 Bcr-Abl protein architecture, domain structures and regulation 
The two genes involved in the t(9;22) translocation constituting the 
Philadelphia chromosome and its translation Bcr-Abl are the proto-oncogene 
Abelson non-receptor tyrosine kinase ABL1 (chromosome 9), the human 
homologue of the v-Abl oncogene encoded by the Abelson murine leukemia 
virus (A-MuLV) (de Klein, van Kessel et al. 1982) and the breakpoint cluster 
region gene BCR (chromosome 22) (Groffen, Stephenson et al. 1984), both 
ubiquitously expressed genes (Laneuville 1995). Human c-Abl is a 145kDa 
protein expressed as two isoforms upon alternative splicing of its first exon, c-
Abl-1a and c-Abl-1b. The c-Abl-1b isoform, which is slightly longer than isoform 
c-Abl-1a, carries a myristate group attached to the glycine residue at position 
two (Figure 1.2B) (Hantschel, Nagar et al. 2003). This myristate group was 
shown to be crucially involved in the intra-molecular regulation of c-Abl and 
maintenance of c-Abl in an inactive state following a “latching” mechanisms 
induced by binding of the myristate into a deep hydrophobic pocket within the 
C-lobe of the kinase that leads to close “clamping” of the structure with the SH2-
SH3 domains attached to the backside of the kinase (Figure 1.3B) (Hantschel, 
Nagar et al. 2003; Nagar, Hantschel et al. 2003). The importance of this 
“clamping” mechanism is confirmed by directed mutational disruption of SH2 
and SH3 domain residues that lead to activation of the kinase (Barilá and 
Superti-Furga 1998; Hantschel, Nagar et al. 2003; Nagar, Hantschel et al. 
2003). Equally, loss of the myristate upon mutation of the glycine residue to 
alanine led to dramatic increase in c-Abl tyrosine kinase activity compared to 
wild-type c-Abl (Hantschel, Nagar et al. 2003). The myristoylation consensus 
site is absent in c-Abl-1a and all Bcr-Abl fusion proteins and although 
hydrophobic residues in the Abl cap-domain were proposed to replace the 
missing myristate (Hantschel, Nagar et al. 2003; Nagar, Hantschel et al. 2003) it 
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is still unknown how c-Abl-1a compensates for the missing myristate in terms of 
intra-molecular auto-inhibitory regulation. Additionally, c-Abl features numerous 
domains and motifs critical for its enzymatic and signaling activity, most of 
whose structures have been solved in detail. The N-terminal Src homology 2 
(SH2) and 3 domains (SH3) mediate protein-protein interactions with other 
proteins via binding of phospho-tyrosine or proline-rich sequences (PXXP-
motifs), respectively (Cicchetti, Mayer et al. 1992; Mayer, Jackson et al. 1991). 
After its discovery by Tony Pawson as a stretch of 100 residues conserved in v-
Src and other non-receptor tyrosine kinases (Sadowski, Stone et al. 1986), the 
structure of the SH2 domain of v-Src tyrosine kinase has been solved in 1992 in 
complex with phosphotyrosyl peptides using X-ray crystallography (Waksman, 
Kominos et al. 1992; Waksman, Shoelson et al. 1993) showing that the domain 
features a central antiparallel beta-sheet flanked by two alpha-helices, where 
the peptide is bound by the beta-sheet, intervening loops and one of the alpha-
helices. In addition to hydrogen-bond formation and ionic interactions with the 
phosphate-group, specific recognition of the phosphotyrosine peptide by the v-
Src SH2 domain was shown to involve two specificity pockets often compared 
to a “two-pronged plug engaging a two-holed socket” involving a phospho-
tyrosine binding pocket and amino-aromatic interactions between lysine and 
arginine side-chains with the “+3 specificity determining region”. The structure 
without bound peptide was also determined and displayed only small local 
changes (Waksman, Kominos et al. 1992; Waksman, Shoelson et al. 1993). 
Additionally, the in solution structure of the SH2 domain of the p85α subunit of 
PI3-kinase had been solved by nuclear magnetic resonance spectroscopy 
(NMR) and confirmed the basic structure determined by X-ray diffraction before 
(Booker, Breeze et al. 1992). These results on the structure and specificity of 
the SH2 domain (Waksman and Kuriyan 2004) initiated a line of discoveries that 
ultimately led to the elucidation of the regulatory mechanisms in both c-Src and 
c-Abl that were decisive for explaining the specificity of imatinib for c-Abl 
(Nagar, Hantschel et al. 2003). While in c-Src, the SH2 domain binds the 
tyrosine-phosphorylated C-terminal tail, in c-Abl the SH2 domain is positioned 
closely to the kinase domain (Hantschel and Superti-Furga 2004) where access 
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to the SH2 ligand-binding site is blocked by the kinase domain (Figure 1.3B) 
(Nagar, Hantschel et al. 2003). The SH2 domain of Bcr-Abl/c-Abl is crucially 
involved in leukemogenesis via complex formation with other tyrosine-
phosphorylated signaling proteins, as inactivation by mutation of the arginine 
residue within the conserved FLVRES motif (R171K, mAbl-1b and hAbl-1b; 
R152K, hAbl-1a) renders the SH2 domain unable to bind phosphotyrosine-
containing proteins, which correlates with reduced in vitro phosphotyrosine 
binding and transforming ability (Mayer, Jackson et al. 1992). The structure of 
the SH3 domain of spectrin was solved at 1.8 Å resolution (Musacchio, Noble et 
al. 1992) and revealed a compact beta-barrel consisting of five antiparallel beta-
strands, with a region consisting of conserved aromatic and acidic amino acids 
on one side of the molecule that was assumed to mediate ligand binding. The 
elucidation of the function of the SH3 domain and structures of Abl and Fyn 
tyrosine kinase SH3 domains in complex with proline-rich peptide showed that 
proline-rich peptides (PXXP-ligands), whose majority forms a left-handed 
polyproline type II-helix, are bound over their entire length (about 10 residues) 
via hydrogen-bonding and van-der-Waals contacts (Musacchio, Saraste et al. 
1994; Musacchio, Wilmanns et al. 1994). As for the regulation of c-Abl (Barilá 
and Superti-Furga 1998), the SH3 domain is also implicated in the negative 
regulation of Bcr-Abl by binding to P1124 in the linker between the SH2 and 
catalytic domains (SH2-CD linker) in the monomeric and unphosphorylated 
state of Bcr-Abl (Smith, Yacobi et al. 2003). Oligomerization of Bcr-Abl via its 
coiled-coil domain (Figure 1.2), however, disrupts the autoinhibited 
conformation by inducing intramolecular autophosphorylation of tyrosine 
residues in the activation loop of the catalytic domain (CD) and the SH2-CD 
linker and is required for leukemogenesis (Hantschel and Superti-Furga 2004; 
Smith, Yacobi et al. 2003). The tyrosine kinase domain of c-Abl carries tyrosine 
kinase activity and structural studies of the kinase domain (Nagar, Bornmann et 
al. 2002; Schindler, Bornmann et al. 2000) and in consequence of the kinase 
domain together with the SH2-SH3-unit (Nagar, Hantschel et al. 2006; Nagar, 
Hantschel et al. 2003) showed that the outward orientation of the activation loop 
away from the kinase domain in combination with activatory phosphorylation on 
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Y412 represents another crucial mechanism involved in regulation of c-Abl 
activity. Upon “unclamping” of the kinase other protein ligands to the SH2 and 
SH3 domains further open up the kinase followed by further Y412 
phosphorylation and full kinase activation (Hantschel and Superti-Furga 2004). 
Overall, these mechanisms show how similar the regulatory mechanisms of c-
Abl are to Src kinases (Harrison 2003). Besides these functional protein 
domains that enable enzymatic activity and binding of other proteins, c-Abl also 
harbors C-terminal proline-rich sequences that mediate binding of other SH3 
domains as well as three C-terminal nuclear localization signals (NLS), DNA-
binding (Kipreos and Wang 1992) and an F-actin binding domain (FABD) at the 
very C-terminus (McWhirter and Wang 1993) (Figure 1.2). The NLS and DNA-
binding domains are located in the so-called ʻlast exon regionʼ of c-Abl. It was 
shown that this ʻlast exon regionʼ is not required for autoinhibition of c-Abl and 
its functional role is still unclear (Pluk, Dorey et al. 2002). The NMR structure of 
the FABD of Bcr-Abl/c-Abl revealed a compact left-handed four-helix bundle 
and provided first insight into the mechanism of cytoskeletal association and 
localization of Bcr-Abl/c-Abl (Figure 3.1C) (Hantschel, Wiesner et al. 2005; 
Wiesner, Hantschel et al. 2005). Importantly this study identified that a nuclear 
export signal (NES) reported within the FABD (Taagepera, McDonald et al. 
1998) is ʻburriedʼ inside the hydrophobic core and nonfunctional while residues 
within helix alpha-III were identified to be crucial for F-actin binding and 
association with the cytoskeleton (Hantschel, Wiesner et al. 2005). c-Abl has 
recently been implicated in regulation of actin remodeling at the immune 
synapse during T-cell activation (Huang, Comiskey et al. 2008). Generally, c-
Abl presumably controls various cellular signaling processes as Abl knockout 
mice show a variety of phenotypes from splenic/lymphic atrophy and 
lymphopenia (Zipfel, Grove et al. 2000) to osteoporosis (Li, Boast et al. 2000). 
The 160kDa Bcr protein also features several structural protein 
domains, including a N-terminal coiled-coil domain (McWhirter, Galasso et al. 
1993), a central region with homology to Rho guanine nucleotide exchange 
factors (Rho-GEF) and pleckstrin-homology (PH) domains (Sahay, Pannucci et 
al. 2007) and a C-terminal Rac-GAP (Diekmann, Brill et al. 1991). The N-
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terminal coiled-coil domain (residues 1-72) was shown to mediate 
homotetramerization of Bcr-Abl correlating with activation of c-Abl tyrosine 
kinase and F-acting-binding activity as well as Bcr-Abl transforming potential in 
vitro (McWhirter, Galasso et al. 1993). The structure revealed a new 
mechanism of oligomer formation by dimerization of two N-shaped monomers 
followed by tetramerization of two dimers (Zhao, Ghaffari et al. 2002). The Rho-
GEF domain, autoinhibited in Bcr, is activated in Bcr-Abl, activates RhoA and is 
required for full transforming activity by Bcr-Abl (Sahay, Pannucci et al. 2007). 
Accordingly, RhoA, Rac1 and Cdc42 interact with p210Bcr-Abl in vivo, but not 
with p190Bcr-Abl, which does not harbor the Rho-GEF domain, and p210Bcr-
Abl but not p190Bcr-Abl was able to activate RhoA in vitro and in vivo (Harnois, 
Constantin et al. 2003) further underlining the importance of the Rho-GEF 
domain together with its target RhoA for transforming potential of Bcr-Abl. Bcr 
also encodes a Rac-GAP domain (residues 1065-1249), with GTPase activating 
protein (GAP) function for p21Rac, a Ras superfamily small GTPase known to 
regulate actin polymerization (Diekmann, Brill et al. 1991; Thomas, Cancelas et 
al. 2008). Small G proteins such as Rac are crucial molecular switches involved 
in cytoskeleton dynamics, cell proliferation and JNK signaling (Diekmann, Brill 
et al. 1991). GAPs interactwith small G proteins and serve as catalyzing 
enhancers of small G protein function by increasing GTP hydrolysis (Rittinger, 
Walker et al. 1997). A structure of the small Rho family G protein Cdc42Hs in 
complex with the GAP domain of p50rhoGAP has been solved at 2.7 Å 
resolution (Peck, Douglas et al. 2002; Rittinger, Walker et al. 1997). While the 
Rac-GAP domain is absent in the Bcr-Abl fusion proteins, overexpression of Bcr 
in p190Bcr-Abl expressing fibroblasts reduced the transforming potential of 
p190Bcr-Abl (Wu, Ma et al. 1999), which supports a potential regulatory role of 
the Rac-GAP domain of Bcr in light of its absence in constitutively active Bcr-
Abl. While Bcr serine-threonine kinase activity seems to target only itself 
(Laneuville 1995) and the 14-3-3 protein Bap-1 (Reuther, Fu et al. 1994), 
serine-phosphorylated Bcr within Bcr-Abl, featuring serine 354, was shown to 
bind the SH2 domain of Bcr-Abl and to consequently inhibit the oncogenic 
activity of Bcr-Abl (Arlinghaus 2002). As for c-Abl, however, also the biological 
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function of endogenous Bcr is still controversial such as the function of its 
serine-threonine kinase domain (Maru and Witte 1991) is. BCR knockout mice 
are viable and only few subtle defects were recognized, probably hinting 
towards signaling redundancy in the context of Bcr (Voncken, van Schaick et al. 
1995). 
 
1.4 The Bcr-Abl phospho-tyrosine profile 
The major feature of the oncogenic fusion tyrosine kinase Bcr-Abl is its 
constitutive tyrosine kinase activity, which is central to Bcr-Ablʼs ability to 
transform haematopoietic cells (Daley, Van Etten et al. 1990; Konopka, 
Watanabe et al. 1984). Expression of constitutively active Bcr-Abl leads to the 
phosphorylation of a large number of proteins in the cell causing activation of a 
large number of key signaling components (Sattler and Griffin 2003; Steelman, 
Pohnert et al. 2004). Furthermore, Bcr-Abl, which is itself phosphorylated on 
numerous tyrosine residues upon autophosphorylation, recruits a set of proteins 
containing SH2 and/or PTB domains and also binds to tyrosine-phosphorylated 
proteins via its own SH2 domain. These signaling effects were shown to be 
responsible for the oncogenic effect of Bcr-Abl and are the major rationale for 
targeted therapy using Bcr-Abl tyrosine kinase inhibitors. Bcr-Abl 
autophosphorylation is the consequence and a major driver of its constitutive 
activity alike. While the autoinhibited form of c-Abl is not tyrosine 
phosphorylated in unstimulated cells (Brasher and Van Etten 2000; Hantschel 
and Superti-Furga 2004), c-Abl acquires tyrosine phosphorylation at several 
residues upon activation of the kinase (Van Etten, Debnath et al. 1995). 
Tyrosine phosphorylated c-Abl residues include Y412 in the activation loop and 
Y245 in the SH2-CD linker (Figure 1.3). Phosphorylation of Y412 was shown to 
affect the positioning of the activation loop in a way that favors kinase activation 
and to positively correlate with catalytic activity of c-Abl (Figure 1.3B) (Brasher 
and Van Etten 2000; Dorey, Engen et al. 2001). In addition, phosphorylation of 
Y245 is required for full activation of c-Abl (Brasher and Van Etten 2000). 
Further tyrosine phosphorylation sites in c-Abl were determined from cells co-
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transfected with constitutively active Src (Plattner, Kadlec et al. 1999) (Superti-
Furga lab, unpublished observations) and Bcr-Abl tyrosine phosphorylation sites 
have been systematically mapped by mass spectrometry (Salomon, Ficarro et 
al. 2003; Steen, Fernandez et al. 2003). Besides Y245 and Y412 (see above), 
these include the c-Abl tyrosine residues Y134 (SH3-domain, ligand-binding 
surface), Y204 (SH2 domain ʻsouth faceʼ), Y251 (SH2-CD linker), Y272 (CD/P-
loop), Y276 (CD/N-lobe), Y283 (CD/N-lobe-SH3 interface) and Y488 (CD/C-lobe 
ʻsouth faceʼ) (Figure 1.3B) (Hantschel and Superti-Furga 2004). Two of these, 
Y272 and Y276, are particularly interesting, as they confer resistance to imatinib 
in vitro (Azam, Latek et al. 2003; Pendergast, Quilliam et al. 1993) and Y272 
could accordingly be identified in imatinib - resistant patients (Roumiantsev, 
Shah et al. 2002). Also, Y134 is interesting, as it is conserved in SH3 domains 
and crucially involved in PXXP ligand binding (Musacchio, Wilmanns et al. 
1994). Phosphorylation of Y134 potentially clashes with the SH3-linker-CD 
interface and disturbs kinase autoinhibition (Figure 1.3) (Hantschel and Superti-
Furga 2004). Tyrosine phosphorylation of Bcr-Abl by Src family kinases such as 
Hck, Lyn and Fyn was assessed in more detail and shown to affect residues 
Y89 and Y134 (Abl SH3 domain), Y147 (SH3-SH2 connector) and Y158, Y191, 
Y204 and Y234 in the SH2 domain and phenylalanine substitution of the SH2-
SH3 domain phospho - tyrosine residues confirmed their influence on Bcr-Abl 
transforming potential (Figure 1.3) (Meyn, Wilson et al. 2006). 
Also Bcr was shown to be phosphorylated on several tyrosine residues, 
most importantly on Y177 within the first exon of Bcr, which is the crucial event 
for binding of the small adaptor protein Grb2 and a link to the Ras-pathway, 
activated by Bcr-Abl and crucial for Bcr-Abl - mediated leukemogenesis 
(Pendergast, Quilliam et al. 1993; Zhang, Subrahmanyam et al. 2001). Besides 
Y177, Bcr is also phosphorylated on Y283, Y328 and Y360 and tyrosine-
phosphorylated Bcr, phosphorylated by Bcr-Abl, has reduced serine-threonine 
kinase activity (Liu, Wu et al. 1996; Wu, Liu et al. 1998). The first exon of 
p160Bcr is predominantly tyrosine phosphorylated in trans by Bcr-Abl or 
autophosphorylated within Bcr-Abl as was shown by p160Bcr / p185Bcr-Abl and 
p210Bcr-Abl co-precipitation studies (Liu, Campbell et al. 1993). Another study 
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reported phosphorylation of the Bcr-Abl kinase on tyrosine Y644 using 
metabolic labeling with light or heavy tyrosine (SILAC) and detection by 
quantitative mass spectrometry (Liang, Hajivandi et al. 2006). 
 
 
Figure 1.3 The Bcr-Abl phospho-tyrosine profile 
(A) Location of known phospho-tyrosine residues mapped onto the domain-structure 
representation of Bcr-Abl. Domains and location of phospho-tyrosine residues shown in 
scale (mapped using Prosite MyDomains - Image Creator (http://www.expasy.ch/cgi-
bin/prosite/mydomains/)). 
(B) Inlet showing phosphorylation sites within the SH3-SH2-Kinase-domain unit of Bcr-
Abl mapped onto the regulated Abl structure (PDB entry 1OPK) and shown as green 
sticks (SH3 domain (yellow), SH2 domain (green) and kinase domain (blue)). Some 
phospho-serine and -threonine residues as well as bound imatinib (STI-571) and a 
myristoylated peptide are shown (Figure adapted from Hantschel and Superti-Furga 
2004). 
 
Besides tyrosine phosphorylation of Bcr-Abl itself, also numerous 
tyrosine-phosphorylation sites on other signaling proteins associated with Bcr-
Abl activity have been mapped and recent phospho-proteomics approaches in 
combination with mass spectrometric detection have led to an enlarged global 
profile of tyrosine-phosphorylation sites in Bcr-Abl expressing cells (Goss, Lee, 
Moritz, Nardone, Spek, MacNeill et al. 2006). The p210 Bcr-Abl expressing cell 
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line K562, for instance, is now known to harbor about 89 Bcr-Abl associated 
tyrosine-phosphorylation sites (Goss, Lee, Moritz, Nardone, Spek, MacNeill et 
al. 2006). Several tyrosine phosphorylation targets of Bcr-Abl, for instance in 
K562 cells, are kinases themselves, such as PI3K, c-Abl, Bcr, Btk, Cdc2, Cdk2, 
DYRK1A, Erk1/2, Fyn, GSK3-β, HIPK1, Lck, Lyn, p38-α, PRP4 (Goss, Lee, 
Moritz, Nardone, Spek, MacNeill et al. 2006; Hornbeck, Chabra et al. 2004). 
The overall ʻphospho-tyrosine signatureʼ varies for the different Bcr-Abl 
expressing cell-lines and Bcr-Abl fusion types expressed (b2a2/e13a2; 
b3a2/e14a2 for p210 Bcr-Abl and e1a2 for p190 Bcr-Abl). However, a defined 
common signature of the tyrosine-phosphorylated proteins Bcr, c-Abl, VASP, 
Ship2, Shc1, c-Cbl, CD2AP (novel) and GRF1 (novel) could be concluded for 
Bcr-Abl positive cell lines (Goss, Lee, Moritz, Nardone, Spek, MacNeill et al. 
2006). Ship2 tyrosine phosphorylation by Bcr-Abl (Y1135) was confirmed by an 
independent quantitative proteomics study (tyrosine SILAC) that additionally 
identified Dok-2 (Y299) as tyrosine phosphorylation target of Bcr-Abl, both of 
which were reduced by about 90% following imatinib treatment (Liang, Hajivandi 
et al. 2006). These proteins could therefore represent a ʻconsensusʼ target set 
of Bcr-Abl tyrosine kinase activity irrespective of cellular background or fusion 
type and could therefore serve as candidate Bcr-Abl therapy response 
biomarkers (Goss, Lee, Moritz, Nardone, Spek, MacNeill et al. 2006). 
 
1.5 Bcr-Abl, its interactors and affected signaling pathways 
As a consequence of the constitutive tyrosine kinase activity of Bcr-Abl, 
tyrosine phosphorylation sites on Bcr-Abl and its substrates act as docking sites 
thereby initiating and modifying protein-protein interactions via SH2 and PTB 
domains (Mayer, Jackson et al. 1991). Thereby, Bcr-Abl is thought to serve as a 
large docking framework assembled in a multi-protein complex, which is itself in 
the centre of a protein-protein interaction network (Hantschel and Superti-Furga 
2004; Ren 2005; Salomon, Ficarro et al. 2003; Steen, Fernandez et al. 2003). 
Numerous individual interactions with Bcr-Abl have been described in the past 
so that it seems hard to picture an overview of Bcr-Abl signaling. These include 
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the well-described “canonical” interactors of Bcr-Abl Grb2 (Patel, Marley et al. 
2006; Pendergast, Quilliam et al. 1993), Grb4 (Coutinho, Jahn et al. 2000), 
Grb10 (Bai, Jahn et al. 1998), Cbl (Gaston, Johnson et al. 2004; Patel, Marley 
et al. 2006), Syp (Tauchi, Feng et al. 1994), Gab2 (Sattler, Mohi et al. 2002), 
Shc1 (Tauchi, Boswell et al. 1994), Nck1 (Miyoshi-Akiyama, Aleman et al. 2001; 
Smith, Katz et al. 1999), SHP-2 (Tauchi, Miyazawa et al. 1997), Ship2 
(Wisniewski, Strife et al. 1999), Abl-interacting protein 1 and 2 (Abi-1/2) (Dai 
and Pendergast 1995; Fan, Cong et al. 2003; Shi, Alin et al. 1995), 14-3-3 
family proteins such as Bcr-associated protein (Bap-1) (Reuther, Fu et al. 1994) 
and CrkL (Patel, Marley et al. 2006; Sattler and Salgia 1998). Many of these 
interactors are phosphorylated by Bcr-Abl, such as CrkL, Crk, Shc1 (Goga, 
McLaughlin et al. 1995), Dok-1, Gab2, Cbl, p130Cas (Salgia, Pisick et al. 1996), 
Stat5, PI3KR2 (p85β), Vav1 (Bassermann, Jahn et al. 2002), Fes, Paxillin or 
PLCγ (Ren 2005). Besides CrkL, also c-Crk (Crk-I/II) was found interacting with 
Bcr-Abl (Feller, Knudsen et al. 1994). Of the three Crk isoforms expressed in 
hematopoietic cells (CrkL, Crk-I and Crk-II), however, CrkL is considered the 
most prominent substrate of Bcr-Abl and often used as readout for Bcr-Abl 
activity (Feller, Posern et al. 1998) and it was shown to be in a complex with 
Bcr-Abl, Cbl and Grb2 (Patel, Marley et al. 2006). Also, the Src kinase Hck has 
been reported to directly interact with Bcr-Abl via its SH2 and/or SH3 domain 
(Stanglmaier, Warmuth et al. 2003).  
Via some of these interactors, Bcr-Abl manages to harness important 
proliferative and anti-apoptotic signaling pathways, including the Ras-
MAPK/JNK, PI3K-Akt and Jak/STAT pathways, which were shown to be 
activated in Bcr-Abl expressing cells and to contribute to transformation of 
haematopoietic cells (Mahlmann, McLaughlin et al. 1998; Raitano, Halpern et 
al. 1995; Steelman, Pohnert et al. 2004). Grb2, Gab2, Shc1 and Crk are 
involved in the activation of the Ras-MAPK pathway (Pendergast, Quilliam et al. 
1993; Tanaka, Gupta et al. 1995; Tauchi, Boswell et al. 1994). As Grb2 binds 
the Bcr-Abl autophosphorylation site Y177 it co-recruits Gab2, which is crucial 
for activation of the Ras-MAPK pathway via Sos-1, the guanine-nucleotide 
exchange factor for Ras (Puil, Liu et al. 1994). The interaction between Grb2 
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and Bcr-Abl seems to be counteracted by expression of the phosphatase 
PTP1B (LaMontagne, Flint et al. 1998; LaMontagne, Hannon et al. 1998). 
Furthermore, binding of Grb2/Gab2 to Y177 leads to binding of Shp2 and 
phosphatidylinositol 3-kinase (PI3K) via Gab2 and activation of the PI3K-Akt 
pathway (Sattler, Mohi et al. 2002). The resistance of Gab2 knockout mice to 
Bcr-Abl mediated transformation confirmed the importance of Bcr-Abl, Gab2 
and these two pathways in Ph+ leukemia (Sattler, Mohi et al. 2002). Shc1 is also 
involved in Grb2-mediated activation of the Ras-MAPK pathway, as it binds the 
SH2 domain of Abl and, following tyrosine phosphorylation, recruits Grb2 
(Goga, McLaughlin et al. 1995). Next, in v-Abl and Bcr-Abl transformed cells, 
the oncogenes have been shown to activate Janus kinase (JAK) tyrosine 
kinases consequently leading to constitutive phosphorylation of signal 
transducer and activator of transcription 5 (Stat5), independently of cytokines 
such as GM-CSF (granulocyte-macrophage colony stimulating factor) (Danial, 
Pernis et al. 1995; Danial and Rothman 2000; Shuai, Halpern et al. 1996). 
Regarding Stat5 there is evidence that, in addition to its activity as signal 
transducer and activator of transcription, it can serve as cytoplasmic signalling 
effector in a complex with Gab2 and the p85 subunit of PI3K (Harir, Pecquet et 
al. 2007). Apart from the activation of proliferative pathways also apoptosis 
signalling is influenced in Bcr-Abl expressing cells. For instance, Bcr-Ablʼs 
inhibitory effect on Ship1 phosphatase leads to decreased apoptotic signalling 
(Sattler, Verma et al. 1999). Furthermore, Stat transcription factors, which are 
activated by Bcr-Abl (Shuai, Halpern et al. 1996), induce expression of anti-
apoptotic genes, such as Bcl-XL (Danial and Rothman 2000). In line with these 
insights, various downstream activation markers have been described for Bcr-
Abl expressing cells such as total phosphotyrosine, phospho-Stat5 (Frank and 
Varticovski 1996; Shuai, Halpern et al. 1996), phospho-Akt (Chu, Li et al. 2007), 
phospho-Erk1/2 and total Erk1/2 levels (Mizuchi, Kurosu et al. 2005; Steelman, 
Pohnert et al. 2004).  
Despite this wealth of protein interactors and downstream signaling 
pathways described, however, the precise molecular setup of the endogenous 
Bcr-Abl protein and the molecular mechanism of downstream signaling pathway 
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regulation is still unknown (Deininger, Buchdunger et al. 2005; Wong and Witte 
2004). At this point it has to be stated that the majority of the past studies on 
Bcr-Abl signaling have been performed mostly on individual protein associations 
that were characterized in different cell types by different methods and 
investigators. Therefore, there is a lack of a systematic, standardized and 
comprehensive approach to map the Bcr-Abl signaling network that would allow 
a unifying view on the identity of the Bcr-Abl binding partners in a qualitative 
and quantitative sense. 
 
1.6 The human leukemia model cell line K562 
The human leukemia model cell line K562 was derived from leukemic 
cells from a pleural effusion of a 53 year old patient suffering from chronic 
myeloid leukemia at terminal blast crisis stage in 1970, reported as Ph+ cell line 
in 1975 (Lozzio and Lozzio 1975) and characterized in further detail already 
about 32 years ago (Klein, Ben-Bassat et al. 1976). The K562 cell line is, by far, 
the most widely used Ph+ model cell line in CML research with more than 
10,000 PubMed entries to date. While a good proportion of data on Bcr-Abl 
signaling was accumulated using K562 cells as a leukemia model, this cell line 
represents numerous other key advantages that justify its use for a systematic 
Bcr-Abl signaling pathway mapping approach, as described in this thesis: 
- ease of culture (standard media) and rapid division ensure production of 
sufficient amounts of cells (from 1x108), typically needed for the TAP-
LC-MSMS procedure 
- well-characterized prototypic CML cell line ((Hantschel, Gstoettenbauer 
et al. 2008; Klein, Ben-Bassat et al. 1976)) 
- expression of endogenous p210Bcr-Abl present in the majority of CML 
patients from the Bcr promoter 
- no need to co-infect with Bcr-Abl 
- pathways activated by Bcr-Abl are already switched-on 
- cells respond to tyrosine kinase inhibitor treatment (imatinib, dasatinib, 
nilotinib) 
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- Bcr-Abl has “normal” expression level, close to c-Abl from non-
translocated allele 
- high transduction rates (up to 95%) can be achieved routinely with a 
single infection (Superti-Furga lab observation) 
Besides this line of advantages, K562 cells suffer from the fact that they 
do not allow for an easy Bcr-Abl - dependent readout assay as they 
endogenously express constitutively active Bcr-Abl. Furthermore, as the K562 
cell line was derived from a CML patient in blast crisis and given that it is now 
established in cell culture for almost four decades (Lozzio and Lozzio 1975), it 
has undergone numerous additional karyotypic changes, featuring gains and 
losses of chromosomal material, that may underlie unpredictable biological 
alterations as compared to a clinical CML setting. Karyotypic analysis of long-
term culture K562 cell lines have found varying manifestations from Ph+ 
hyperdiploid (Collins and Groudine 1983) to hypotriploid karyotypes (Dimery, 
Ross et al. 1983). In addition to the Philadelphia chromosome (t9;22), a more 
recent complete karyotypic characterization has corroborated previous findings 
and identified a hypotriploid karyotype with a modal chromosome number of 67 
and 21 unique marker chromosomes, including five entirely novel karyotypic 
markers (Naumann, Reutzel et al. 2001). Overall, these studies show that the 
K562 karyotype has undergone numerous changes but, at the same time, 
remained relatively stable over about three decades of sub-culture (Naumann, 
Reutzel et al. 2001). Nevertheless, several sub-lines of K562 might exist 
displaying distinct marker sets (Dimery, Ross et al. 1983). 
 
1.7 “Oncogene addiction” 
The phenomenon “oncogene addiction” describes the dependency of 
cancer cells on an oncogene and its associated signaling pathway for survival 
or proliferation (Weinstein and Joe 2008). This hitherto unexplained 
phenomenon has been documented in a series of tumor models and cancer cell 
lines, such as the Ph+ K562 cell line expressing the oncogenic fusion tyrosine 
kinase Bcr-Abl (Sharma, Gajowniczek et al. 2006). ʻAddictionʼ to the respective 
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oncogene can be so strong, that even transient inactivation of the oncogene 
can result in reduced transforming activity, as was shown in cell culture models. 
For instance, in a conditional transgenic mouse model for Myc-induced 
tumorigenesis (Felsher and Bishop 1999), brief inactivation of Myc by 
doxycycline durg treatment resulted in the sustained loss of the neoplastic 
phenotype, regression of tumors and differentiation of osteogenic sarcoma cells 
into mature osteocytes (Jain, Arvanitis et al. 2002). Even subsequent 
reactivation of the oncogene Myc was unable to restore the cellsʼ neoplastic 
phenotype and induced apoptosis instead, probably as a consequence of 
durable epigenetic changes that render the cells insensitive to Myc-induced 
tumorigenesis. This shows, at hands of the example oncogene Myc, that brief 
inactivation of an oncogene might represent effective cancer therapy in relevant 
cases and clearly classifies oncogenes as the ʻAchillesʼ heelʼ of the cancer they 
cause (Jain, Arvanitis et al. 2002; Weinstein 2002). As regards the underlying 
molecular mechanism, evidence points towards a possible therapeutic strategy 
that could harness a signaling cascade common to several oncogenes such as 
Src, Bcr-Abl or EGF receptor in order efficiently target the ʻaddictedʼ cells into 
remission. Following inactivation of these three oncogenes in cell culture 
models, all shared a similar ensuing profile of signal attenuation represented by 
diminution of phospho-ERK, -Akt and -STAT3/5 levels accompanied by a 
delayed increase in the proapoptotic effector phospho-p38MAPK 
(Bandyopadhyay, Biswas et al. 2004). In the TonB210.1 conditional Bcr-Abl 
expressing cell line, for instance, decrease in the survival effectors Akt, STAT5 
and ERK1/2 phosphorylation coincided with Bcr-Abl inactivation following 
doxycycling treatment for about 8hrs as did the increase of the levels of the 
phosphorylated proapoptotic Bcr-Abl downstream target p38 MAP kinase 
(Bandyopadhyay, Biswas et al. 2004) at 24hrs of doxycycline treatment 
(Sharma, Gajowniczek et al. 2006). Harnessing this transient imbalance 
between rather short-lived survival versus longer persisting apoptotic oncogenic 
outputs upon oncogene inactivation by using targeted kinase inhibitor treatment 
in a discontinuous cyclic fashion rather than continuously could be a more 
effective therapeutic option (Sharma, Gajowniczek et al. 2006). ʻAddictionʼ of 
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K562 cells to their oncogenic ʻAchilles heelʼ Bcr-Abl may explain the dramatic 
success of targeted Bcr-Abl tyrosine kinase inhibitors such as imatinib and 
excellent clinical response rates in CML patients treated with these inhibitors, 
providing a paradigmatic rationale for targeted molecular therapy (Druker 2004; 
Weinstein and Joe 2008). Similarly, RNA interference (RNAi) mediated 
inactivation of Bcr-Abl with a Bcr-Abl breakpoint-specific short-interfering RNA 
(siRNA) was shown to efficiently inhibit Bcr-Abl dependent cell growth 
(Wohlbold, van der Kuip et al. 2003). In the case of drug resistances, however, 
alternative strategies such as synergistic combination therapy might be required 
to overcome oncogene addiction (Chen, Gandhi et al. 2006; Weinstein and Joe 
2008; Weinstein and Joe 2006). 
 
1.8 Targeted therapy by imatinib: the current front-line therapy for Ph- 
positive CML and ALL 
For a long time, kinases were considered ʻundruggableʼ, as it seemed 
basically impossible to achieve the required specificity, a debate that is having 
its revival when it comes to the ʻdruggabilityʼ of protein-protein interactions 
(Mayer and Dimarchi 2005). However, as tyrosine kinases represent a major 
fraction of known oncogenes, they were destined the prime target for 
development of targeted small molecule inhibitors and the strategy ʻdrugging 
the cancer kinomeʼ lead to the development of successful drugs like 
trastuzumab (Herceptin) targeting ERBB2/HER2 (Workman 2005; Workman, 
Clarke et al. 2006). Also, the central role of the oncogenic Bcr-Abl kinase in the 
pathophysiology of CML represented a paradigmatic chance for molecular 
targeted therapy and ultimately lead to the development of the highly specific 
Bcr-Abl tyrosine kinase inhibitor imatinib (imatinib mesylate, Gleevec®, Novartis) 
that is now the frontline therapy for CML in all disease stages (Deininger, 
Buchdunger et al. 2005). A screening of inhibitors against protein kinase C-α 
(PKC-α) at Ciby-Geigy (now Novartis) identified phenylaminopyrimidines as 
selective ATP competitive inhibitors against PKC-α, although the IC50 values 
were not satisfactory (Traxler, Bold et al. 2001). Upon modification of the 
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candidate compound, CGP53,716 was shown to be effective against PDGF-R 
(Traxler, Bold et al. 2001), but surprisingly also quantitatively inhibited Gag-Abl 
tyrosine kinase (Buchdunger, Zimmermann et al. 1995). Upon further 
optimization for v-Abl inhibition imatinib mesylate (Gleevec, STI571 or 
CGP57148B), a 2-phenylaminopyrimidine derivative with very high affinity and 
specificity for the tyrosine kinases PDGF-R, c-KIT (Buchdunger, Cioffi et al. 
2000), c-Abl (Buchdunger, Zimmermann et al. 1996) and Arg (Okuda, Weisberg 
et al. 2001), was engineered (Figure 1.4A) (Traxler, Bold et al. 2001). 
 
 
Figure 1.4 Targeted therapy by the small-molecule tyrosine kinase inhibitor 
imatinib 
(A) Structural formula of imatinib mesylate (STI-571, Gleevec), a 2-
phenylaminopyrimidine derivative with very high affinity and specificity for the ATP 
binding pocket of the Abl tyrosine kinase domain active site (Buchdunger, Zimmermann 
et al. 1996). 
(B) Cartoon outlining the mechanism of action of imatinib. Binding of ATP and 
phosphate transfer from ATP onto substrates by the constitutively active tyrosine 
kinase Bcr-Abl is inhibited by the action of imatinib. This leads to inhibition of Bcr-Abl 
kinase activity and suppression of myeloid cell proliferation (Figure adapted from 
(Druker 2008)). 
(C) Structural representation of the Abl kinase domain (PDB entry 1OPJ, (Nagar, 
Hantschel et al. 2003)) with imatinib (STI-571) complexed in the ATP binding pocket. 
The activation loop (shown in green) is forced into an inactive conformation (Figure 
adapted from (Hantschel and Superti-Furga 2004)). 
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B
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Imatinib is now a clinically highly successful small-molecule inhibitor 
that binds to and inhibits the kinase domain of Bcr-Abl by competing with ATP 
(Figure 1.4B,C) (Nagar, Bornmann et al. 2002; Schindler, Bornmann et al. 
2000), thereby effectively abrogating signaling by Bcr-Abl and selectively 
inhibiting growth of Ph+ cells in vitro and tumor formation in mice in vivo 
(Deininger, Goldman et al. 1997; Druker, Tamura et al. 1996). The antileukemic 
response is believed to be due to activation of the p38 mitogen-activated protein 
(MAP) kinase signaling pathway upon imatinib treatment of Bcr-Abl positive 
cells, corroborating the possibility that Bcr-Abl, besides activating mitogenic 
pathways, also promotes CML by suppression of apoptotic pathways 
(Bandyopadhyay, Biswas et al. 2004; Parmar, Katsoulidis et al. 2004). The high 
selectivity and promising pharmacological properties of imatinib led to a dose-
escalation clinical phase I trial in CML patients refractory, resistant or intolerant 
to standard therapy (e.g. IFN-α) that concluded with successful outcome, good 
tolerability of the drug, normalization of blood cell counts and 98% (53/54 
patients) of complete hematologic response (CHR) and within one year follow-
up only one patient relapsed (Druker, Talpaz et al. 2001). Even 55% (21/38 
patients) of patients in myeloid blast crisis responded (Druker, Sawyers, 
Kantarjian et al. 2001). Following phase II and III trials, about 95% of IFN-α 
refractory patients responded with CHR of which 89% remained free of disease 
progression (Kantarjian, Sawyers et al. 2002) and only 1.5% of patients, not 
previously treated with IFN-α, had disease progression (Druker, O'Brien et al. 
2002). 60% of the patients achieved a major cytogenetic response (defined as 
reduction in the percentage of Ph chromosome-positive metaphases to less 
then 35 (Druker 2008)) (Kantarjian, Sawyers et al. 2002). These clinical success 
rates led to quick approval of the drug less than three years after the first clinical 
trials in May 2001 (Arnold 2001). However, chronic phase patients frequently 
relapse due to drug resistance despite of promising initial response and a 
significant proportion of accelerated and blast phase CML patients does not 
respond to imatinib at all or not well enough, or relapses despite of the 
treatment (Deininger, Buchdunger et al. 2005; Druker, Sawyers, Kantarjian et al. 
2001). 
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1.9 Molecular determinants of CML patients relapse 
Targeted treatment with imatinib is a success story with an overall six-
year progression-free survival of about 90%. However, despite this success, 
many patients develop resistance mutations and eventually relapse or do not 
respond to the drug when treatment starts in accelerated phase or blast crisis 
(REFs) (Capdeville, Buchdunger et al. 2002; Wong and Witte 2004). Different 
hallmarks can lead to drug resistance, most importantly point mutations in the 
drug target Bcr-Abl, but also gene amplifications (including Bcr-Abl) (Gorre, 
Mohammed et al. 2001) and chromosomal aberrations. During accelerated 
phase and blast crisis, other secondary chromosomal aberrations and 
duplication of the Ph chromosome have been reported, suggesting that imatinib 
resistance might also be caused by oncogenic events other than point 
mutations (Figure 1.1) (Mitelman 1993; Wong and Witte 2004). This increase of 
chromosomal aberrations in advanced stage CML may be due to increased 
levels of Bcr-Abl expression and the downregulation of one of the major DNA 
repair protein DNA-PK by Bcr-Abl (Deutsch, Dugray et al. 2001). Indeed, 
studies in CD34+ cells indicated that Bcr-Abl-overexpression levels directly 
influence response or resistance to imatinib (Barnes, Palaiologou et al. 2005). 
This obstacle was partly successfully addressed by administration of an 
increased dose of imatinib (600 vs 400mg daily), however, toxicity effects at 
high imatinib dose, such as frequent pancytopenia at 800mg daily, limits the 
applicability of the dose escalation concept (Kantarjian, Talpaz et al. 2003; 
Talpaz, Silver et al. 2002). Also, Bcr-Abl independent overexpression of Lyn 
tyrosine kinase was shown to be associated with imatinib resistance in cell 
culture and resistant patients cells by influencing phosphorylation levels of Bcr-
Abl and some of its targets (Donato, Wu et al. 2003) (Wu, Meng et al. 2008). 
However, mutations within the Abl kinase domain that prevent imatinib from 
binding have been found to be by far the most common mechanism of 
resistance to Imatinib (Deininger, Buchdunger et al. 2005; Griswold, MacPartlin 
et al. 2006; Leguay, Desplat et al. 2005; Shah, Nicoll et al. 2002), eventually 
leading to relapse and disease progression (Shah and Sawyers 2003). 
Following identification of several kinase domain mutations in imatinib - 
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resistant patients, an in vitro screen of randomly mutated Bcr-Abl recovered all 
of these plus many additional mutations (Azam, Latek et al. 2003). This study 
provided many insights on allosteric regulation of the Bcr-Abl kinase and has 
clinically predictive potential (Azam, Latek et al. 2003; Azam, Raz et al. 2003). 
Other screens followed, also to predict the resistance profiles for other inhibitors 
(von Bubnoff, Barwisch et al. 2005; von Bubnoff, Veach et al. 2005). Of all these 
mutations, the ʻgatekeeperʼ residue mutation T315I, which is critically involved 
in hydrogen bond formation with imatinib but also with nilotinib and dasatinib 
(Tokarski, Newitt et al. 2006; Weisberg, Manley et al. 2005), and E255K turned 
out to be the most problematic mutations in terms of disease prognosis, as they 
not only confer drug resistance but also increased activity of Bcr-Abl kinase 
(Gorre, Mohammed et al. 2001; Yamamoto, Kurosu et al. 2004). As E255K 
mutants were found to respond well to ʻsecond generationʼ inhibitors such as 
dasatinib, which inhibits all imatinib-resistant mutants except T315I (Shah, Tran 
et al. 2004), the T315I mutations remains the major problem in terms of tyrosine 
kinase inhibitor resistance (Druker 2008). Some mutations were reported to 
occur before inhibitor treatment indicating a gain of fitness of Bcr-Abl kinase 
domain mutations and indeed, mutation of the gatekeeper residue T315, that 
confers resistance to all current inhibitors of Bcr-Abl, was shown to positively 
influence ATP binding loop (P-loop) phosphorylation (Y253 and Y257) and Bcr-
Abl activity levels (Skaggs, Gorre et al. 2006). 
 
1.10 Second generation tyrosine kinase inhibitors 
The occurrence of secondary imatinib resistance leading to patient 
relapse and disease progression lead to the development and approval of 
ʻsecond-generationʼ inhibitors such as the highly specific nilotinib (AMN107, 
Tasigna®, Novartis) (Weisberg, Manley et al. 2005) and the potent dual Src/Abl 
kinase inhibitor dasatinib (BMS-354825, Sprycel®, Bristol-Myers Squibb) 
(Lombardo, Lee et al. 2004; Shah, Tran et al. 2004) that target most imatinib 
resistant Bcr-Abl point mutated variants (O'Hare, Walters, Stoffregen, Jia et al. 
2005; Quintas-Cardama, Kantarjian et al. 2007). Despite of 20- and 325-fold 
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higher activity against wild-type Bcr-Abl for nilotinib and dasatinib, respectively, 
and activity against > 90% of clinically isolated mutants in vitro, these new 
inhibitors still fail to target the most common imatinib-resistance mutation, T315I 
(O'Hare, Walters, Stoffregen, Jia et al. 2005; Weisberg, Manley et al. 2006). As 
for imatinib, clinical trials are promising at all CML disease stages (Guilhot, 
Apperley et al. 2007), even in imatinib resistant patients (Kantarjian, Giles et al. 
2006; le Coutre, Ottmann et al. 2007), but it seems likely that similar clinical 
resistances might develop even with these second generation drugs. Besides 
dasatinib and nilotinib, some newer ʻthird generationʼ compounds are also 
active against imatinib-resistant forms of Bcr-Abl, such as INNO-406, a novel 
Bcr-Abl / Lyn dual tyrosine kinase inhibitor (Tanaka and Kimura 2008; Yokota, 
Kimura et al. 2007). Bosutinib (SKI-606), a novel dual Src / Abl tyrosine kinase 
inhibitor, is active against Bcr-Abl at low nanomolar range and is equally 
effective against the majority of imatinib resistant mutations (Golas, Arndt et al. 
2003; Redaelli, Piazza et al. 2008). Although inactive against T315I in vivo, 
bosutinib was found to inhibit this mutant weakly in vitro (Remsing Rix, Rix et al. 
2008). INNO-406, bosutinib and dasatinib also target Lyn tyrosine kinase (Rix, 
Hantschel et al. 2007; Weinstein and Joe 2006; Yokota, Kimura et al. 2007), 
thereby simultaneously addressing the problem of frequent Lyn overexpression 
(Donato, Wu et al. 2003; Wu, Meng et al. 2008). The differential profiles of 
activity of dasatinib, nilotinib, INNO-406 and bosutinib against imatinib-resistant 
kinase domain mutations raises the possibility of case-dependent combination 
of these drugs upon resistance mutation related imatinib failure (Redaelli, 
Piazza et al. 2008). Furthermore, as the global target profiles of these inhibitors 
are known in more and more detail, their use might be rationalized dependent 
on the molecular disease background and side effect occurrences in individual 
patients (Rix, Hantschel et al. 2007). After all, the clinically effective T315I 
inhibitor still remains to be identified (O'Hare and Druker 2005; Tanaka and 
Kimura 2008) and the general shortcomings of primary and secondary 
resistance, especially in advanced disease stages (Tanaka and Kimura 2008), 
and issues with long-term tolerability of Bcr-Abl inhibitors remain a major clinical 
problem (Schiffer 2007). 
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1.11 Combination-therapies and alternative approaches 
Despite of further attempts to develop even more powerful ʻthird 
generationʼ Bcr-Abl kinase inhibitors and attempts to even target different 
regulatory mechanisms of Bcr-Abl, using drugs like ON012380 that bind non-
ATP competitively (Gumireddy, Baker et al. 2005) or GNF-2 that binds the 
myristate binding pocket (Adrian, Ding et al. 2006; Hantschel, Nagar et al. 2003; 
Ohren and Sebolt-Leopold 2006) or targeting the coiled-coil domain (Beissert, 
Puccetti et al. 2003), different therapeutic options than targeting Bcr-Abl alone 
are clearly needed to overcome resistance (Weinstein and Joe 2006). Already 
during early phase II clinical trials of imatinib, the advent of resistance mutations 
to a single inhibitory agent was foreseen and combinations with conventional 
chemotherapeutic agents such as IFN-α, hydroxyurea (HU), daunorubicin 
(DNR) and cytosine arabinoside (Ara-C) were tested in vitro and showed overall 
synergism in combination with imatinib, motivating clinical trials with these drug 
combinations (Thiesing, Ohno-Jones et al. 2000). Resistance problems together 
with the inability of current Bcr-Abl inhibitors to target leukemia stem cells 
require additional targets that are critical for Bcr-Abl action to be identified and 
exploited for pathway specific combination therapy in order to ultimately result in 
a curative strategy for CML rather than maintaining patients in remission with 
conventional chemotherapy (O'Hare, Corbin et al. 2006; O'Hare, Eide et al. 
2007). Some approaches have already tried to exploit this strategy by 
combining imatinib with drugs that act on potentially critical components of the 
Bcr-Abl signaling pathway such as mTOR (rapamycin) (Mayerhofer, Aichberger 
et al. 2005; Mohi, Boulton et al. 2004), PI3-kinase (wortmannin and LY294002) 
(Chu, Holtz et al. 2004; Klejman, Rushen et al. 2002), cyclin-dependent kinases 
(flavopiridol) (Yu, Krystal et al. 2002), MEK-1 (Chu, Holtz et al. 2004), Raf-1 
(Neshat, Raitano et al. 2000) and farnesyl transferase (SCH66336) (Hoover, 
Mahon et al. 2002; Nakajima, Tauchi et al. 2003), showing promising results in 
vitro. Also, chlorogenic acid (Chl) and sodium chlorogenate (NaChl) alone were 
shown to inhibit Bcr-Abl, which led to activation of p38 MAPK and apoptosis in 
K562 cells (Bandyopadhyay, Biswas et al. 2004). Simultanous targeting of Src 
family kinases Src / Abl inhibitors such as dasatinib together with imatinib 
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showed promising compatibility in vitro and might indeed be a promising 
therapeutic option (O'Hare, Walters, Stoffregen, Sherbenou et al. 2005). Lyn 
tyrosine kinase, shown to be involved in imatinib resistance upon 
overexpression, is being targeted by the inhibitors INNO-406, bosutinib and 
dasatinib (Donato, Wu et al. 2003; Wu, Meng et al. 2008; Yokota, Kimura et al. 
2007). Furthermore, targeted knock-down of Bcr-Abl using breakpoint-specific 
short-interfering RNA (siRNA) represents another approach taken and 
confirmed that reduction of Bcr-Abl protein levels by siRNA is able to sensitize 
for imatinib in Bcr-Abl over-expressing cells and even in a cell line carrying the 
imatinib resistant mutant H396P (Wohlbold, van der Kuip et al. 2003). 
Despite these largely successful and promising efforts to approach the 
suppression of CML by targeted tyrosine kinase inhibitor therapy and alternative 
approaches, Ph+ CML stem cells are left unaffected, because they are residing 
in a dormant state, while the inhibitors are only effectively targeting proliferating 
cells (Clarkson, Strife et al. 2003; Goldman 2004). Therefore, the Ph+ stem cells 
represent an unaffected pool of cells that are able, at any time, to lead to 
disease relapse, especially upon the advent of resistance mutations (O'Hare, 
Corbin et al. 2006). Such resistance mutations are likely to persist in CML stem 
cells throughout long-term tyrosine kinase inhibitor therapy, later leading to 
resistance when these stem cells exit their dormant state and start proliferating. 
For this process, precise mathematical kinetics models have already been 
generated (Michor, Hughes et al. 2005). Therefore, the ultimate goal of curative 
CML therapy must be the inhibition and elimination of Ph+ CML stem cells 
(Shteper and Ben-Yehuda 2001). Besides the only curative strategy so far, 
consisting of bone marrow ablation by chemotherapy or irradiation followed by 
syngeneic or allogeneic bone marrow transplantation (Clarkson, Strife et al. 
2003), alternative stem cell targeting strategies, such as the use of 
differentiating agents like retinoic acid or bryostatin (Lilly, Tompkins et al. 1990), 
need to be identified and applied in addition to prior therapy with conventional 
and targeted therapeutic approaches in a step-wise patient-specific regimen 
(Clarkson, Strife et al. 2003).  
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1.12 Signaling pathway mapping by Tandem Affinity Purification 
coupled to liquid chromatography and tandem mass spectrometry 
(TAP-LC-MSMS) 
Protein – protein signal transduction networks can be mapped using an 
integrated approach comprised of tandem affinity purification (TAP), liquid 
chromatography coupled to tandem mass spectrometry (LC-MSMS) and 
bioinformatic network analysis (Figure 1.5). The TAP procedure is a sensitive 
and highly selective method of purifying, under close-to-physiological conditions 
(Rigaut, Shevchenko et al. 1999), multi-protein complexes formed in vivo by two 
consecutive affinity purification steps (Gavin, Bosche et al. 2002) for 
subsequent analysis by mass spectrometry and was successfully applied to 
map the yeast cellular machinery (Gavin, Bosche et al. 2002). Proteins of 
interest (ʻentry pointsʼ), such as known and candidate interaction partners or 
substrates implicated in the protein complex or signaling pathway under 
investigation are cloned into retroviral transduction vectors using the Gateway® 
technology (Invitrogen) enabling expression of N- or C-terminal TAP-tag fusion 
proteins. The Gateway® cloning technology is convenient for the cloning of large 
numbers of pathway ʻentry pointsʼ, as it circumvents limitations often 
encountered in restriction enzyme based cloning (Walhout, Temple et al. 2000). 
The TAP-tag consists of a tandem immunoglobulin G (IgG)-binding unit of 
protein A from Staphylococcus aureus and a calmodulin binding domain (CBP) 
with a tobacco etch virus (TEV) protease cleavage site between the two affinity 
tags (Rigaut, Shevchenko et al. 1999). Virus stocks containing the coding 
sequences of the N- or C-terminal TAP-tag fusion proteins are generated in a 
HEK293 Gag-Pol packaging cell line (Somia, Miyoshi et al. 2000). Viruses 
obtained from the supernatant of this packaging cell line are then used to infect 
the model expression cell line of choice as target cells, the human leukemia cell 
line K562 in this study (Klein, Ben-Bassat et al. 1976). Upon infection of the 
expression cell line K562 with the “entry point” bait construct, cells are cultured 
and assessed for infection efficiency by FACS, measuring the proportion of 
GFP-positive cells. GFP-positive cells are then FACS-sorted in order to 
establish homogenous cell lines stably expressing the TAP-tagged bait protein. 
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For tandem affinity purification of protein complexes of interest, cells are grown 
to about 2-5x108 cells and lysed in TAP buffer (see Materials and Methods). 
The purification of the TAP-tagged protein and bound interaction partners 
consists of two sequential high-affinity binding and two mild elution steps 
(Figure 1.5A). Using the conventional Gateway® system the protein A moiety is 
first bound to IgG beads and protein complexes are released upon TEV 
protease cleavage. Then, in the second affinity-binding step the Calmodulin 
binding domain (CaM BD) is bound to CaM beads and subsequently eluted with 
EGTA (Ca2+ chelation) (Rigaut, Shevchenko et al. 1999). 
 
 
Figure 1.5 Signaling pathway mapping by Tandem Affinity Purification coupled 
to liquid chromatography and tandem mass spectrometry (TAP-LC-MSMS) 
(A) Proteins of interest (ʻentry pointsʼ) are cloned into retroviral transduction vectors 
using the Gateway® technology (Invitrogen) as N- or C-terminal TAP-tag fusion 
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proteins. Virus stocks containing the coding sequences are generated in a packaging 
cell line and used to infect the target expression cell line of choice. TAP-tagged bait 
protein and bound interaction partners are purified by two sequential high-affinity 
binding and two mild elution steps. Upon binding of the protein G moiety of the tag to 
IgG beads, protein complexes are released by TEV protease cleavage, then the SBP 
moiety is bound to streptavidin beads and protein complexes are either eluted with 
biotin or by boiling in SDS sample buffer (Burckstummer, Bennett et al. 2006). 
(B) A fraction of each TAP sample is separated by 1D-SDS-PAGE and silver stained. 
Entire gel lanes are sliced into a defined number of equal pieces, digested with trypsin 
and analyzed by LC-MSMS. 
(C) Statistically significant bait interactors identified by LC-MSMS, here represented as 
'star'-diagram, are compared to human protein-protein interaction databases (e.g. 
HPRD, IntAct). Annotated interactions are shown as white circles, whereas black 
circles represent novel interactions. 
(D) Computational combination of several TAP purification datasets results in a single 
protein-protein interaction network. 
 
As the yield represented one of the crucial shortcoming of this method 
in mammalian cells, work in our laboratory resulted in an optimization of the 
TAP procedure following optimization of the TAP-tag composition and sequence 
(codon usage) for use in mammalian cells, which resulted in an approximately 
10-fold overall yield increase compared to the conventional TAP system 
(Burckstummer, Bennett et al. 2006). The optimized TAP protocol for use in 
mammalian cells (Burckstummer, Bennett et al. 2006) instead uses a tag based 
on protein G and the streptavidin-binding-peptide (SBP) (GS-TAP). Here upon 
binding of the protein G moiety to IgG beads, protein complexes are released 
upon TEV protease cleavage, then the SBP is bound to streptavidin beads and 
protein complexes are either eluted with biotin or by boiling in SDS sample 
buffer.  
Following TAP, eluted protein complexes are separated by 1D-SDS-
PAGE, the entire gel lane is sliced into sections, in situ - digested with trypsin 
and analyzed by data-dependent nanocapillary reversed-phase LC-MSMS 
(Figure 1.5B). Proteins are identified by automated searching of the human IPI 
protein database (Kersey, Duarte et al. 2004) and, following at least two 
technical repeats of the TAP purification, identified proteins are analyzed for 
their statistical consistency and significance (Figure 1.5C). Finally, the data sets 
of multiple TAP purifications are combined in the bioinformatic analysis of the 
interaction network (Figure 1.5D) (as described in (Bouwmeester, Bauch et al. 
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2004) (for details see Materials and Methods). The raw data set of interactions 
can be filtered either against reference TAP purifications or a ʻcore proteomeʼ 
(Schirle, Heurtier et al. 2003) of the cell line used, representing a defined list of 
the most prevalent proteins in the cell line, usually representing cytoskeletal 
proteins and proteins of general housekeeping function. This allows for the 
identification of proteins specifically enriched in the TAP-purifications by 
comparing TAP versus ʻcore proteomeʼ datasets applying SAM statistical tests 
(Tusher, Tibshirani et al. 2001). In the past, the TAP procedure has been 
successfully used for small- and large-scale purification of protein complexes in 
bacteria and eukaryotic cells (Rigaut, Shevchenko et al. 1999) (Puig, Caspary et 
al. 2001) (Westermarck, Weiss et al. 2002) (Veraksa, Bauer et al. 2005). The 
TAP-LC-MSMS pathway mapping approach therefore enables the fast mapping 
of protein - protein interaction networks in eukaryotic cells (Brajenovic, Joberty 
et al. 2004; Drewes and Bouwmeester 2003; Gavin, Aloy et al. 2006; Gavin, 
Bosche et al. 2002) and has been successfully used in human cell lines before, 
for instance, to map the TNF-α signaling pathway that results in activation of the 
NF-κB family of transcription factors (Bouwmeester, Bauch et al. 2004). 
 
1.13 Quantitative proteomics 
As biological processes are exerted by proteins complexed in protein 
machines (Gavin, Bosche et al. 2002), quantitative proteomics analysis of the 
abundance of an entire proteome or at least of the proteins involved in the 
biological process under investigation represents a crucial layer of information 
to understand those processes. While DNA chip based quantitative 
transcriptomics studies are powerful in quantifying mRNA levels, quantitative 
proteomics methods provide a more direct measure of the quantities and 
characteristics of proteins (Ong and Mann 2005). When it comes to the 
understanding of the “logic” of a signal transduction pathway, quantitative 
parameters, like cellular protein copy number and protein complex 
stoichiometry, represent advantageous information in addition to the qualitative 
(physical and functional) description of participating proteins and their 
interactions and enrich the predictive value of the analysis for the development 
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of pharmacological intervention strategies (Kolch, Calder et al. 2005; Papin, 
Hunter et al. 2005). Quantitative protein chip technology suffers from the 
limitations of antibody availability and specificity, whereas MS-based 
approaches are thought to be the most powerful approach to quantitative 
proteomics (Ong and Mann 2005). Several MS-based experimental tools have 
been developed in order to facilitate this transition towards more quantitative 
proteomics (Ong and Mann 2005). These can be divided into into (i) absolute 
quantification methods that measure the absolute amount of protein in the 
sample, whereas (ii) relative quantification strategies focus on the relative 
change in protein amounts between two states (e.g. time points). 
A straightforward absolute quantification method named XIC (extracted 
ion chromatogram) allows extracting quantitative information directly from mass 
spectra. Here, the signal intensity of a peptide eluting from a chromatographic 
column is plotted over time and the area under the curve (XIC) is linearly related 
to the amount of the peptide. While this approach suffers from various 
limitations related to the differing physico-chemical properties of individual 
proteins or peptides, more accurate ʻprotein abundance indicesʼ (PAI) have 
been developed to normalize the XICs for the individual proteinʼs characteristics 
(Andersen, Wilkinson et al. 2003). Overall however, MS-based quantification 
strategies using stable isotope labeling turned out to be advantageous. Here, 
labeling of peptides with stable isotopes (preferably 13C and 15N) introduces a 
defined mass difference between the heavy versus the unlabeled peptide from 
two experimental conditions (Zhang and Regnier 2002). A straightforward 
absolute quantification technique (AQUA) uses known quantities of chemically 
synthesized stable isotope-labeled peptides spiked into samples as internal 
standards (Kusmierz, Sumrada et al. 1990). Although AQUA suffers from the 
limitation that suitable peptide markers have to be identified, it can be 
successfully used at small or medium scale to quantify proteins and 
phosphoproteins from cells lysates (Gerber, Rush et al. 2003) and is applicable 
to identify biomarkers in body-fluids (Kuhn, Wu et al. 2004).  
Relative protein quantification can be accomplished by stable isotope 
labeling by amino acids in cell culture (SILAC), a simple and powerful protocol 
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for metabolic incorporation of stable isotopes (Amanchy, Kalume et al. 2005), 
where an essential stable isotope labeled amino acid is supplied in the growth 
media upon which it is introduced into each newly synthesized protein of the 
proteome (Ross, Huang et al. 2004). Upon comparison of the labeled to the 
unlabeled reference sample, each peptide pair of the entire proteome is 
separated by the mass difference corresponding to the introduced labeled 
amino acid (Ong, Blagoev et al. 2002). This technique increases the feasibility 
of large-scale quantifications (entire proteomes) (Aebersold 2003; Aebersold 
and Mann 2003; Beynon, Doherty et al. 2005). Chemical tagging-based 
approaches like ʻisotope-coded affinity tagʼ (ICAT) (Gygi, Rist et al. 1999), 
where stable isotope-carrying chemical reagents are targeted towards a 
reactive functional group of a peptide, are an attractive alternative. The ICAT 
reagent contains a reactive group targeting cysteins specifically and a biotin 
group for purification of labeled peptides via an avidin column. The heavy ICAT 
reagent features a polyether linker region containing eight deuteriums and 
allows quantification next to the ʻlightʼ reference sample. However, as only 
cysteine containing peptides are labeled and isolated, the lack of cysteine in 
proteins and peptides represents a major limitation.  
Another approach to relative protein quantification, ʻisobaric tag for 
relative and absolute quantitationʼ (iTRAQ), uses four tags that generate 
specific reporter ions of 114, 115, 116 and 117Da mass in their respective 
fragmentation spectra but, via a carbonyl balance group, finally add up to the 
same mass (Ross, Huang et al. 2004; Wiese, Reidegeld et al. 2007). Upon 
proteolytical digest, peptides are labeled with either one of the four isobaric 
isotope-coded tags via their lysine side chains, the four samples are combined, 
peptides are separated by liquid chromatography coupled to mass spectrometry 
(LC-MSMS) and peptides are detected, distinguishable by the tag-specific mass 
reporter ion. Relative quantification is then accomplished by calculation of the 
ratios of the four reporter signal intensities (Unwin, Pierce et al. 2005). This 
multiplexing strategy allows analysis of four separately labeled protein samples 
within one single analysis, thereby helping to increase analytical throughput 
(Bantscheff, Eberhard et al. 2007; Unwin, Pierce et al. 2005). The method has 
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been further expanded to 8-plex relative quantification proteomics and was, as 
an example, successfully applied to compare the activities of six leukemogenic 
tyrosine kinases, including Bcr-Abl, as regards their effect on the proteome 
(Pierce, Unwin et al. 2008). The complexity of the proteome including splice 
isoforms and post-translational modifications (PTMs) in concordance with the 
complex functional implication of proteins in biological processes calls for the 
use of these accurate and multiplexed quantitative proteomics tools in order to 
update a proteinʼs function and position within a physical interaction network 
with quantitative information about its interaction partners, ideally in a temporal 
dimension (Ong and Mann 2005). 
 
1.14 Aim of the thesis 
Despite decades of work on the oncogenic Bcr-Abl protein and its 
signaling properties, the following fundamental questions on the cellular 
mechanism of action of the endogenous drug target Bcr-Abl are still open: 
- What are the critical effectors of Bcr-Abl? 
- Is it possible to derive a comprehensive and coherent map of Bcr-Abl 
signaling in a defined, standardized cellular setting? 
- In the light of resistance problems with current small-molecule inhibitors, is 
it possible to identify pivotal elements in the Bcr-Abl pathway that could 
represent potential targets for alternative or combination therapy? 
 
Aware of these unresolved fundamental questions and the existing 
extensive, but heterogeneous data on Bcr-Abl interacting proteins, substrates 
and downstream signaling components, the aim of this study was to  
- undertake a systematic and unbiased approach to study Bcr-Abl signaling 
with the aim to  
- complement the diverse existing data and provide a more consolidated 
view on actual set-up of the endogenous drug-target Bcr-Abl in a defined 
cellular setting, within the long-term interest to 
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- identify signatures of molecular endpoints of Bcr-Abl signaling useful to 
address unresolved resistance problems to first and second-generation 
anti-Bcr-Abl tyrosine kinase inhibitors, to monitor drug effectiveness and 
disease progression and to provide a rationale for combination therapy. 
 
We decided to use K562 cells as a defined cellular setting for 
purification of protein complexes by large-scale immunoprecipitation and TAP-
LC-MSMS (Bouwmeester, Bauch et al. 2004) in order to generate a physical 
map of the Bcr-Abl signaling pathway upon statistical analysis of significantly 
interacting proteins and bioinformatic network modeling. Herein, we planned to 
concentrate on the immediate interactors of Bcr-Abl in order to define the Bcr-
Abl ʻcoreʼ complex (Gavin, Aloy et al. 2006), (Tong, Drees et al. 2002), which is 
thought to consist of Bcr-Abl itself and its most intimately associated 
stoichiometric protein binders. For Bcr-Abl and its ʻcoreʼ interactors, we 
furthermore planned to introduce quantitative parameters by determining the 
absolute cellular copy numbers and the ʻcoreʼ complex interaction stoichiometry 
in order to enable the development of an interaction model and to set the 
foundation for a quantitative analysis of Bcr-Abl signaling. Finally, we decided to 
characterize the Bcr-Abl ʻcoreʼ complex further by studying the effects of siRNA 
knock-down of its components on the proliferative potential of K562 cells and by 
monitoring the consequences of tyrosine kinase inhibitor perturbation on the 
composition of the Bcr-Abl ʻcoreʼ complex. 
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2 MATERIALS AND METHODS 
2.1 DNA constructs 
cDNAs were obtained from RZPD (Crk-I, Grb2, Sts-1, Eps15, AP2µ1), 
OriGene Technologies (Shc-1, p85β) or kindly provided by S. Decker (SHIP-2) 
and B. Mayer (c-Cbl). p210Bcr-Abl was a kind gift from Owen Witte and pSGT-
Abl and -Bcr-Abl constructs were generated in our lab using standard molecular 
cloning techniques and described before (Barilá and Superti-Furga 1998; Pluk, 
Dorey et al. 2002). 
The cDNAs were amplified by PCR and cloned into the respective destination 
vectors for expression as N-or C-terminal fusions to the tandem affinity 
purification cassette using the Gateway cloning system (Invitrogen, Carlsbad, 
CA) (Burckstummer, Bennett et al. 2006). pETM30 and pETM41 vectors were 
used for expression of recombinant epitope standard proteins as His-GST or 
His-MBP fusion proteins, respectively, using standard molecular biology 
techniques. The pETM30 vector was a kind gift of Gunther Stier (EMBL 
Heidelberg) and the pETM41 vector was obtained from the EMBL Protein 
Expression and Purification Facility. Constructs cloned as His-GST-fusion 
proteins in pETM30 were Crk-I (full-length, residues 1-204), Grb2 (full-length, 
residues 1-217), p85β RhoGAP-domain (residues 102-307), Shc1 SH2-domain 
(residues 358-474) and the Sts-1 C-terminus (residues 636-649). Constructs 
cloned as His-MBP-fusion proteins in pETM41 were the c-Cbl UBA-domain 
(residues 853-906) and the Ship2 SAM-domain (residues 1184-1258). Point 
mutations were obtained using the quick-change site directed mutagenesis kit 
(Stratagene). All cloned vectors and mutations were confirmed by sequencing.  
The table below gives and overview of the constructs I generated during the 
time of my thesis: 
Maxi # Vector Insert Comments 
2254 pDONRT201 p210 Bcr-Abl Gateway, TAP entry vector, CTAP 
2255 pDONRT201 p210 Bcr-Abl Gateway, TAP entry vector, NTAP 
2256 pRVCTAP-CZ69 p210 Bcr-Abl Gateway, TAP destination vector, CTAP, clone #3.1 
2257 pRVCTAP-CZ69 p210 Bcr-Abl Gateway, TAP destination vector, CTAP, clone #3.2 
2297 pPinco-Tet p210 Bcr-Abl Tet-inducible 
2303 pRVNTAP-GS p210 Bcr-Abl Gateway TAP destination vector, NTAP-GS 
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2325 pRVNTAP-GS Pxn Gateway, TAP destination vector, NTAP-GS 
2326 pRVCTAP-SG Akt1 Gateway, TAP destination vector, CTAP-SG 
2335 pRVCTAP-SG Dok2 Gateway, TAP destination vector, CTAP-SG 
2336 pRVCTAP-SG Fes Gateway, TAP destination vector, CTAP-SG 
2337 pRVCTAP-GS Hck Gateway, TAP destination vector, CTAP-GS, GSGS linker 
2338 pRVNTAP-GS Shp2 Gateway, TAP destination vector, NTAP-GS 
2353 pDONRT201 Akt1 Gateway, TAP entry vector, CTAP 
2354 pDONRT201 Dok2 Gateway, TAP entry vector, CTAP 
2355 pDONRT201 Fak Gateway, TAP entry vector, CTAP 
2356 pDONRT201 Fes Gateway, TAP entry vector, CTAP 
2357 pDONRT201 Hck Gateway, TAP entry vector, CTAP 
2358 pDONRT201 Myc Gateway, TAP entry vector, NTAP 
2359 pDONRT201 Pxn Gateway, TAP entry vector, NTAP 
2360 pDONRT201 Shp2 Gateway, TAP entry vector, NTAP 
2361 pDONRT201 p210 Bcr-Abl Gateway, TAP entry vector, with start and stop codons 
2421 pETM-30 Grb2_1-217 N-6His-GST-Grb2 recombinant epitope standard, full length 
2422 pETM-30 c-Cbl_853-906 N-6His-GST-c-Cbl recombinant epitope standard, C' UBA 
2423 pETM-30 c-Cbl_721-906 N-6His-GST-c-Cbl recombinant epitope standard, C' UBA 
2428 pRVNTAP-GS Myc Gateway, TAP destination vector, NTAP-GS 
2429 pRVCTAP-SG Fak Gateway, TAP destination vector, CTAP-SG 
2430 pRVNTAP-GS Nck Gateway, TAP destination vector, NTAP-GS 
2432 pRVCTAP-SG Crk-II Gateway, TAP destination vector, CTAP-SG 
2457 pRVNTAP-GS c-Cbl Gateway, TAP destination vector, NTAP-GS 
2458 pRVNTAP-GS Sts-1 Gateway, TAP destination vector, NTAP-GS 
2459 pDONRT201 c-Cbl Gateway, TAP entry vector 
2460 pDONRT201 Crk-II Gateway, TAP entry vector, CTAP 
2461 pDONRT201 Sts-1 Gateway, TAP entry vector 
2466 pETM-30-XhoI - N-6His-GST, TEV, NcoI mutagenized to XhoI 
2470 pRVNTAP-GS p85β Gateway, TAP destination vector, NTAP-GS 
2471 pRVNTAP-GS Shc1 Gateway, TAP destination vector, NTAP-GS 
2472 pRVNTAP-GS PSTPIP1 Gateway, TAP destination vector, NTAP-GS 
2473 pRVCTAP-SG PKCδ Gateway, TAP destination vector, CTAP-SG 
2489 pETM-30-XhoI Shc1_358-474 N-6His-GST-Shc1 recombinant epitope protein standard 
2497 pRVNTAP-GS/2xT Ship2 Gateway, TAP destination vector, NTAP-GS, 2xTEV 
2498 pRVCTAP-SG/2xT Ship2 Gateway, TAP destination vector, CTAP-SG, 2xTEV 
2500 pDONRT201 Ship2 Gateway, TAP entry vector, NTAP 
2501 pDONRT201 Ship2 Gateway, TAP entry vector, CTAP 
2502 pDONRT201 p85β Gateway, TAP entry vector, NTAP 
2518 pETM-30 Ship2_2-108 N-6His-GST-Ship2 recombinant epitope standard, N' SH2 
2688 pETM-30 p85β_619-728 N-6His-GST-p85β recombinant epitope standard, C' SH2 
2689 pETM-30 Sts-1_254-322 N-6His-GST-Sts-1 recombinant epitope standard, SH3 
2690 pETM-30 Crk-II_1-304 N-6His-GST-Crk-II recombinant epitope standard, full 
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length 
2718 pETM-30 Ship2_1193-1258 N-6His-GST-Ship2 recombinant epitope standard, C'SAM 
2719 pETM-30 Ship2_1190-1258 N-6His-GST-Ship2 recombinant epitope standard, C'SAM 
2720 pETM-30 Ship2_1184-1258 N-6His-GST-Ship2 recombinant epitope standard, C'SAM 
2722 pRVCTAP-SG/2xT Bcr-Abl-TEV Gateway, TAP destination vector, CTAP-SG, 2xTEV, 
p210 Bcr-Abl C' TEV - FABD 
2723 pRVCTAP-SG/2xT ΔCC-Bcr-Abl-TEV Gateway, TAP destination vector, CTAP-SG, 2xTEV, 
Δcoiled-coil p210 Bcr-Abl, C' TEV - FABD 
2738 pDONRT201 Bcr-Abl-TEV Gateway, TAP entry vector, CTAP, p210 Bcr-Abl 
2739 pDONRT201 ΔCC-Bcr-Abl-TEV Gateway, TAP entry vector, CTAP, Δcoiled-coil p210 Bcr-
Abl, Cʼ TEV - FABD 
2791 pDONRT201 Shc1 Gateway, TAP entry vector, NTAP 
2804 pETM-30 p85β_1-154 N-6His-GST-p85β recombinant epitope standard, N' SH3 
2828 pDONRT201 AP2µ1 Gateway, TAP entry vector, NTAP 
2829 pRVNTAP-GS/2xT AP2µ1 Gateway, TAP destination vector, NTAP-GS, 2xTEV 
2830 pDONRT201 Eps15 Gateway, TAP entry vector, NTAP 
2831 pRVNTAP-GS/2xT Eps15 Gateway, TAP destination vector, NTAP-GS, 2xTEV 
2832 pDONRT201 Eps15 Gateway, TAP entry vector, CTAP 
2833 pRVCTAP-SG/2xT Eps15 Gateway, TAP destination vector, CTAP-SG, 2xTEV 
2860 pMSCV-GW Bcr-Abl-TEV Gateway, p210 Bcr-Abl, C' TEV - FABD 
2861 pMSCV-GW ΔCC-Bcr-Abl-TEV Gateway, Δcoiled-coil p210 Bcr-Abl, C' TEV - FABD 
2874 pETM-30 Sts1_636-649 N-6His-GST-Sts-1 recombinant epitope standard, C' 
peptide 
3049 pETM-41 Crk-L_1-303 N-6His-MBP-Crk-L recombinant epitope standard, full 
length 
3205 pRVCTAP-SG/2xT Crk-I Gateway, TAP destination vector, CTAP-SG, 2xTEV 
3275 pETM-41 Ship2_1184-1258 N-6His-MBP-Ship2 recombinant epitope standard, C' 
SAM 
3279 pDONRT201 Crk-I Gateway, TAP entry vector, CTAP 
3782 pETM-30 p85β_102-310 N-6His-GST-p85β recombinant epitope standard, 
RhoGAP 
3783 pETM-41 c-Cbl_853-906 N-6His-MBP-c-Cbl recombinant epitope standard, C' UBA 
3784 pETM-30 Crk-I_1-204 N-6His-GST-Crk-I recombinant epitope standard, full 
length 
 
2.2 Antibodies and epitopes 
Antibodies used included: Abl (mouse monoclonal 24-21, Ab-3, 
Calbiochem), Abl (rabbit polyclonal, K-12, Santa Cruz), Ship2 (rabbit polyclonal, 
kind gift by D. Wisniewski), c-Cbl (rabbit polyclonal, produced in-house against 
recombinant c-Cbl UBA domain), Grb2 (rabbit polyclonal, C-23, Santa Cruz) 
and Grb2 (mouse monoclonal, clone 81, BD), c-Crk (mouse monoclonal, clone 
22, BD), CrkL (mouse monoclonal, #05-414, Millipore), Shc-1 (mouse 
monoclonal, clone 30, BD), Sts-1 (rabbit polyclonal, Rockland Inc.), p85β   
(mouse monoclonal, clone T15, AbD-Serotec), Sos 1 (mouse monoclonal, A-9, 
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Santa Cruz) and GST antiserum (rabbit polyclonal, Z-5, Santa Cruz). The table 
below indicates the detailed conditions the antibodies were used with during this 
study. 
 
 
The epitope of the 24-21 antibody directed against the C-terminal F-
actin binding domain of Bcr-Abl / c-Abl and used for large-scale 
immunoprecipitation of Bcr-Abl / c-Abl complexes was mapped by generating a 
series of mutants covering most surface exposed residues of the Abl F-actin 
binding domain (1026-1149) (Hantschel, Wiesner et al. 2005). The mutants 
were expressed in E. coli as recombinant GST-fusion proteins, purified to 
homogeneity and 5µg of each mutant recombinant fusion protein were 
immunoblotted against Abl FABD (24-21) and GST. Protein levels were 
quantified and protein recognition was monitored as ratio of 24-21- over GST-
signal. Only mutation of residues Q1094, Q1095 and M1096 showed reduced 
binding of 24-21 of about 50%. 
The table below summarizes the details of the antibodies used for 
quantifications and co-immunoprecipitation studies and indicates the regions of 
the protein within which the antibody epitope resides. 
  
2nd Ab (AlexaFluor-680/-800)
(1:7000, 0.1% Tween in 1x PBS)
Bcr-Abl/c-Abl Calbiochem Ab-3 (21-24) mouse 1:2000 3% BSA, 0.1% Tween in 1x PBS goat anti-mouse
Bcr-Abl/c-Abl Santa Cruz K-12 rabbit 1:500 5% Milk, 0.1% Tween in 1x PBS goat anti-rabbit
Ship2 D. Wisniewski - rabbit 1:2500 Odyssey blocking buffer (Li-Cor) goat anti-rabbit
c-Cbl this study #3377/#3378 rabbit 1:1000 Odyssey blocking buffer (Li-Cor) goat anti-rabbit
p85! AbD-Serotec T15 mouse 1:1000 5% Milk, 0.1% Tween in 1x PBS goat anti-mouse
Sts-1 Rockland Inc. 600-401-870 rabbit 1:1000 5% Milk, 0.1% Tween in 1x PBS goat anti-rabbit
Sts-1-IRDye-800 this study 600-401-870 rabbit 1:1000 5% Milk, 0.1% Tween in 1x PBS -
Shc1 BD 30 mouse 1:1000 5% Milk, 0.1% Tween in 1x PBS goat anti-mouse
Shc1-IRDye-800 this study 30 mouse 1:500 5% Milk, 0.1% Tween in 1x PBS -
Grb2 BD 81 mouse 1:1000 Odyssey blocking buffer (Li-Cor) goat anti-mouse
Grb2-IRDye-800 this study 81 mouse 1:250 Odyssey blocking buffer (Li-Cor) -
Grb2 BD C-23 rabbit 1:500 5% Milk, 0.1% Tween in 1x PBS goat anti-rabbit
Crk-I/II BD 22 mouse 1:500 Odyssey blocking buffer (Li-Cor) goat anti-mouse
Crk-I/II-IRDye-800 this study 22 mouse 1:250 Odyssey blocking buffer (Li-Cor) -
CrkL Millipore #05-414 mouse 1:5000 Odyssey blocking buffer (Li-Cor) goat anti-mouse
Sos 1 Santa Cruz A-9 mouse 1:500 Odyssey blocking buffer (Li-Cor) goat anti-mouse
GST Santa Cruz Z-5 rabbit 1:2000 5% Milk, 0.1% Tween in 1x PBS goat anti-rabbit
Antibody (Ab) ID Species Dilution Blocking & 1st AbSupplier
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Primary antibodies were detected with AlexaFluor-680 labeled goat anti-
mouse or goat anti-rabbit secondary antibodies, detected using the Odyssey 
imaging system (Li-Cor Biosciences, Lincoln, NE, USA). Primary Antibodies 
used for detection of Grb2 and Crk-I, that migrate at the apparent molecular 
weight (MW) of IgG-light chain and antibodies against Shc1 and Sts-1, 
migrating within the MW - range of IgG-heavy chain, were directly labeled with 
the IRDye® 800CW microscale protein labeling kit (Li-Cor® Biosciences) in order 
to avoid cross-reaction of fluorescent secondary antibodies with IgG-light and -
heavy chains. Grb2, c-Crk and Shc1 antisera (BD Biosciences) were depleted 
from BSA that would compete with antibody primary amine groups and lead to 
reduced labeling efficiency. For BSA removal, 400µl of antibody (100µg) were 
incubated with 50µl bed-volume proteinG-sepharose, pre-washed in ʻbinding 
bufferʼ (20mM Na2PO4 pH 7.0), for 2hrs at 4°C. The beads were transferred to 
MoBiCon columns and washed with ʻbinding bufferʼ. Antibodies were then 
eluted in 100µl ʻelution bufferʼ (0.1M glycine-HCl pH 2.7) and neutralized with 
10µl ʻneutralization bufferʼ (1M Tris pH 10.0), yielding a final antibody 
concentration of 1µg/µl, depleted of BSA. BSA-free Grb2, c-Crk, Shc and Sts-1 
antisera were dialyzed in Na2PO4 pH 8.5 and fluorescently labeled with IRDye® 
800CW by addition of 0.8µl of reconstituted dye to 100µg (100µl) of antibody. 
Following incubation in the dark at room temperature for 2hrs, dye-conjugated 
antibody was separated from free dye by passing the sample through 0.5ml 
ZebaTM desalting spin columns (Pierce, Rockford, IL). 
 
Antibody ID Supplier Species IgG type Epitope region
c-Abl / Bcr-Abl Ab-3 (21-24) Calbiochem mouse monoclonal IgG FABD residues Q1094,Q1095,M1096
c-Abl / Bcr-Abl K-12 Santa Cruz rabbit polyclonal IgG kinase - domain
Ship2 - D. Wisniewski rabbit polyclonal IgG SAM - domain, residues D1230 - K1247
c-Cbl #3377/#3378 this study rabbit polyclonal IgG UBA - domain, residues A853 - T906
p85! T15 AbD-Serotec mouse monoclonal IgG1 RhoGAP - domain, residues D122 - L292
Sts-1 600-401-870 Rockland Inc. rabbit polyclonal IgG C' peptide, residues P636 - E649
Shc1 30 BD mouse monoclonal IgG1 SH2 - domain, residues L359 - K473
Grb2 81 BD mouse monoclonal IgG1 full length protein
Grb2 C-23 Santa Cruz rabbit polyclonal IgG C-terminal peptide
Crk-I 22 BD mouse monoclonal IgG2a residues E102 - N204 (- S304 of Crk-II)
Sos 1 A-9 Santa Cruz mouse monoclonal IgG2b residues Q1057 - S1178
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2.3 Cell culture, tyrosine kinase inhibitor treatment, immuno -
precipitation and immunoblot assays 
K562 (DSMZ #ACC 10) cells were grown in RPMI-1640, 10% fetal calf 
serum, 1% penicillin/streptomycin. Dasatinib (Sprycel, BMS-354825) and 
nilotinib (Tasigna, AMN107) were dissolved in DMSO and used at final 
concentrations of 100nM and 1µM, respectively. K562 cells were mock-, 
dasatinib- or nilotinib - treated at the indicated concentrations for 3 hours. K562 
total cell lysates for immunoprecipitation and immunoblot experiments were 
prepared by washing cells in ice-cold PBS and lysed in ʻlysis bufferʼ containing 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA, 
25 mM NaF, 1mM Na3VO4, 1mM PMSF, 5µg/ml TLCK, 1µg/ml leupeptin, 
1µg/ml aprotinin, 10µg/ml soybean trypsin inhibitor. K562 total cell lysates for 
tandem affinity purification and ʻlarge-scaleʼ immunoprecipitation were prepared 
in ʻTAP lysisʼ buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5% glycerol, 0.2% 
NP-40, 1.5 mM MgCl2, 25 mM NaF, 1 mM Na3VO4 and protease inhibitors) 
(Burckstummer, Bennett et al. 2006; Hantschel, Rix et al. 2007). Insoluble 
material was removed by high-speed centrifugation and protein concentration 
was determined by Bradford-assay using γ-globulin as reference standard 
(Biorad). For immunoprecipitation, total cell lysates were incubated with the 
antibodies for 3 hrs at 4°C followed by pull-down of the immune-complexes by 
protein G-SepharoseTM 4 Fast Flow (GE Healthcare) for 1 h at 4°C. Immunoblot 
assays were routinely performed by blotting proteins separated by SDS-PAGE 
on nitrocellulose membranes (Schleicher & Schuell) for 1 h at 1mA/cm2.  The 
membranes were blocked and incubated with primary antibody diluted in 
convenient blocking buffer (3% BSA – PBS - 0.1% Tween, 5% Milk – PBS - 
0.1% Tween or Li-Cor blocking reagent).  We then incubated the membranes 
using IRDye680- or IRDye800-coupled goat anti-rabbit or rabbit anti-mouse 
secondary antibodies at 1:7000 dilution in PBS-Tween (1x PBS, 0.1% Tween in 
H2O) for detection using the Odyssey fluorescent imaging system (Li-Cor). 
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2.4 Large-scale immunoprecipitation of endogenous protein 
complexes of Bcr-Abl and its stoichiometric candidate ʻcoreʼ 
interactors 
For large-scale immunoprecipitation of endogenous protein complexes 
from K562 cells, c-Abl-, Sos-1, Ship2-, c-Cbl-, p85β-, Sts-1-, Shc1-, Grb2- and 
c-Crk(-I/II) antibodies were coupled to NHS-activated sepharose as follows:  
 c-Abl (21-24) antibody was first affinity purified on an Äkta FPLC using 
HiTRAP ProteinG HP 1ml sepharose columns (Amersham). c-Abl antibody 
aliquots were centrifuged at 14,000rpm for 15min to remove antibody 
aggregates, diluted at a 1:10 ratio in ʻbinding bufferʼ (20mM Na2PO4 pH 7.0), 
loaded onto the proteinG column equilibrated in ʻbinding bufferʼ, washed with 
ʻbinding bufferʼ, eluted with a pH-shift by applying ʻelution bufferʼ (0.1M glycine-
HCl pH 2.7) and collected in 250µl fractions. Elution fractions were collected in 
a 96-well plate with 25µl ʻneutralization bufferʼ (1M Tris-HCl pH 9.0) provided 
per well. Elution fractions corresponding to high protein content were pooled 
and checked by immunoblotting. Ship2 antibodies were purified from the 
antiserum kindly provided by David Wisniewski by adding 100µl bed-volume 
Protein G SepharoseTM (4 Fast Flow, GE Healthcare) (PGS), pre-washed in 
ʻbinding bufferʼ, to 600µl serum and incubation for 2hrs at 4°C. The beads were 
transferred to MoBiCon columns and washed twice with 1ml ʻbinding bufferʼ, 
followed by elution with 200µl ʻelution bufferʼ and neutralization with 20µl 
ʻneutralization buffer. Shc1 and c-Crk antibodies (BD Biosciences) were 
depleted from BSA as described for fluorescent labelling with IRDye800CW, 
prior to NHS-sepharose coupling (see section 3.2). c-Abl, Ship2, c-Cbl, Sts-1, 
Shc1 and c-Crk antibodies were then dialyzed twice in 2ltrs 1x PBS at 4°C. 
Grb2 (C-23, Santa Cruz), p85β, c-Cbl and Sos-1 (A-9, Santa Cruz) antibodies 
were directly used for coupling, without prior purification nor dialysis. Prior to 
coupling, 500µl bed-volume NHS-sepharose beads were activated by addition 
of an excess (about 15ml) of 1mM HCl pH3.0 and protonization of the NHS 
ester groups. The HCl was removed by centrifugation and the beads were 
mixed with about 100µg antibody and incubated on a rotary incubator for 2hrs at 
room temperature. Upon completion of the coupling, the antibody beads were 
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recovered by centrifugation and un-reated ester-groups were saturated with an 
excess (10ml) 100mM Tris pH8.0 over night at 4°C. The next morning, the Tris 
was removed by centrifugation and ion-bonded interactors were washed off the 
antibody beads by three consecutive washing steps, alternating between 
100mM Tris pH8.0 and 100mM Acetate pH4.0. The covalently coupled antibody 
beads were then stored as 50% slurry in 1x PBS containing 0.03% NaN3 until 
use. 
For immunoprecipitation, 1*109 K562-cells were harvested and lysed in 
TAP lysis buffer (see section 3.5) (Burckstummer, Bennett et al. 2006), cleared 
by high-speed centrifugation at 27,500rpm for 1h and incubated with respective 
antibodies covalently coupled to NHS-Sepharose beads at 4 °C for 6 hrs. For 
purification of Bcr-Abl / c-Abl complexes we used 250µl bed-volume and for 
purification of Bcr-Abl interactors we used 75µl bed-volume of antibody beads. 
Bcr-Abl large-scale immunoprecipitations were performed in triplicates from 
mock- and dasatinib-treated cells. Bcr-Abl large-scale immunoprecipitations for 
analysis by iTRAQ quantification were perfomed once, from mock- and 
dasatinib- and from mock- and nilotinib treated cells, each. Large-scale 
immunoprecipitations of Grb2 for iTRAQ quantification and of Bcr-Abl 
interactors were performed once from mock- and nilotinib treated cells, each. 
We washed bound proteins with TAP lysis buffer. Bcr-Abl / c-Abl protein 
complexes for analysis by gel-base LC-MSMS were eluted several times with 
one column volume 1% SDS. Bcr-Abl / c-Abl protein complexes and protein 
complexes of the candidate Bcr-Abl ʻcore complexʼ interactors Ship2, c-Cbl, 
p85β, Sts-1, Shc1, Grb2 and Crk-I for analysis by 1D-shotgun LC-MSMS and 
for relative iTRAQ quantification by MALDI-TOFTOF MS, protein complexes 
were transferred to a buffer free of amines and detergent (50mM HEPES NaOH 
pH 7.5, 5% Glycerol, 150mM NaCl and 1.5mM MgCl2) via a second washing 
step. These protein complexes were then eluted several times with one column 
volume of 150mM HCl and neutralized with triethylammonium bicarbonate at a 
final concentration of 200mM. To assess the efficiency of the elution, we boiled 
the remaining antibody-beads in SDS sample buffer. We assessed performance 
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of the large-scale immunoprecipitations and final yield of protein complexes by 
immunoblot analysis of the respective purification fractions. 
 
2.5 Generation of stable transgenic cell lines and Tandem Affinity 
Purification (TAP) 
K562 cells stably expressing NTAP- or CTAP-fusion entry point proteins 
were generated by stable transduction by retroviral gene transfer 
(Bouwmeester, Bauch et al. 2004). Tandem affinity purifications were performed 
as described earlier (Burckstummer, Bennett et al. 2006) (for details see section 
1.12).  
 
2.6 Mass Spectrometry and Bioinformatics 
 All mass-spectrometric analysis described in sections 3.6.1, 3.6.2 and 
3.6.5 was performed by our mass spectrometry group at CeMM, headed by 
Keiryn Bennett with the valuable assistance of Gregor Schütze, Melanie 
Planyavsky and André Müller. André Müller was critically involved in the 
processing of the 1D-shotgun samples (section 3.6.5). Relative quantification 
studies by iTRAQ mass-spectrometry were performed by Thomas Köcher and 
Karl Mechtler at the IMP, Vienna (see section 3.6.6). All bioinformatics analysis 
described in sections 3.6.3 and 3.6.4 was performed by our bioinformatics team 
at CeMM, headed by Jacques Colinge. 
In brief, proteins were separated by SDS-PAGE, visualized by silver- or 
Coomassie staining, entire gel lanes were sliced into pieces, digested in situ 
with trypsin, purified, concentrated and analyzed by nano-LC-MSMS. Tryptic 
digests were analyzed by data-dependent nanocapillary reversed-phase LC-
MSMS and proteins were identified by automated database searching. Proteins 
significantly enriched in the large-scale immunoprecipitations were identified by 
statistical analysis that resulted in a list of 18 candidate Bcr-Abl ʻcore complexʼ 
components. Of these 18, nine representative components were used for TAP 
experiments. Using a different statistical analysis, proteins significantly 
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identified in the TAP experiments were determined and network modeling 
resulted in the generation of the Bcr-Abl signaling network. 
 
2.6.1 Sample preparation for mass spectrometry and in situ tryptic 
digestion 
Tandem affinity purification (TAP), large-scale immunoprecipitate (IP) 
samples and the total cell lysate of wild-type K562 cells (50 mg total protein) in 
4× Laemmli buffer (containing 10% b-mercaptoethanol) were boiled for 3 min, 
cooled to room temperature and alkylated by incubation with iodoacetamide 
(final concentration, 13 µg/µL) for 20 minutes in the dark.  Reduced and 
alkylated samples were separated by 1D SDS-PAGE on a 4 – 12% bis-Tris gel 
(NuPAGE, Invitrogen, CA). After visualisation of the proteins by silver staining 
(TAP) (Shevchenko, Wilm et al. 1996), or Coomassie Brilliant Blue G Colloidal 
(Sigma) (K562 total cell lysate and large-scale IP), entire gel lanes were sliced 
into 20 equal pieces (TAP and large-scale IPʼs) or 48 equal pieces (K562 total 
cell lysate). 
Proteins in the gel slices were reduced with dithiothreitol, alkylated by 
incubation with iodoacetamide and digested in situ with modified porcine trypsin 
(Promega Corp., Madison, WI) (Shevchenko, Wilm et al. 1996). The resultant 
peptide mixture was extracted from the gel slices and desalted with customised 
reversed-phase stage tips (Rappsilber, Ishihama et al. 2003). The volume of the 
eluted sample was reduced to approximately 2 µL in a vacuum centrifuge and 
reconstituted to 10 µL with LC Phase A (see below). Depending on the intensity 
of the protein band staining, additional multiples of 8 µL LC Phase A were 
added to specific samples prior to analysis by LCMS. 
 
2.6.2 Gel-based LC-MSMS and data analysis of protein complexes 
obtained by Bcr-Abl large-scale immunoprecipitation and TAP 
Mass spectrometry was performed on a quadrupole time-of-flight 
(QTOF) mass spectrometer (QTOF Ultima, Waters, Manchester, UK) equipped 
with a nanoelectrospray ion source coupled to a high-performance liquid 
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chromatography Agilent 1100 nanoflow system (Agilent, Palo Alto, CA).  The 
HPLC system was comprised of a solvent degasser, a binary pump and a 
nanoflow pump. Phase A consisted of 0.4 percent acetic acid, 0.005% 
heptafluorobutyric acid (HFBA) in water and Phase B consisted of 0.4 percent 
acetic acid, 0.005% heptafluorobutyric acid (HFBA) in 90 percent acetonitrile.  
From the thermostatted micro-autosampler, 8 µL of the tryptic peptide mixture 
was automatically loaded onto a trap column (Zorbax 5 mm, Agilent 
Technologies, Palo Alto, CA) with the binary pump at a flow rate of 50 µL/min 
(3% Phase B). After the trap column was washed with 3% Phase B, the 
peptides were back-flushed onto a customised eight cm fused silica analytical 
column (inner diameter 75 µm) packed with C18 3 µm diameter Reprosil beads 
(Maisch, Germany). The peptides were eluted from the analytical column with a 
25 minute gradient ranging from 13 to 35 percent Phase B, followed by a 3 
minute gradient from 35 to 50 percent Phase B and a 4 minute gradient from 50 
to 100 percent Phase B at a constant flow rate of 250 nL/min. The analysis was 
performed in a data-dependent acquisition mode using one MS channel for 
every three MSMS channels and a dynamic exclusion for selected ions of 60 s 
(MassLynx, Waters, Manchester, UK). 
The acquired data were processed with ProteinLynx Global Server 2.2.1 
(Waters, Manchester, UK) and searched against an internally curated version of 
the International Protein Index protein sequence database (human IPI version 
3.32, European Bioinformatics Institute, www.ebi.ac.uk/IPI/) with the search 
engine MASCOT. This compilation of entries from Swiss-Prot, TrEMBL, RefSeq, 
and Ensembl was appended with frequently observed non-human contaminants 
(e.g., TEV protease). Submission to MASCOT was via a Perl script that 
performs an initial search with broad mass tolerances on both the precursor and 
fragment ions (200 ppm and 0.15 Da, respectively). High confidence peptide 
identifications are used to recalibrate all precursor and fragment ion masses 
prior to a second search with narrower mass tolerances (15 ppm and 0.05 Da). 
One missed tryptic cleavage site was allowed.  Carbamidomethyl cysteine was 
set as a fixed modification, and oxidised methionine was set as a variable 
modification. A false-discovery detection rate (FDR) of less than 0.25 percent 
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was estimated by searching the data set against a reversed database. Criterion 
for a positive protein identification was identification of a minimum of 2 peptides 
with a Mascot peptide score of ≥ 20. Protein identifications were grouped 
according to shared peptides and only one protein per group, having all the 
peptides, is reported as identified. 
 
2.6.3 Identification of Bcr-Abl ʻcoreʼ complex candidates 
The total cell lysate of wild-type K562 cells (ʻcore proteomeʼ) was 
analysed by LC-MSMS as technical duplicates, and the large-scale Bcr-Abl 
immunoprecipitates were analysed as technical triplicates. Results obtained 
from each of the five gel lanes were merged to give five data files. Comparison 
of the IP samples with the ʻcore proteomeʼ was based on peptide counts (PC), 
i.e., the total number of unique peptides. This approach has been used before 
by our laboratory and other groups to report protein abundance in a semi-
quantitative manner (Colinge, Chiappe et al. 2005; Liu, Sadygov et al. 2004; 
Rix, Hantschel et al. 2007). Analysis of the data using a Perl script enabled the 
association of each protein identified in one of the samples with the 
corresponding identified peptides. This resulted not only in a peptide count for 
each sample, but also reduced the number of proteins identified to groups of 
proteins distinguishable by MS (Nesvizhskii and Aebersold 2005). The resultant 
table of peptide counts was processed using an R script to perform statistical 
analysis and flag the proteins that were significantly more abundant in the IP 
samples versus the ʻcore proteomeʼ samples. A test based on ʻsignificance 
analysis of microarraysʼ (SAM) (Tusher, Tibshirani et al. 2001) was used and 
imposed a ʻfalse discovery rateʼ (FDR) of 5% (Zaykin, Young et al. 2000). 
 
2.6.4 Identification of confident binders in TAP experiments and 
statistical analysis of the protein-protein interaction network 
Each TAP experiment was analyzed by LC-MSMS as technical 
duplicates. The statistical method outlined above for the large-scale 
immunoprecipitates, however, could not be applied in these experiments. Thus 
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empirical criteria were used: a protein identified from a TAP sample was 
considered a confident binder provided the protein was identified in each of the 
duplicate TAP samples, with a minimum peptide count (PC) of 3, or in only one 
TAP sample with a minimum PC of 4, but was not identified in the ʻcore 
proteomeʼ. Alternatively, if the ratio of the minimum TAP PC by the maximum 
core proteome PC was greater than 3, then the protein was also considered as 
a confident interactor. 
To identify the group of proteins significantly related to BCR-ABL, which 
we postulated as the ʻcore complexʼ around the latter, the topology of the 
network, represented as an ʻundirected graphʼ obtained by linking each complex 
candidate to confident binders, was exploited. We then applied random network 
simulations and generated 100,000 random graphs by shuffling edges and 
searched each for the largest k with a non-empty k-core (Tong, Drees et al. 
2002). Thereby we learned the null distribution of the largest k, which is 
significant at the 10-5 level for values equal or larger than 4 and not significant 
under 4. We then considered the real network and found the 4- and 5-cores (no 
6-core). 
 
2.6.5 1D-shotgun LC-MSMS analysis of protein complexes obtained by 
large-scale immunoprecipitation 
HCl elution fractions of large-scale immunoprecipitated protein 
complexes were assessed by immunoblotting for recovery of bait protein and 
known interactors, fractions enriched in the protein complexes were pooled and 
30µl were analyzed in by 1D-shotgun LC-MSMS analysis in technical 
duplicates. Samples were resuspended in 100mM triethylammonium 
bicarbonate buffer, pH8.53, reduced with 10mM dithiothreitol for 30 minutes at 
56°C, free cystein residues blocked with 55 mM iodacetamide and digested by 
adding 2.5µg trypsin (Promega, Madison, USA). Digestion was carried out at 
37°C overnight and subsequently quenched by the addition of TFA to final 
concentration of 1%. Peptides were extracted using in-house fabricated stage-
tips utilizing C18 embedded mesh material (Empore C18 extraction discs, 3M 
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Centre, Minnesota, USA) and used for a total of two injections onto a NanoLC 
system.  
Analysis was performed on a Thermo LTQ Orbitrap XL (Thermo Fisher 
Scientific Inc.) coupled to a split NanoLC system (Agilent Technologies) 
operated with a trap-column setup. Peptides were separated on in-house 
fabricated 16 cm x 50 µm reversed-phase-columns (Reprosil pur, Maisch, 
Germany) at a constant flow rate of 100 nl/min with a gradient time of 175 min 
from 3 to 50%, then ramped up to 100% acetonitrile within 15min, in 0.4% 
acetic acid with 0.005% heptafluorobutyric acid as ion pairing agent. The LTQ 
Orbitrap XL mass analyzer was operated using Excalibur 2.0.6 software. For 
internal calibration of the mass spectrometer, the signals of the following 
background ions were used as lock masses: [Si(CH3)2O]5H+, (Si(CH3)2O)6H+, 
[Si(CH3)2O]6H+ + NH3, [Si(CH3)2O]7H+ + NH3, and [Si(CH3)2O]8H+ + NH3 at 
m/z 371.101233, m/z 445.120025, m/z 462.146573, m/z 536.165365 and m/z 
610.184156, respectively. The analyses were performed in a data-dependent 
acquisition mode using a top 10 collision-induced dissociation (CID) method (up 
to 10 CID spectra were acquired following each MS scan) and a dynamic 
exclusion for selected ions of 60 seconds. Maximal ion accumulation time 
allowed on the LTQ Orbitrap in CID mode was 150 ms for MSn in the LTQ and 
1000 ms in the C-trap. Automatic gain control was used to prevent overfilling of 
the ion traps and was set to 5000 ions in MSn mode for the LTQ and 1 million 
ions for a full FTMS scan. Intact peptides were detected in the Orbitrap at 
60,000 resolution. For statistical purposes, samples were analysed by LCMSMS 
as technical duplicates. 
The acquired data were processed with Bioworks V3.3.1 SP1 
(ThermoFisher, Manchester, UK), data files merged with an internally-
developed program, and searched against the human IPI database version 
v3.41 with the search engine MASCOT (Matrix Sciences). Submission to 
MASCOT was executed via a Perl script that performs an initial search with 
relatively broad mass tolerances on both the precursor and fragment ions ( ±10 
ppm and ±0.6 Da, respectively). High-confidence peptide identifications are 
used to recalibrate all precursor and fragment ion masses prior to a second 
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search with narrower mass tolerances (±4 ppm and ±0.3 Da, respectively). One 
missed tryptic cleavage site was allowed. Carbamidomethyl cysteine was set as 
a fixed modification, and oxidised methionine was set as a variable modification.  
For unambiguous protein identification at least two unique peptides with a 
MASCOT peptide ion score greater than, or equal to, 20 were required. A false-
positive detection rate of less than 1 percent was estimated by searching the 
data set against a reversed database. 
 
2.6.6 Quantitative iTRAQ mass spectrometry analysis of Bcr-Abl- and 
Grb2-protein complexes obtained by large-scale 
immunoprecipitation in the presence of tyrosine kinase inhibitors 
Bcr-Abl- and Grb2-complexes were immunoprecipitated from mock-, 
dasatinib- or nilotinib-treated K562 cells, washed in detergent- and amine-free 
HEPES-buffer, eluted with 150mM HCl and neutralized with 0.5M 
triethylammonium bicarbonate (TEAB). Elution fractions were pooled, reduced, 
alkylated and digested with trypsin. Each sample was split into two aliquots and 
labeled with the respective iTRAQ reagents (two channels per sample after 
splitting). The peptide mixture was separated with reversed phase HPLC, 
spotted onto a MALDI plate and analyzed by MALDI-TOF/TOF tandem mass 
spectrometry (4800 MALDI TOF/TOF, Applied Biosystems, Toronto, Canada). 
Data interpretation was performed by computing the median of all 4 iTRAQ 
ratios (116:114, 117:114, 116:115, 117:115) for each protein and assuming they 
are dominated by proteins whose abundance is not modulated by nilotinib or 
dasatinib treatment. Therefore we fit a Gamma distribution to capture the 
random ratios by using robust estimates, where the average is replaced by the 
median and standard deviation is replaced by the median absolute deviation 
(MAD), and we set a threshold corresponding to a P-value < 0.005. 
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2.7 Quantitative characterization of the Bcr-Abl ʻcoreʼ complex 
2.7.1 Expression and purification of recombinant epitope protein 
standards  
Mouse c-Abl-1b recombinant kinase domain (residues 248-534) was 
expressed in Sf9 cells and purified as described previously (Nagar, Bornmann 
et al. 2002). Recombinant F-actin binding domain of Bcr-Abl/c-Abl (FABD) was 
generated by cloning the coding region (residues 1026 – 1149, human c-Abl 
spliceform 1b numbering) into the pETM30 vector, providing an N-hexa-His-
GST-tag, as described before (Hantschel, Wiesner et al. 2005). The constructs 
spanning the epitopes recognized by each of the antibodies for Ship2, c-Cbl, 
p85β, Sts-1, Shc1, Grb2 and Crk-I were cloned in pETM30 and pETM41 vectors 
for expression of recombinant protein as C-terminal fusions to 6xHis-GST or 
6xHis-MBP (mannose binding peptide), respectively, including a Tobacco Etch 
Virus protease cleavage site. Initially all epitopes were cloned as 6xHis-GST 
fusion proteins and purified from E.coli. In consequence, different amounts of 
recombinant protein were analyzed by immunoblotting next to recombinant GST 
for antibody cross-reaction with GST alone. Recombinant epitope proteins, 
whose antibodies displayed cross-reactivity with GST alone were replaced by 
6xHis-MBP fusion proteins in order to exclude cross-reactivity with GST as an 
error source during quantitative immunoblotting using the Odyssey imaging 
system (Li-Cor Biosciences, Lincoln, NE, USA). The following table shows 
details and fusion-type of the recombinant epitope protein standard used in this 
study:  
 
 
 
Protein Epitope Residues Vector Fusion tag MW (kDa)
c-Abl / Bcr-Abl Kinase - domain S248 - T534 - - 34
c-Abl / Bcr-Abl FABD S1026 - R1149 pETM-30 N-6-His-GST 43
Ship2 SAM - domain E1184 - K1258 pETM-41 N-6-His-MBP 53
c-Cbl UBA - domain A853 - T906 pETM-41 N-6-His-MBP 50
p85! RhoGAP - domain D102 - P307 pETM-30 N-6-His-GST 55
Sts-1 C' peptide P636 - E649 pETM-30 N-6-His-GST 31
Shc1 SH2 - domain A358 - L474 pETM-30 N-6-His-GST 42
Grb2 full length M1 - V217 pETM-30 N-6-His-GST 54
Crk-I full length M1 - N204 pETM-30 N-6-His-GST 52
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The recombinant plasmids were transformed into BL21(DE3) and 
protein expression was induced by addition of 1mM IPTG followed by 
incubation at room temperature. 3h post induction cells were harvested and 
resuspended in ʻnickel-wash bufferʼ (50mM Tris-HCl pH 7.5, 20mM imidazole, 
500mM NaCl, 5% Glycerol, 5mM β-mercaptoethanol, 1mM PMSF) and flash 
frozen in liquid N2. Cells were lysed using a French press (Avestin Emulsiflex-
C3 high pressure homogenizer) and a cell-free extract was obtained by high-
speed centrifugation. The extract was loaded onto a 1ml Ni-NTA column 
(Qiagen) equilibrated in ʻnickel-wash bufferʼ. Recombinant fusion protein was 
eluted as 0.5ml fractions with ʻnickel-elution bufferʼ (50mM Tris-HCl pH 7.5, 
250mM imidazole, 500mM NaCl, 5% Glycerol, 5mM β-mercaptoethanol) 
applying a linear imidazole gradient (20mM – 250mM) and fractions containing 
the recombinant protein (as determined by SDS-PAGE and Coomassie 
staining) were pooled. Pooled protein was re-buffered with ʻnickel wash bufferʼ 
using Amicon® Ultra centrifugal filter devices (Millipore). In individual cases, gel 
filtration on a Superdex75 (XK16/60 column) in ʻgel filtration bufferʼ (20mM Tris-
HCl pH7.5, 300mM NaCl, 3mM dithiothreitol (DTT)) resulted in increased 
homogeneity of the protein preparation. Protein concentration was determined 
by measuring a UV absorbance-spectrum (250-350nM) of an adequate dilution 
in 50mM Na2PO4-buffer (pH 7.0). Protein concentration was determined by 
multiplying the absorption at 280nm with the dilution factor and dividing by the 
extinction coefficient of the purified protein construct. Extinction coefficients 
were determined using the ExPASy ProtParam tool 
(http://www.expasy.ch/tools/protparam.html). Based on these protein 
concentration values, 1:1.5 dilution series were generated for each recombinant 
epitope protein standard, starting at appropriate amount (according to detection 
by immunoblot). 
 
2.7.2 Absolute quantification of total cellular protein copy numbers 
We used 50, 100, 150 and 200 µg K562 total cell lysate of known cell 
count (9,903*105 viable cells/ml), known protein concentration (27,2 µg/µl) and 
known lysis volume (8 ml) to quantify absolute cellular protein copy numbers of 
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each of the 8 Bcr-Abl ʻcore complexʼ members. Following SDS-PAGE and 
immunoblotting relative quantification was performed using the Odyssey 
imaging system (Li-Cor Biosciences, Lincoln, NE, USA). Knowing cell count, 
protein concentration and lysis volume allowed calculation of protein amount 
per K562 cell P(cell). Each quantification was performed in technical triplicates. 
Per quantification experiment internal triplicates of K562 total cell lysate 
quantifications (50, 100, 150, 200µg each) were performed in parallel. Primary 
antibodies were detected with AlexaFluor-680 labeled goat anti-mouse or goat 
anti-rabbit secondary antibodies, detected using the Odyssey imaging system 
(Li-Cor Biosciences, Lincoln, NE, USA) and quantified. Integrated pixel 
intensities per band were quantified for the 50, 100, 150 and 200µg and 
quantified at hands of a standard curve generated using recombinant epitope 
protein standards. 
For absolute quantification, recombinant protein standards 
corresponding to the respective antibody epitopes were expressed in E. coli, 
purified to homogeneity and immunoblotted as internal reference standard as 
1:1,5 serial - dilutions in each quantification experiment along with the total cell 
extracts. The concentration ranges of these recombinant epitope standard 
dilution series was adjusted to the detection intensity of the respective 
endogenous reference proteins as follows: 
 
 
 
The seven recombinant epitope standard curve bands were quantified 
as described above and blotted against the amount of input (ng). Following 
quantification, values corresponding to the 50, 100 and 150µg samples were 
Protein Recombinant epitope standard Dilution series from (ng)
c-Abl / Bcr-Abl Kinase - domain 22.7
c-Abl / Bcr-Abl FABD 8.6
Ship2 SAM - domain 57.4
c-Cbl UBA - domain 8.1
p85! RhoGAP - domain 10.2
Sts-1 C' peptide 9.7
Shc1 SH2 - domain 19.9
Grb2 full length 18.2
Crk-I full length 7.0
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normalized to the value corresponding to the 200µg sample. The 4 values of 
each triplicate were averaged and we finally determined the median of the three 
average values. For some quantifications, more than three average values were 
generated in order to reduce the error of the median. This “median of the 
averages” - value M(ng) was used to calculate total protein copy numbers per 
cell (c(x)/cell) considering the molecular weight (Da) of the respective 
recombinant protein epitope standard as well as Avogadroʼs number as follows: 
Protein/K562-cell = P(cell) = 4,395 * 10-4 µg protein/cell 
Li-Cor “median of the averages” = M(ng): 
 
1. Bcr-Abl:  7.74; 4.92; 10.75; 6.21 
2. Ship2:  13.25; 17.33; 26.83 
3. c-Cbl:  15.35; 11.86; 14.68 
4. p85β:  5.23; 6.78; 9.4; 11.08 
5. Sts-1:  4.37; 3.65; 2.24; 2.51; 5.56; 5.36; 5.22 
6. Shc1:  16.08; 9.46; 8.37; 14.46 
7. Grb2:  8.2; 6.6; 11.4; 11.06; 6.61; 7.81 
8. Crk-I:  1.5; 0.9; 0.8 
Core interactor protein (g) / µg total cell lysate = g(x)/µg = 
€ 
M(ng) ×10−9g
200  
Core interactor protein (%) / cell = %(x)/cell = 
€ 
(g(x) /µg) × (1×108) 
Core interactor protein (g) / cell= g(x)/cell = 
€ 
(%(x) /cell) × P(cell)
100  
Absolute protein copy number / cell = c (x)/cell = 
€ 
(6,02 ×1023 × (g(x) /cell))
MW(standardx )(Da)
 
 
Following quantification of the total copy number per cell of each of the 
proteins, the error was calculated as % standard deviation (% STDEV). 
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2.7.3 Quantification of the Bcr-Abl ʻcoreʼ complex interaction 
stoichiometry and overall Bcr-Abl – associated proportions of 
each protein 
For stoichiometry calculation, we immunoprecipitated Bcr-Abl 
complexes from 150 mg K562 total cell lysate using 24-21 anti-Abl antibody 
covalently coupled to NHS-Sepharose beads. Protein complexes were eluted 
from the beads by boiling in Lämmli SDS-PAGE sample buffer (containing β-
mercaptoethanol). Following quantitative immunoblotting using the Odyssey 
system (Li-Cor), protein copy numbers of Bcr-Abl and each of the seven Bcr-Abl 
ʻcore complexʼ candidate proteins per 2% immunoprecipitate were quantified. 
Quantifications were performed by including the corresponding recombinant 
epitope protein standard in each quantification experiment, as described in the 
previous section. The interaction stoichiometry within the Bcr-Abl core complex 
was determined by calculating the ratios of each core interactorʼs copy numbers 
over the Bcr-Abl copy numbers in the IP-fraction. Each quantification was 
performed at least in triplicates and the average values and standard deviations 
were determined. In addition, taking the total cellular protein copy numbers into 
account, quantification of the band intensities in the input- and supernatant 
samples of the IP allowed calculation of the proportion of depleted versus 
undepleted protein corresponding to distribution of each core interactor as Bcr-
Abl-associated (%) versus “free” cellular protein (%) (free or in different protein 
complexes). 
 
2.8 Biophysical characterization of the Bcr-Abl ʻcoreʼ complex 
2.8.1 1-step TAP of Saccharomyces cerevisiae Pwp2 complexes  
Pwp2 (pre-ribosomal complex) protein complexes were purified from 
Saccharomyces cerevisiae under the courtesy of Anne-Claude Gavin at the 
European Molecular Biology Laboratory (EMBL) in order to serve as size-
standards for ʻsizingʼ of the Bcr-Abl ʻcore complexʼ by density gradient 
centrifugation. Eight liters of Pwp2+ yeast culture were grown to an OD of 3.5 - 
3.8 in YPD medium and harvested at 4,000rpm for 15min. The supernatant was 
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discarded, the pellets were washed with 1x PBS containing 0.5mM PMSF and 
the centrifugation was repeated in 50ml tubes (Falcon). The supernatant was 
removed and the pellets were flash-frozen in liquid nitrogen. Pellets were 
thawed in a wather bath at 37°C, transferred to room temperature and lysed in 
lysis buffer containing 50mM Tris-HCl pH7.5, 100mM NaCl, 0.15% Igepal, 
1.5mM MgCl2, 0.5mM DTT, 1mM PMSF and 1x self-made protease inhibitor 
cocktail. Yeast cells were further lysed 3 x 4min at 350rpm in a planetary ball 
mill containing 25ml glass beads at 0.5mm diameter per beaker. Lysate of each 
strain was split in four equal parts. For each strain, three technical repeats of 
one-step TAP was performed using 250µl bed-volume IgG-sepharose 
(Amersham). After 1h incubation, beads were sedimented by 3min 
centrifugation at 1,200rpm, supernatant was recovered and kept as IgG-
supernatant fraction for immunoblot analysis. The beads were transferred to 
0.8ml MoBiTech columns and washed with 10ml ʻyeast lysisʼ buffer containing 
1mM DTT. Aliquots of the wash fraction were kept for immunoblot analysis. 
TEV-cleavage was then performed by adding 250µl lysis buffer and 16µl TEV 
protease (1mg/ml) and incubated 1h at 16°C in a thermo shaker at 750rpm. 
After elution of the TEV-cleaved protein complexes from the columns, glycerol 
was added to a final concentration of 5%, aliquots were flash frozen and stored 
at -80°C. Input, IgG-supernatant and TEV-eluate fractions were then analyzed 
by immunoblotting. 
 
2.8.2 Glycerol density gradient centrifugation of Saccharomyces 
cerevisiae Pwp2 complexes and K562 Bcr-Abl / c-Abl complexes 
20 – 80% gradients of glycerol (in 10mM Tris-HCl pH 7.5, 100mM NaCl 
0.5mM EDTA, 0.2% NP40) were generated using a gradient maker (model 
#GM-20: C.B.S. Scientific Co., Del Mar, CA, USA) in 2ml polyallomer centrifuge 
tubes (11x34mm, No.: 347357,Beckman). Gradients were loaded with 50µl 
Pwp2 complex TEV eluate for calibration of gradient conditions or with 3mg of 
mock- and dasatinib-treated K562 cell lysate and ultra-centrifuged at 54,000rpm 
for 7hrs (Beckman Coulter OptimaTM Max-E ultracentrifuge). 16 gradient 
fractions à 125µl were collected with a pipette from top to bottome. 
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2.8.3 Analysis of K562 cell lysates in the presence of tyrosine kinase 
inhibitors by fluid phase liquid chromatography gel filtration 
Mock-, dasatinib- and nilotinib-treated K562 cell lysate was analyzed by 
fluid phase liquid chromatography (FPLC) gel filtration in order to study changes 
in co-migration of Bcr-Abl and its seven ʻcoreʼ interactor proteins. A SuperoseTM 
6 (10/300 GL, Pharmacia Biotech) gel filtration column was calibrated by 
analyzing a run of a mixture of gel filtration standards (Bio-Rad Laboratories; 
catalog: 151-1901) containing a lyophilized mixture of the molecular weight 
markers ranging from 1350 to 670000 Da, thyroglobulin (bovine) 670000 Da, γ-
globulin (bovine) 158000 Da, ovalbumin (chicken) 44000 Da, myoglobulin 
(horse) 17000 Da and vitamin b12 1350 Da. Next, 500µl of mock-, dasatinib- 
and nilotinib-treated K562 cell lysate were run, fractions were collected within 
the MW-range of the smallest Bcr-Abl interactor (Crk-I: 23kDa) up to the MDa 
MW-range compatible with high molecular weight tetrameric Bcr-Abl multi-
protein complexes between 1 and 4MDa and the fractions were analyzed by 
immunoblotting. 
 
2.9 siRNA perturbation of protein expression 
Small interfering RNA (siRNA) knock-down was performed by 
transfecting K562 cells with SmartpoolTM (Dharmacon RNAi Technologies, Inc., 
Chicago, IL, USA) siRNA duplexes targeting c-Abl, Ship2, c-Cbl, p85α, p85β, 
Sts-1, Shc1, Grb2 and Crk-I or a control siRNA using HiPerFect® transfection 
reagent (QIAGEN Inc., Valencia, CA, USA). The day before transfection, cells 
were diluted at a density of 3*105 / ml in RPMI medium containing 10% fetal calf 
serum (FCS) and 1% antibiotics (penicillin/streptomycin) and incubated at 
standard conditions (37°C, 5% CO2). On the day of transfection 106 K562 cells 
in logarithmic growth phase were each plated in a well of a 6-well plate in 500µl 
RPMI culture medium (10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin). 1.5µg of the respective siRNAs (5µl) and 18µl 
HiPerFect® were diluted in 500µl culture medium without FCS and mixed by 
vortexing. Samples were incubated for 5-10min at room temperature in order to 
allow formation of transfection complexes. These were then drop-wise added to 
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the cells while gently swirling the culture dish to ensure uniform distribution of 
the transfection complexes. Cells were then incubated under standard 
conditions and, after 6hrs, 2ml RPMI culture medium (10% fetal calf serum 
(FCS) and 1% penicillin/streptomycin) were added and cells were incubated for 
24 hours, harvested and analyzed for gene silencing by immunoblotting. For 
48h and 72h gene-silencing experiments, K562 cells were re-transfected after 
24h, adding fresh medium, harvested after 48h or 72h and analyzed for protein 
knock-down by immunoblotting. 
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3 RESULTS  
3.1 Epitope mapping of the 24-21 Abl antibody 
K562-cells endogenously express both Bcr-Abl and, from the other 
allele, the c-Abl protein. In order to identify endogenous Bcr-Abl interactors, we 
chose to isolate endogenous Bcr-Abl / c-Abl protein complexes from cell lysates 
of the CML cell line K562 by immunoprecipitation with the monoclonal Abl 
antibody 24-21 (Schiff-Maker, Burns et al. 1986), of which we had sufficient 
amounts in the lab. The antibody recognizes the very C-terminal F-actin binding 
domain of Bcr-Abl / c-Abl (residues 1026 – 1149 of h-Abl1b). A comprehensive 
set of recombinant proteins of a series of mutants of surface-exposed residues 
of the c-Abl F-actin binding domain from earlier work on the structure of the C-
terminal F-actin binding domain (FABD) of Bcr-Abl by Oliver Hantschel 
(Hantschel, Wiesner et al. 2005) opened the possibility to precisely map the 
epitope of this antibody from the beginning of the project. The epitope of the Abl 
24-21 antibody was mapped by quantitative immunoblotting of these 
recombinant mutant proteins using the Odyssey system (Li-Cor). These 
mutants were expressed in E. coli as recombinant GST-fusion proteins, purified 
to homogeneity and 5µg of each mutant recombinant fusion protein was 
immunoblotted against Abl FABD using the 24-21 antibody and against the 
GST-tag, including glutathione-S-transferase (GST) only as a control 
(recombinant proteins kindly provided by Oliver Hantschel). Protein levels were 
quantified and FABD-construct recognition by the 24-21 antiserum was 
monitored as the ratio of 24-21- over GST-signal, normalized to the ratio of wild-
type FABD over GST. Mapping of the epitope of this antibody showed that only 
the construct containing mutations of the residues Q1094, Q1095 and M1096 
within the FABD displayed reduced binding of the antibody (Figure 3.1). The 
epitope Q1094, Q1095, M1096 is located within the αII-αIII loop of the FABD 
(PDB entry 1ZZP; (Hantschel, Wiesner et al. 2005);Figure 3.1). While residues 
1097, 1099, 1100, 1104 and 1108 within helix αIII have been shown to be 
critical for F-actin binding and cytosceletal association (Hantschel, Wiesner et 
al. 2005) and hence to be a critical determinant of Bcr-Abl / c-Abl localization, 
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the epitope Q1094, Q1095, M1096 is not involved in F-actin binding or any 
other known protein-protein interaction (Hantschel, Wiesner et al. 2005).  
 
Figure 3.1 Epitope mapping of the Abl antibody 24-21 (Ab-3) 
(A) The epitope of the Abl 24-21 antibody was mapped by immunoblotting recombinant 
proteins of Abl F-actin binding domain mutants (kindly provided by Oliver Hantschel). 
The mutants were expressed in E. coli as recombinant GST-fusion proteins, purified to 
homogeneity and 5µg of each mutant recombinant fusion protein were immunoblotted 
against Abl FABD (24-21) and GST.  
(B) Protein levels were quantified and protein recognition was monitored as ratio of 24-
21- over GST-signal, normalized to the ratio of wild-type FABD over GST. Only 
mutation of residues Q1094, Q1095 and M1096 within the αII-αIII loop showed 
reduced binding of the antibody. 
(C) The epitope Q1094, Q1095 and M1096 is highlighted on the NMR-structure of the 
Abl F-actin binding domain (PDB entry 1ZZP) (Hantschel, Wiesner et al. 2005).  
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Therefore, the elucidation of the precise location of this antibodies 
epitope at the very beginning represented a vital control, as we could now 
exclude the interference of the antibody with protein-protein interactions to the 
best of our knowledge. Furthermore, knowing the epitope, we could is it 
together with recombinant FABD protein as recombinant epitope protein 
standard, besides recombinant Abl kinase domain, for absolute quantification of 
endogenous Bcr-Abl / c-Abl proteins by quantitative immunoblotting, as will be 
discussed later (see section 3.6). 
 
3.2 Proteomic identification of the endogenous Bcr-Abl multi-protein 
complex 
In order to identify endogenous interactors of Bcr-Abl, we 
immunoprecipitated Bcr-Abl/c-Abl protein complexes from cell lysates of the 
CML cell line K562 using the monoclonal Abl antibody 24-21 (Schiff-Maker, 
Burns et al. 1986). Bcr-Abl/c-Abl and interacting proteins were isolated using 
the Abl antibody covalently coupled to sepharose beads and, after washing the 
protein complexes with TAP lysis buffer (Burckstummer, Bennett et al. 2006), 
protein complexes were eluted using detergent (1% SDS). The efficiency of the 
purifications was checked by immunoblotting the input, wash and eluate 
fractions for Bcr-Abl/c-Abl and, as a control, the known Bcr-Abl interactor Shc1 
(Tauchi, Boswell et al. 1994). Both Bcr-Abl and c-Abl were depleted completely 
from the extract and enriched in the elution fractions and Shc-1 co-eluted with 
Bcr-Abl/c-Abl (Figure 3.2B). Elution fractions that contained most Bcr-Abl 
(elution fractions 2-4,Figure 3.2) were pooled, separated by 1D-SDS-PAGE, 
stained with coomassie and analyzed by mass spectrometry (Figure 3.2C,D). 
Searching the mass spectrometry data against the human IPI protein database 
yielded a primary dataset of 427 proteins (Kersey, Duarte et al. 2004). In 
parallel, by analyzing 50µl of crude K562 cell lysate by LC-MSMS in a technical 
duplicate, we identified the 708 proteins most prevalent in K562 cells, 
representing the ʻK562 core proteomeʼ (Figure 3.2A). This set of the 708 most 
abundant proteins is likely to primarily reflect the cellular repertoire of abundant 
housekeeping and structural proteins (Schirle, Heurtier et al. 2003). Based on 
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these data sets, specific proteins were identified by comparing pull-down versus 
ʻcore proteomeʼ datasets applying the ʻsignificance analysis of microarraysʼ 
(SAM) statistical test (Tusher, Tibshirani et al. 2001). This process greatly 
improved the signal-to-noise ratio and even allowed the selection of abundant 
proteins (present in the K562 core proteome) based on their enrichment in the 
purifications. However, the cellular abundance of some proteins, e.g. HSP90 
that is known to be complexed with Bcr-Abl and potentially of therapeutic 
interest (Shiotsu, Soga et al. 2002; Wu, Xu et al. 2008), precludes significant 
detection in a pull-down, because the enrichment does not yield a ratio 
sufficiently high to allow protein selection according to SAM criteria. This 
statistical procedure, gauged at 5% false discovery rate, yielded 18 high 
confidence interactors of Bcr-Abl/c-Abl with an average sequence coverage of 
31% that is within the range of the observed sequence coverage for Bcr-Abl and 
would be compatible with a high stoichiometry interaction (Figure 3.2D). A 
number of these 18 Bcr-Abl/c-Abl complex component candidates were known 
interactors of Bcr-Abl and are well-described signalling proteins (Figure 3.2D). 
Grb2, Shc-1 and Crk-I are adaptor proteins containing SH3, SH2 and PTB 
domains that serve as adaptor interfaces in tyrosine kinase signaling (Pawson 
2007). p85α and β are two of five regulatory subunits, that associate with the 
catalytic subunits (p110α,β, or δ) of the dimeric enzyme phosphatidylinositol-3-
kinase (PI3K) that is playing a prominent role in oncogenesis as one of its 
components, PIK3CA (encoding p110α), is frequently found mutated in 
common human cancers such as breast, prostate and colon carcinoma 
(Geering, Cutillas et al. 2007; Zhao and Vogt 2008). The E3-ubiquitin ligases c-
Cbl and Cbl-B typically bind and ubiquitinate activated tyrosine kinases and 
negatively regulate their activity (Thien and Langdon 2001). Ship2 is a SH2 
domain-containing phosphatidylinositol-5-phosphatase known to bind the Abl 
SH3 domain and also, via its PTB domain, Shc1, with yet unknown function in 
Bcr-Abl signaling (Wisniewski, Strife et al. 1999). 
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Figure 3.2 Proteomic identification of endogenous Bcr-Abl interactors 
(A) Large-scale immunoprecipitation purification of endogenous Bcr-Abl/c-Abl protein 
complexes were performed in a technical triplicate from 1*109 K562 cells, each, using 
an anti-Abl antibody (24-21) recognizing the c-terminal F-actin binding domain (FABD) 
of Bcr-Abl/c-Abl (see B,C) coupled to sepharose beads. Also, 50µg of K562 cell lysate 
were analyzed by LC-MSMS in a technical duplicate and resulted in the K562 ʻcore 
proteomeʼ of the 708 most abundant proteins. 
(B) Immunoblot analysis of the purification of endogenous Bcr-Abl/c-Abl complexes 
showing efficient purification of Bcr-Abl/c-Abl and the known Abl interactor Shc1. 100µg 
of the total cell lysate, equivalent volumes of the flow-through and wash fraction and 
5% of the elution fractions were loaded. Of the three technical repeats, one 
representative immunoblot is shown here.  
(C) Of each triplicate immunoprecipitation, elution fractions 2, 3 and 4 were pooled, 
separated by SDS-PAGE and analysed by mass spectrometry. 
(D) Table of the 18 high confidence interactors of Bcr-Abl/c-Abl at 5% false discovery 
rate identified by mass spectrometry. The table shows the protein name, the Entrez 
gene name, the number of unique peptides identified by mass spectrometry in three 
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technical repeats, the average sequence coverage, protein function and the domain 
composition. Proteins are ranked by molecular weight (kDa) in a decreasing order. 
 
Sts-1 (suppressor of T-cell receptor signaling 1) was initially identified 
as a JAK2 interactor containing an SH3 domain. Subsequently, Sts-1 was 
described as a negative regulator of the EGF receptor, ZAP70 and Syk, which 
can be attributed to the presence of a non-canonical tyrosine phosphatase 
domain in the C-terminus of the protein (Carpino, Kobayashi et al. 2002; 
Mikhailik, Ford et al. 2007). Sts-1 is a hitherto not described interactor of Bcr-
Abl and may be a novel regulator or antagonist of Bcr-Abl action. In line with our 
observations, Sts-1 was recently found to co-elute with a similar kinetic than 
Bcr-Abl in drug binding and competition experiments further corroborating its 
possible partnership in a protein complex with Bcr-Abl (Bantscheff, Eberhard et 
al. 2007). Besides these, the remaining interactors within the list of top-18 
candidate Bcr-Abl interactors belong mainly to the clathrin-mediated endocytic 
machinery, including the adaptor protein 2 (AP2) complex subunits AP2α1, 
AP2β1 and AP2µ1, or are known to be tightly associated with the latter, here 
represented by the epidermal growth factor receptor substrate 15 (Eps15), 
Stonin-2 (STN2), BMP-2-inducible protein kinase (BMP2K/BIKE) and RALBP1-
associated EPS domain-containing protein (REPS1) (Figure 3.2D) (Pearse, 
Smith et al. 2000). These AP2 adaptor protein complex components will be 
described in more detail in section 3.5. In addition to the 18 interactors 
compatible with stoichiometric interactions (Figure 3.2D), we identified many 
additional previously characterized Bcr-Abl/c-Abl interacting proteins, such as 
Abi-1, Abi-2, DNA-PK, WAVE-2, SHP-2 and Crk-L, but with lower peptide 
counts (Pendergast 2002). As the Abl immunoprecipitation experiment of 
endogenous complexes did not allow to distinguish between interactors of Bcr-
Abl and c-Abl, we engineered K562 cell lines expressing Bcr-Abl and versions 
of wild-type c-Abl (autoinhibited) and the constitutively active c-Abl PP variant 
(Barilá and Superti-Furga 1998) fused to a tandem affinity purification (TAP-) 
tag (Burckstummer, Bennett et al. 2006) and performed duplicate TAP 
purifications. TAP-tagged Bcr-Abl showed only a very low degree of 
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overexpression in K562 cells that also decreased rapidly over only a few 
passages. Nevertheless, TAP purifications with N- and C-terminally tagged Bcr-
Abl were performed and despite only a low yield of purified bait protein, the few 
interactors coincided with proteins identified most significantly in the 
purifications of endogenous c-Abl/Bcr-Abl, e.g. SHIP-2, Cbl and Grb2 (data not 
shown). In contrast, both c-Abl and c-Abl PP TAP purifications from K562 cells 
yielded large amounts of the c-Abl bait protein, but none of the 18 interactors 
described above. Furthermore, an additional technical triplicate set of large-
scale immunoprecipitations of endogenous Bcr-Abl/c-Abl protein complexes 
was performed using dasatinib-treated K562 cells and the same protocol. 
Convincingly, the majority of the 18 proteins described above were either 
completely absent upon dasatinib treatment or retrieved levels (peptide count) 
were significantly reduced (Figure 3.3). 
 
 
Figure 3.3 All 18 high confidence Bcr-Abl complex member candidates are either 
absent or present at significantly reduced levels upon dasatinib treatment 
Graph displaying the average peptide coverage of the triplicate large-scale Bcr-Abl/c-
Abl immunoprecipitations from mock- (black bars) or dasatinib-treated (grey bars) K562 
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cells for each of the 18 candidate Bcr-Abl interactor proteins. Average peptide count 
was normalized to the molecular weight of each protein and assuming that 2/3 of all 
Bcr-Abl/c-Abl peptides identified by LC-MSMS can be attributed to Bcr-Abl. Bcr-Abl is 
set to 1,00, the other 17 protein are ordered by decreasing normalized average peptide 
coverage. (AP2A1 = AP2α1, AP2B1 = AP2β1, AP2M1 = AP2µ1, Shc1 = p52Shc1 and 
p62Shc1, p85a = p85α, p85b = p85β) 
 
This underlines that these interactors are specific for constitutively 
active Bcr-Abl kinase, that the majority of them might use SH2-phosphotyrosine 
dependent interaction modes and that they are not interacting with endogenous 
c-Abl. This strongly argues that the candidate proteins identified in our 
immunoprecipitation approach are bona fide interactors of Bcr-Abl, but not of c-
Abl. 
 
3.3 Duplicate tandem affinity purification of 9 candidate interactors 
yields high co-occurrence and numerous known and novel 
interacting proteins 
We performed medium-scale TAP complex purifications of nine Bcr-Abl 
interacting proteins from K562 cells with a two-fold aim: (i) to obtain reciprocal 
confirmatory data on the interaction with Bcr-Abl of the individual proteins and 
(ii) to perform a topological analysis of the enlarged network obtained from the 
entire analysis. Of the 18 putative Bcr-Abl complex members, we chose Shc-1, 
SHIP-2, Crk-I, Grb2, Sts-1 and one member each of the Cbl and p85 families (c-
Cbl and p85β, respectively). Of all the proteins thought to be involved in the 
AP2 adaptor complex (AP2α1, AP2β1, AP2µ1, Eps15, Stn2, Bike, Reps1), we 
chose to analyze two representative members (Eps15 and AP2µ1) taking 
amenability and size into account. All nine TAP purifications were performed as 
biological duplicates, following the same protocol used for the c-Abl and c-Abl 
PP TAP purifications (see 3.2), and statistically significant interactors were 
identified using core proteome enrichment (Figure 3.5,Figure 3.6). In all cases 
the bait protein was identified abundantly in the final TAP eluate by 
immunoblotting and LC-MSMS analysis (Figure 3.4). 
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Figure 3.4 Shc1- and Grb2-NTAP tandem affinity purification  
Following all TAP purifications, total extract (TE), IgG-beads supernatant (IgG-SN), 
streptavidin-beads supernatant (SBP-SN) or calmodulin-beads supernatant (CBP-SN) 
and the boiled beads (SBP/CBP boiled) fractions were analyzed by 1D SDS-PAGE and 
immunoblotting against the bait protein to monitor protein complex purification yield in 
each respective TAP purification. The assessment of the TAP purifications Shc1 and 
Grb2 (A: Shc1-NTAP, B: Grb2-NTAP) are shown here as representative examples. A 
fraction of each boiled beads sample was separated by 1D-SDS-PAGE and silver 
stained. Entire gel lanes were sliced into 16 equal pieces, digested with trypsin and 
analyzed by LC-MSMS. 
 
Rewardingly, with the exception of Eps15 and AP2µ1, all remaining bait 
proteins (Ship2, c-Cbl, p85β, Sts-1, Shc1, Grb2 and Crk-I) interacted with at 
least half of the other bait proteins, including Bcr-Abl at a high level of co-
occurrence and reproducibility (Figure 3.5). All reverse TAP purifications, except 
Ship2, Eps15 and AP2µ1, recovered Bcr-Abl peptides. For unknown reasons, 
Ship2 was found to perform poor in TAP as far as reciprocal recovery of the 
other candidate Bcr-Abl complex members and Bcr-Abl is concerned (Figure 
3.5). In the Eps15 and AP2µ1 TAP purifications the bait protein and the other 
partner were identified abundantly. No other core interactor of the postulated 
Bcr-Abl core complex was identified except for 3 and 5 Crk-I peptides in the 
Eps15- and AP2µ1 TAP purifications, respectively, and 4 peptides Bcr-Abl in 
the AP2µ1 TAP purification. This suggests that Eps15 and AP2µ1 are not part 
of a stoichiometric Bcr-Abl complex but that they may be indirectly associated 
with Bcr-Abl as members of a distinct more remotely Bcr-Abl associated 
complex. Overall, the TAP experiments show a high level of reciprocal co-
occurrence between Bcr-Abl, c-Cbl, Shc1, Grb2, Crk-I, Ship2 and p85β. In 
contrast, Sts-1 was only observed in the Crk-I TAP-purification and recovers 
only two other core complex members (Ship2 and Crk-I) besides Bcr-Abl, when 
A
82
64
49
TE
Ig
G
-S
N
TE
V-
El
ua
te
SB
P-
SN
SB
P 
bo
ile
d
SBP-Shc1
Protein G-SBP-Shc1
?-Shc1
MW
(kDa)
SB
P 
bo
ile
d
116
82
64
49
37
MW
(kDa)
Silver 
Staining
B
TE
Ig
G
-S
N
TE
V-
El
ua
te
C
B
P-
SN
C
B
P 
bo
ile
d
CBP-Grb2
Protein A-CBP-Grb2
C
B
P 
bo
ile
d
?-Grb2
MW
(kDa)
182
116
82
64
49
37
MW
(kDa)
Silver 
Staining
64
49
37
26
3 Results 
 
 71 
used as bait. However, in contrast to Eps15, Bcr-Abl peptides are retrieved 
abundantly. Therefore it can be hypothesized that six proteins are highly 
interconnected in a Bcr-Abl-centered ʻcoreʼ protein complex while Sts-1 is either 
more transiently bound or member of a separate Bcr-Abl protein sub-complex 
(Figure 3.5). Out of 56 possible pairwise interactions among the seven 
candidate Bcr-Abl complex members, 30 were experimentally observed, of 
which 21 were detected in both directions (Figure 3.5). 
 
 
Figure 3.5 High level of reciprocal co-occurrence between seven of the nine TAP 
baits and Bcr-Abl 
Cross-matrix displaying the numbers of unique peptides identified for each protein, 
identified in each of the nine duplicate TAP purifications. The heat map color-coding 
shows bait proteins in dark red, proteins reciprocally and bi-directionally identified in 
red and proteins reciprocally but only uni-directionally identified in light red. 
 
 
In CML, Bcr-Abl mimics an activated tyrosine kinase signalling setting 
that physiologically only occurs upon stimulation with a cognate biological 
trigger. Five of our seven Bcr-Abl core complex candidates, Cbl, Shc, Grb2, p85 
and Crk, are known to generally co-occur in activated TK signalling, such as 
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EGF receptor signalling (Fukazawa, Miyake et al. 1996), and Cbl, Shc, Grb2 
and p85 have also been described to co-occur in the same protein complex in 
activated B-cell receptor signalling (Panchamoorthy, Fukazawa et al. 1996). 
Besides the Bcr-Abl ʻcoreʼ complex candidates, we identified numerous 
additional signalling proteins, including kinases, phosphatases and GTPases 
(Figure 3.6). In addition to the kinases BMP2K, PKCδ, TTBK2, AAK1 and Btk 
we identified Csk in three TAP purifications (Cbl, Sts-1 and Shc1 baits). 
Phosphatases identified include PTPN11, PTPN12, PPP1R9B and PTPRA. In 
addition to the regulatory PI3-kinase subunits p85α/β we repeatedly identified 
the catalytic PI3K subunits PIK3CA, PIK3CB, PIK3CD and also PIK3C2B. 
Additionally, we identified the phosphatidylinositol 4,5-bisphosphate-dependent 
Arf1GAP DDEF1. Other GTPase activating proteins (GAPs) identified are 
DNM2 isoforms 1, 2 and 4. We also identified the guanine nucleotide exchange 
factors (GEFs) Sos1, Sos2 and RapGEF1. Adaptor proteins identified are Gab1, 
Gab2, Traf2 and NCKIPSD. Besides AP2α1, AP2β1 and AP2µ1, we additionally 
identified the AP2 adaptor protein complex components AP2α2 and AP2σ1. We 
also found the Sts-1 homologue Sts-2 (TULA) (Figure 3.6). Overall, each of the 
nine bait proteins identified a number of known interactors, validating the 
experimental approach, whereas about 2/3 of all interactors may be considered 
as novel according to the HPRD or IntAct databases (Figure 3.6). Not 
unexpectedly, the small SH2/SH3/PTB domain containing adaptor proteins 
Grb2, Shc-1 and Crk-I displayed most interactors, many of which link to 
important downstream signaling pathways (Figure 3.6). 
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Figure 3.6 TAP purifications with nine Bcr-Abl interactors recover the majority of 
known and numerous novel protein-protein interactions 
Schematic representation of the domains and known tyrosine phosphorylation sites of 
the nine Bcr-Abl interactors that were tagged on their N- or C-terminus and subjected 
to TAP. Identified interactors are represented as 'star'-diagram with the respective bait 
protein in the middle. Interactors that had been annotated in HPRD or IntAct are shown 
as white circles, whereas black circles represent potential novel interactions. 
 
This dataset enriches the still scanty database of human mass 
spectrometry-analyzed protein-protein interactions and the accumulation of 
interesting signalling proteins as members of the Bcr-Abl core complex 
candidatesʼ protein complexes prompted us to further analyze the physical 
protein-protein interaction network around the Bcr-Abl ʻcoreʼ complex. 
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3.4 Bcr-Abl protein network analysis identifies a 4- and 5-core Bcr-Abl 
ʻcoreʼ complex 
The combination of the datasets from the nine TAP purifications 
resulted in a single coherent protein-protein interaction network around the nine 
bait proteins embedding Bcr-Abl in its center. Analysis of the network topology 
revealed a high level of interconnectivity (Figure 3.7). To monitor the 
significance and degree of interconnectivity, we considered ʻk-coresʼ in the 
network (Tong, Drees et al. 2002), which were first used by Christopher Hogue 
and Charlie Boone. A ʻk-coreʼ is a sub-network of proteins (nodes) containing at 
least k nodes, where each node is linked to at least k other nodes. For example, 
in a 4-core (i.e. k=4) each node is connected to at least four other members of 
the protein network constituting the 4-core network. If, according to our 
hypothesis, the candidate members of endogenous Bcr-Abl ʻcoreʼ complexes 
were indeed more intimately associated with Bcr-Abl than any other protein 
identified in the enlarged TAP protein-protein interaction network, then they 
should cluster around Bcr-Abl by having many more links amongst each other. 
Indeed, the eight proteins (nodes) Bcr-Abl, Ship2, c-Cbl, p85α/β, Sts-1, Shc-1, 
Grb2 and Crk-I form a 4-core. Interestingly, if Sts-1 is excluded, the closer Bcr-
Abl interactors form an even more connected 5-core (Figure 3.7,Figure 3.9). To 
assess the significance of our finding of a 4- and 5-core Bcr-Abl ʻcoreʼ complex, 
we performed randomized network simulations. Generating 105 different 
randomized networks resulted only in 2- and 3-cores in approximately equal 
proportion (Figure 3.8, grey histogram), but no k-cores with k larger than 3. 
Therefore, the observed 4- and 5-core networks are statistically highly 
significant (P<10-5, Figure 3.8, red and blue line graph). In other words, no 4- 
and 5-cores were found in 100,000 randomly simulated networks of the size 
(number of nodes = 91) of our experimentally generated network (Figure 3.7). 
The two TAP baits of the AP2 adaptor protein complex (Eps15 and AP2µ1) 
display three (AP2µ1) and only one edge (Eps15) to the members of the 5-core 
and are therefore positioned more distantly in the network (Figure 3.7,Figure 
3.10). 
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Figure 3.7 The Bcr-Abl protein-protein interaction network 
Combination of the nine TAP purification datasets results in a single protein-protein 
interaction network. The nine TAP bait proteins are shown as rectangles, Bcr-Abl as 
diamond-shape and all other identified interactors as ellipses. The 4-core Bcr-Abl 'core 
complex' is highlighted in red, the associated AP2 adaptor complex is highlighted in 
blue. Interactors with three, two or one edge(s) to the Bcr-Abl core network are shown 
in light blue, turquoise and dark green, respectively. Sts-1 is shown in yellow, as its 
removal from the 4-core Bcr-Abl ʻcore complexʼ results in a 5-core complex. The figure 
was created using Cytoscape. 
 
To limit the possible bias introduced by the a priori selection of the nine 
bait proteins, where a protein that was not initially selected as Bcr-Abl interactor 
could have a reduced connectivity with the complex around Bcr-Abl, we 
represent the TAP-MS results as an undirected graph, meaning that the edges 
between the nodes in the network do not contain directionality information on 
the interactions. Therefore, a link created from a bait protein is also valid 
starting from its prey (Figure 3.7). 
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Figure 3.8 Randomized network simulations yield only 2- or 3-cores. 
The grey histogram shows the proportion (density) of random networks that contain a 
k-core with highest possible k. The blue line graph shows the P-value of a k-core 
deduced from the histogram. The red line graph represents the proportion (density) of 
proteins in the network that are found in a k-core with highest possible k for 
k=1,2,3,4,5. Therefore, the experimentally observed 4-core and 5-core networks are 
statistically highly significant. 
 
Clearly, Bcr-Abl is most intimately interconnected with Ship2, c-Cbl, 
p85α/β, Shc1, Sts-1, Grb2 and Crk-I, that we define as the eight member Bcr-
Abl 'core' complex (Gavin, Aloy et al. 2006). From all that is known about the 
biology of p85α and p85β, it is unlikely that both p85 isoforms may have a 
different binding mode nor be present simultaneously in the Bcr-Abl core 
complex (Geering, Cutillas et al. 2007; Zhao and Vogt 2008). Therefore, both 
isoforms are treated equally throughout this thesis. The network analysis also 
revealed some proteins interacting with three different Bcr-Abl core interactors, 
each (Figure 3.7, light blue nodes). These included Spectrin-α, two of the 
catalytic subunits of PI3K (p110α and p110β), the SH2-domain containing 
tyrosine phosphatase Shp-2, the tyrosine kinase Csk, the Grb2 adaptor binding 
protein Gab2 and the guanine nucleotide exchange factor Sos1. Many of these 
proteins are proto-oncogenes and have been described to form critical links to 
downstream signaling pathways (p110α/β for the PI3K/Akt pathway, Sos1, 
Gab2 and SHP-2 for the Ras/MAPK pathway) and were shown to be necessary 
for Bcr-Abl dependent transformation, e.g. SHP-2 and Gab2 (Chen, Yu et al. 
2007), (Sattler, Mohi et al. 2002). 
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Figure 3.9 The Bcr-Abl multi-protein complex is a ʻ4-coreʼ complex 
A representation of the Bcr-Abl protein interaction network in the absence of interactors 
with less than four edges to other nodes (k ≥ 4), highlighting the 4-core Bcr-Abl 'core 
complex'. 
 
3.5 Identification of a 3-core AP2 adaptor protein complex associated 
with the Bcr-Abl ʻcoreʼ complex 
Interestingly, the network analysis of the TAP dataset showed that 
Eps15 and AP2µ1 are part of an 11 member 2-core complex (AP2α1, AP2α2, 
AP2β1, AP2µ1, AP1β1, Bike, Eps15, NECAP2, Stn-2) that included Shc-1 and 
Crk-I (Figure 3.7, blue halo). Within this complex, AP2µ1, Eps15, AP2α1, 
AP2α2 and AP2β1 even form a 3-core complex, again including Shc-1 and Crk-
I. Only AP2µ1 is directly linked to Bcr-Abl (Figure 3.10). However, as Crk-I has 
three edges to AP2α1, Eps15 and AP2µ1 and Shc1 has four edges to AP2α1, 
AP2α2, AP2β1 and AP2µ1, these can clearly be considered as the interface of 
the Bcr-Abl ʻcoreʼ complex to the AP2 adaptor protein complex. Eps15 is an 
interactor of AP2 subunit AP2α1 (Benmerah, Gagnon et al. 1995; Benmerah, 
Lamaze et al. 1998). Stn-2 (Stonin-2), but not Stn-1, was shown to be 
associated with Eps15 via an NPF signature in its proline rich domain and the 
EH-domain (Eps15-homology domain) of Eps15 (Martina, Bonangelino et al. 
2001). This evidence was additionally confirmed by the recent description of the 
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structure of the Eps15-Stonin-2 complex confirming this interaction mode 
between the endocytic sorting adaptor Stonin-2 and the clathrin accessory 
protein Eps15 (Rumpf, Simon et al. 2008). Reps1 has been shown to form 
complexes with the SH3 domains of c-Crk and Grb2, which may link Reps1 to 
AP2 containing endocytic protein complexes in receptor tyrosine kinase 
trafficking (Yamaguchi, Urano et al. 1997). Eps15 also binds c-Crk in an SH3-
domain dependent manner (Schumacher, Knudsen et al. 1995), just as REPS1, 
underlining our finding that the AP2 adaptor protein complex is linked to the Bcr-
Abl ʻcoreʼ complex via Crk-I and Shc1.  
 
 
Figure 3.10 The Bcr-Abl ʻcoreʼ complex complex is linked to the AP2 adaptor 
protein complex 
A representation of the Bcr-Abl protein-protein interaction network in the absence of 
interactors with less than three edges to other nodes (k ≥ 3), highlighting the 
associated 3-core AP2-adaptor protein complex. 
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This raised the possibility that AP2 adaptor complex mediated 
intracellular trafficking is functionally linked to the Bcr-Abl complex in analogy to 
the function of the AP2 adaptor complex in receptor tyrosine kinase trafficking 
via clathrin-coated pits (Beattie, Howe et al. 2000). Interestingly, the small 
adaptor protein Grb2, which is also part of the Bcr-Abl ʻcoreʼ complex, has been 
shown to be involved in this process (Johannessen, Pedersen et al. 2006). 
 
3.6 Quantitative characterization of the Bcr-Abl ʻcoreʼ complex 
All modern systems-biological approaches require quantitative 
information in addition to physical and functional descriptions (Ong and Mann 
2005; Papin, Hunter et al. 2005) and the tools for the comprehensive 
identification and relative quantification of the cellular abundance of entire 
proteomes have already been established (Cox and Mann 2008; de Godoy, 
Olsen et al. 2008). Both the semi-quantitative analysis of the endogenous Bcr-
Abl interactors by mass spectrometry (section 3.2), as well as the ensuing 
network analysis (section 3.4) are compatible with the existence of an eight 
protein Bcr-Abl ʻcoreʼ complex, making the effort worthwhile to determine the 
absolute cellular protein copy numbers as well as the interaction stoichiometry 
of the proteins involved in the Bcr-Abl ʻcoreʼ complex. 
 
3.6.1 Cellular protein copy number quantification of the Bcr-Abl ʻcoreʼ 
complex components 
First, we expressed and purified one recombinant protein of each of the 
Bcr-Abl core complex members containing the epitopes for the respective 
antibodies (Figure 3.11). We used dilutions of these recombinant 'epitope 
standards' and compared them to four dilutions of K562 total cell lysate (50, 
100, 150 and 200µg total protein) by semi-quantitative immunoblotting (see 
Materials and Methods). Knowing the precise cell count, volume and protein 
concentration of the cell lysate, this enabled us to infer the apparent absolute 
protein copy number per K562 cell of Bcr-Abl and the seven core interactors 
(Figure 3.12). 
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Figure 3.11 Recombinant epitope protein standards 
(A) Schematic representation of recombinant protein standards corresponding to the 
epitopes of the antibodies used to detect Bcr-Abl and the seven core interactors. The 
position of the recombinant epitope standard with respect to the full-length protein is 
highlighted (red box). 
(B) Recombinant epitope standards were expressed as GST- or MBP-fusion proteins 
and purified to homogeneity. 10µg of each purified recombinant protein were resolved 
by SDS-PAGE and stained with coomassie to confirm protein size, purity and protein 
concentration. 
 
All eight proteins, except for Crk-I, are expressed within one order of 
magnitude of each other. Bcr-Abl is present at about 300,000 copies per cell. 
This number was generated using recombinant Abl kinase domain (Abl KD) as 
ʻepitope standardʼ. Quantification of total cellular protein copy numbers of Bcr-
Abl using recombinant FABD as ʻepitope standardʼ led to a lower number of 
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about 200,000 copies Bcr-Abl per K562 cell. However, given the possibility that 
Bcr-Abl may degrade from its C-terminal end in the total K562 cell lysates used 
for the absolute quantification, thereby losing the epitope for the 24-21 antibody, 
we focused on quantifications using Abl KD as ʻepitope standardʼ in order to 
exclude this potential error source. Interestingly, c-Abl was found to be 
expressed at about equal protein copy numbers as Bcr-Abl (data not shown). 
p85β, Sts-1 and Grb2 had similar expression levels at approximately 200,000 
copies per cell. Ship2 (~500,000), c-Cbl and Shc1 (~350,000) were found to be 
most abundant among the Bcr-Abl core members (Figure 3.12). These 
measurements were performed at least as technical triplicates and at an overall 
average error of 30% standard deviation (% STDEV) (Figure 3.12). 
Determination of the copy number of the adaptor protein Crk-I was hampered by 
unsolvable ambiguity problems mainly with Crk-II, but also with CrkL, at the 
mass spectrometry and antibody level, so that the derived copy number of 
approximately 25,000 should be considered with caution, particularly as it is 
poorly compatible with the proposed Bcr-Abl stoichiometry (seeFigure 3.3). 
Assuming that all seven proteins interact with Bcr-Abl at stoichiometric levels, 
each K562 cell potentially contains a theoretical number of about 200,000 to 
300,000 Bcr-Abl protein complexes.  
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Figure 3.12 Absolute quantification of total cellular protein copy numbers  
(A) Serial dilutions of K562 total cell lysate were analyzed next to serial dilutions of the 
indicated recombinant epitope standard by immunoblot against Bcr-Abl and the seven 
core complex members. The protein copy number per K562 cell was calculated by 
determining the molarity of the respective protein in the extract using the epitope 
standard dilution series to obtain a partial regression line and the concentration and 
total cell number of protein extract used. The average copy number per cell was 
obtained from at least three independent experiments. 
(B) Bar graph displaying the total cellular protein copy number of Bcr-Abl and the seven 
Bcr-Abl complex comonents. Error bars show the standard deviation, which was 
derived from at least three technical repeats. 
 
This, however, would imply the unlikely scenario that all protein copies 
of the seven interactors are complexed with Bcr-Abl and that no ʻfreeʼ copies 
remain available in the K562 cell for participation in other protein complexes 
and signal transduction pathways. Furthermore, we observed that, albeit 
surprising, the interaction stoichiometry for the majority of the interactors is 
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rather sub-stoichiometric and that, indeed, only proportions of a maximum of 
30% of the total cellular copies of the Bcr-Abl interacting proteins are associated 
with Bcr-Abl upon co-immunoprecipitation (see section 3.6.2,Figure 3.13). 
Therefore, lower actual interaction stoichiometries should be taken into account 
and the absolute protein copy numbers should be treated with caution. 
 
3.6.2 Quantification of the Bcr-Abl ʻcoreʼ complex interaction 
stoichiometry and cellular Bcr-Abl – associated proportions of 
each protein 
Following the quantification of the total protein copy numbers per K562 
cell we quantified the amount of copies of each Bcr-Abl core interactor co-
immunoprecipitating with Bcr-Abl and the interaction stoichiometry between Bcr-
Abl and its ʻcoreʼ complex interactors. From a single medium-scale Bcr-Abl/c-
Abl immunoprecipitation we quantified the absolute copies of Bcr-Abl and the 
co-immunoprecipitated Bcr-Abl interactors using the recombinant ʻepitope 
standardsʼ (Figure 3.13A). We were able to derive the Bcr-Abl ʻcoreʼ complex 
interaction stoichiometry by calculating the ratio of copies of each core complex 
member over Bcr-Abl copies (Figure 3.13A,B). The molarity of 
immunoprecipitated Bcr-Abl was quantified using recombinant Abl KD as 
ʻepitope standardʼ. To our surprise, only Ship2 had a stoichiometry around 1 
(1.3) with Bcr-Abl. Sts-1, Shc1 and Grb2 were found with a lower stoichiometry 
of around 0.5 (0.4, 0.4 and 0.3, respectively) (Figure 3.13B). The sub-
stoichiometric ratios obtained for p85β (0.04) and Crk-I (0.01) are clearly in 
contradiction with our ʻsemi-quantitativeʼ evidence for stoichiometric interaction 
of these two proteins with Bcr-Abl by mass spectrometry (peptide coverage) 
(Figure 3.2, Figure 3.3). As already suggested for the low absolute cellular copy 
number of the Crk-I protein, also in this case detection ambiguity issues with the 
Crk-I antibody are likely to influence the result.  
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We furthermore determined, which fraction of total cellular protein of 
each core complex member was sequestered into Bcr-Abl complexes as 
compared to how much was associated with different complexes that do not 
contain Bcr-Abl. Therefore, we quantified the input- and supernatant bands for 
each core interactor in order to monitor the depletion (equals Bcr-Abl 
association) of each from the cell lysate following c-Abl/Bcr-Abl-
immunoprecipitation (Figure 3.13A). We calculated the fraction of Bcr-Abl 
associated core interactor (%) by subtracting the band intensity of the 
supernatant-sample from the band intensity of the input-sample and 
subsequently deduced the proportion of “Bcr-Abl associated” protein (Figure 
3.13A,C). Bcr-Abl was depleted by about 83%. While ~40% of total Ship2 and 
30% of Sts-1 were found to be Bcr-Abl-associated, ~20% c-Cbl and Shc1 and 
~10% of cellular p85β and Grb2 were Bcr-Abl associated. In contrast again, 
very little of the total Crk-I protein seemed to be bound in Bcr-Abl complexes. 
Protein co-depletion upon Bcr-Abl immunoprecipitation is supposed to be in 
correlation with the total cellular copy numbers and the interaction stoichiometry 
within the complex. We found this correlation by large confirmed upon 
comparison of our stoichiometry and ʻBcr-Abl-associationʼ data (Figure 
3.12,Figure 3.13). 
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Figure 3.13 Absolute quantification of the Bcr-Abl ʻcoreʼ complex stoichiometry 
and cellular Bcr-Abl-association 
(A) Input, immunoprecipitation and supernatant fractions of one Abl-
immunoprecipitation were analyzed next to serial dilutions of the indicated recombinant 
epitope standard by immunoblot against Bcr-Abl and the seven core complex 
members. 
(B) The interaction stoichiometry of the complex was calculated by determining the 
molarity of the respective protein in the immunoprecipitate using the epitope standard 
dilution series to obtain a partial regression line and by calculating the ratios over Bcr-
Abl. The average stoichiometry and standard deviation was obtained from at least 
three independent experiments. 
(C) Bcr-Abl associated versus ʻfreeʼ protein fractions were determined by quantification 
of the input and supernatant bands and calculation of the respective proteinʼs depletion 
(%). 
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Ship2 is expressed at about two-fold the number of Bcr-Abl protein 
copies and was found at highest stoichiometry of about 1:1 with Bcr-Abl. 
Accordingly, about 50% of total Ship2 protein were depleted. Similarly, we found 
roughly twice as much c-Cbl protein depleted (20%) as compared to p85β 
(10%). This is in line with the about three-fold higher stoichiometry measure of 
c-Cbl (0.13) than that of p85β (0.04) and roughly twice as much c-Cbl copies 
expressed (370,000) compared to p85β (200,000). Strikingly, also the 
measurements for Sts-1 and Shc1 nicely correlate. Both were found at the 
same stoichiometry (0.4). With twice as much Shc1 copies (400,000) expressed 
compared to Sts-1 (200,000), accordingly much less total Shc1 is depleted from 
the lysate. Both p85β and Grb2 are present at about 200,000 copies per cell. 
According to their stoichiometries, depletion upon Bcr-Abl immunoprecipitation 
does not correlate. Shc1 and c-Cbl are both present at about 370,000 copies 
per cell. Despite of the higher stoichiometry of Shc1, however, about equal 
levels of c-Cbl and Shc1 were found depleted. Overall however, proteins with 
the highest stoichiometries, Ship2, Sts-1 and Shc1 show the highest degree of 
Bcr-Abl association in this depletion measurement (Figure 3.12,Figure 3.13). 
Overall, taking these results into account, the initially deduced 
stoichiometric interaction of all seven proteins with Bcr-Abl has to be treated 
with caution, because the semi-quantitative measures peptide count and 
sequence coverage might have been biased by the fact that not all peptides in a 
protein have equal chances to be detected by the mass spectrometer due to 
their different physico-chemical properties. Accepting lower stoichiometries for 
the ʻcoreʼ interactors in light of the observed total cellular protein copy numbers 
would consequently match the observed proportions of Bcr-Abl-associated 
versus ʻfreeʼ proteins. This would imply an overall lower number of Bcr-Abl 
ʻcoreʼ complexes containing all seven interactors and also suggest the 
possibility of the existence of various Bcr-Abl sub-ʻcoreʼ-complexes that contain 
only some of the ʻcoreʼ interactors at a time and are not obvious from the 
network analysis (see Discussion, section 4.6, Figure 4.3, Figure 3.7,Figure 
3.9). 
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3.7 Biophysical characterization of the Bcr-Abl ʻcoreʼ complex 
Assuming a stoichiometric interaction of 1:1 of all seven ʻcoreʼ complex 
components with tetrameric Bcr-Abl we postulated a macromolecular Bcr-Abl 
molecular machine of about 3MDa (mega-dalton). In order to confirm this 
concept, we set out to determine the overall size of the complex by glycerol 
density gradient centrifugation and gel-filtration chromatography in mock- and 
tyrosine kinase inhibitor (TKI) - treated K562 cells. According to our preliminary 
evidence, TKI action inhibits Bcr-Abl and, as a consequence, also abrogates 
binding of the interactors significantly (Figure 3.3).  
 
3.7.1 Purification of the Saccharomyces cerevisiae Pwp2 high molecular 
weight pre-ribosomal complex as a size standard 
In order to adjust the gradient conditions to the postulated MDa size-
range, we chose to purify a stable and abundant high molecular weight complex 
from Saccharomyces cerevisiae (S. cerevisiae). Under the courtesy of Anne-
Claude Gavin at the EMBL, Heidelberg, we purified high molecular weight S. 
cerevisiae pre-ribosomal protein complexes to 40S ribosome subunits by 1-step 
TAP using Pwp2 as bait (from here on referred to as ʻPwp2 complexʼ) (Figure 
3.14A) (Grandi, Rybin et al. 2002). The bait protein Pwp2 was recovered 
abundantly alongside with its stoichiometric interactors (Figure 3.14A,B). 
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Figure 3.14 One-step TAP of the Saccharomyces cerevisiae Pwp2 complex 
(A) Pwp2 complexes were purified from eight litres yeast culture by one-step TAP. 5µl 
of input material, equal volume of IgG-supernatant and 20µl of TEV-eluted Pwp2 
complex were separated by 10% SDS-PAGE and visualized by coomassie staining. 
(B) Pwp2 complexes purified by two-step TAP. Protein complexes were eluted from 
calmodulin beads using EGTA and visualized on a 4%-12% gradient gel by coomassie 
staining. Proteins annotated on the right were identified by mass spectrometry (MALDI-
TOF) (Figure (B) taken from (Grandi, Rybin et al. 2002)). 
 
This protein complex has been described in detail by density gradient 
centrifugation and gel-filtration chromatography before and features the inherent 
advantage that it has about 4-6MDa size and also contains a highly stable 
600kDa sub-complex (Grandi, Rybin et al. 2002). As tetrameric Bcr-Abl without 
protein interactors has a molecular weight of about 840kDa and, within our 
postulated ʻcoreʼ complex, around 3MDa, the Pwp2 complexes were chosen to 
adjust the gradients for this size-range. 
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3.7.2 ʻSizingʼ the Bcr-Abl ʻcoreʼ complex by density gradient 
centrifugation 
Our aim was to identify Bcr-Abl in high-molecular weight fractions of 20-
80% glycerol density gradients corresponding to about 3MDa size together with 
all of the seven ʻcoreʼ complex interactors, as well as to, eventually, identify 
smaller sub-complexes. 20-80% glycerol density gradients were able to resolve 
the 600kDa Pwp2 sub-complex (fraction 4, Figure 3.15A) from the high-
molecular weight (4-6MDa) Pwp2 complexes (fractions 7-9, Figure 3.15A). We 
then analyzed mock- and dasatinib-treated K562 cell lysate by density gradient 
centrifugation on 20-80% glycerol, following the same conditions. Interestingly, 
following immunoblot analysis for Bcr-Abl, c-Abl and its ʻcoreʼ interactors Ship2, 
c-Cbl, Sts-1, Shc1 and Grb2, we found the strongest signal for Bcr-Abl starting 
from fraction 5. Stable Pwp2 600kDa complexes were observed at fraction 4. 
Therefore Bcr-Abl appearing primarily in fractions 5, 6 and 7 was in line with its 
primary presence as a tetramer of about 840kDa size (Figure 3.15B,C), 
however without protein interactors bound. c-Abl, however, which lacks the N-
terminal coiled-coil domain responsible for tetramerization of Bcr-Abl, was 
shifted left-wards relative to Bcr-Abl and was detectable already in fraction 2, 
while it was basically absent in fractions 6 and 7. Overall, the majority of the 
Bcr-Abl ineractors migrated in the early fractions 1-5, corresponding to their 
lower molecular weight (Grb2 peak in fraction 1). Interestingly, however, Bcr-Abl 
and Ship2 were both prominently detectable in fractions 7-9, corresponding to 
higher molecular weight complexes (Figure 3.15B), as 4-6MDa Pwp2 
complexes were found in fractions 7-9, too (Figure 3.15A). The other interactors 
were also detectable in these fractions, albeit much more faintly. This profile 
surprisingly mirrors the interaction stoichiometry observed from the Bcr-Abl co-
immunoprecipitation, where Ship2 showed the highest interaction stoichiometry 
as compared to the other proteins. 
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Figure 3.15 Glycerol density gradient centrifugation of the S. cerevisiae Pwp2 
complex and mock- and dasatinib-treated K562 total cell lysate 
50µl of purified S.cerevisiae Pwp2 complex (A) and 3mg mock- (B) and dasatinib-
treated (C) K562 cell lysate were separated on 2ml 20-80% glycerol density gradients 
at 54,000rpm for seven hours. Fractions à 125µl were collected with a pipette from top 
to bottom. 
(A) 50µl of each fraction were separated on a 10% SDS-gel and Pwp2 complexes were 
visualized by silver-staining. 
(B,C) 50µl of each fraction were separated on a 6% and 10% gel and Bcr-Abl and 
candidate ʻcoreʼ interactors were analyzed by immunoblotting. 
 
However, we were not able to observe a clear left-shift of Bcr-Abl and 
its interactors towards lower molecular weight upon treatment with dasatinib 
(Figure 3.15C). Differences observed between the two samples were too subtle 
to explain the disruption of a MDa protein complex and most likely resulted from 
variation in the gradient or fraction harvesting. It is possible, that the high-
molecular weight complexes did not resist the long high-speed centrifugation 
procedure and that the picture above reflects a mixture of monomeric protein 
components and a variety of subcomplexes between Bcr-Abl and its interactors 
as well as between the interactors themselves, not involving Bcr-Abl. 
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3.7.3 Bcr-Abl ʻcoreʼ complex members are found in MDa high molecular 
weight fractions together with Bcr-Abl only in the absence of 
tyrosine kinase inhibitors 
Given the possibility that the high molecular-weight Bcr-Abl ʻcoreʼ 
complexes are destroyed during long-term high-speed density gradient 
centrifugation (see 3.7.2), we applied 500µl of mock- and dasatinib-treated 
K562 cell lysate at equal protein concentration on a FPLC Superose 6 gel-
filtration column. Before, we calibrated the column using molecular weight 
standard proteins and analyzed fractions within a range of 10kDa and several 
MDa molecular weight, in order to capture proteins starting from the smallest 
Bcr-Abl ʻcoreʼ complex component Crk-I up to MDa multi-protein complexes 
around Bcr-Abl. In this experiment we included CrkL as a control, a well-known 
Bcr-Abl interactor that was not found significantly involved within the Bcr-Abl 
multi-protein complex in our TAP-LC-MSMS network analysis. The major 
proportion of the proteins were found distributed in low molecular weight 
fractions with a peak corresponding to their respective molecular weigth, which 
resulted in a right-shifted diagonale pattern with decreasing size of the 
monomeric proteins (Figure 3.16). However, comparing the two FPLC runs 
performed either with untreated or dasatinib-treated K562 cell lysate directly 
next to each other revealed that Bcr-Abl and a proportion of its ʻcoreʼ interactors 
are found together in high molecular weight fractions compatible with a MDa 
multi-protein complex only in the untreated sample. CrkL, on the other hand, is 
completely absent from these fractions and only found in fractions D1-D3 
(Figure 3.16).  
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Figure 3.16 Superose 6 gel-filtration analysis of mock- and dasatinib-treated 
K562 total cell lysate 
500µl of mock- and dasatinib-treated K562 total cell lysate were applied on a FPLC 
Superose 6 gel-filtration column. Fractions were analyzed by SDS-PAGE and 
immunoblotting. The Superose 6 column was calibrated with gel-filtration standard 
proteins of 600, 158, 44 and 17kDa molecular weight. 
 
In the dasatinib-treated samples, proteins shift right towards low-
molecular weight fractions according to their molecular weight. In the untreated 
sample, however, the small proteins Grb2 and Crk-I, but not Crk-L can faintly 
but clearly be seen up to higher molecular weight fractions (fraction C1) (Figure 
3.16). Ship2, p85β and Shc1 are clearly co-eluting with Bcr-Abl within the MDa-
range (fractions B7-C1) in the untreated but not in the treated sample. c-Cbl 
also shows this pattern, however down-shifted between fractions B5 and C5 
probably due to degradation, so that this effect has to be treated with caution 
(Figure 3.16). A slight down-shift can be observed for Ship2 upon treatment, 
which is in line with its loss of tyrosine phosphorylation. Strikingly, however, 
residual levels of Ship2 protein were found at high molecular weight fractions 
even in the treated samples, which would be in line with residual SH3-domain 
mediated interaction of Ship2 with Bcr-Abl after treatment with tyrosine kinase 
inhibitors (Figure 3.16 fractions B7-C1, Figure 3.3). Unfortunately, detection of 
Bcr-Abl was difficult given the dilution of the material upon gel-filtration and did 
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not allow to nicely visualize a shift towards lower molecular weight upon 
dasatinib-treatment. However, the shift becomes obvious, when Bcr-Abl levels 
are compared between fractions B11 to C5, where monomeric Bcr-Abl is 
present at equal amounts. Increased levels of Bcr-Abl are present in the 
untreated sample in fractions B9 and B11. c-Abl, which also appears to be 
present in higher molecular weight complexes, does not show the dasatinib-
dependent pattern described for Bcr-Abl and its interactors, and serves as a 
control (Figure 3.16). Similar results could also be obtained upon nilotinib-
treatment, whereas the differences were less pronounced (data not shown). As 
this analysis is based on total cell lysate, however, and as dasatinib and 
nilotinib both inhibit the major driver of tyrosine-phosphorylation in K562 cells 
(Bcr-Abl), treatment might consequently have affected tyrosine phosphorylation 
- dependent interactions of many other protein complexes involving these 
proteins, besides Bcr-Abl ʻcoreʼ complexes.  
 
3.8 siRNA perturbation of Bcr-Abl ʻcoreʼ interactors neither affects 
K562 cell proliferation nor other known signal transduction 
markers 
In order to assess the functional relevance of the identified Bcr-Abl 
interactors, we performed siRNA knockdown experiments of the 7 core complex 
components including Bcr-Abl/c-Abl itself and reduced the levels of the target 
proteins by at least 75% for all core interactors (Figure 3.17A, data kindly 
provided by Agnes Gstöttenbauer and Ines Kaupe). However, the knockdowns 
of the individual core interactors did not have an effect on Bcr-Abl 
autophosphorylation levels (Figure 3.17B) or K562 proliferation rate or viability 
(data not shown). Furthermore, none of the known signal transduction markers, 
such as phospho-Stat5 (Harir, Pecquet et al. 2007) or phospho-Akt (Steelman, 
Pohnert et al. 2004; Yang, Cron et al. 2002, Chu, 2007 #1233), showed 
conclusive changes in immunoblot analysis of K562 siRNA-knock-down 
samples (data not shown).  
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Figure 3.17 siRNA perturbation of seven Bcr-Abl ʻcoreʼ complex members 
(A) K562 cells were transiently transfected with SmartpoolTM siRNAs targeting c-Abl, 
Ship2, c-Cbl, p85α, p85β, Sts-1, Shc1, Grb2 and Crk-I or a control siRNA and 
retransfected after 24h. 72 h after the first transfection 100µg of total cell lysate was 
analyzed by quantitative immunoblotting for assessment of protein knockdown 
efficiency. 
(B) K562 cell lysates from wildtype, mock-, control- siRNA and SmartpoolTM siRNA-
transfected cells were analyzed by immunoblotting for total Bcr-Abl, c-Abl, total p-Y and 
Actin protein levels. Actin served as control for uniform sample loading. 
 
Even multiple attempts knocking down pairwise combinations of 
interactors or all seven interactors at a time did not affect K562 viability. In 
contrast, K562 cells rapidly stopped proliferating and underwent apoptosis when 
Bcr-Abl protein levels were reduced using an Abl or Bcr-Abl breakpoint-specific 
siRNA (Figure 3.17A and data not shown). This may be in line with the severe 
addiction of K562 cells to their oncogene Bcr-Abl that may be able to override 
many different, even severe perturbations in its downstream signal transduction 
network and may uncover unexpected redundancy in signalling pathways 
exerting Bcr-Abl's oncogenicity. 
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3.9 Tyrosine kinase inhibitors disrupt and remodel the Bcr-Abl ʻcoreʼ 
complex 
The tyrosine kinase inhibitors nilotinib and dasatinib are very potent 
inhibitors of Bcr-Abl and successfully used to treat CML patients (Quintas-
Cardama, Kantarjian et al. 2007). Dasatinib has a markedly broader specificity 
compared to the highly selective nilotinib (Hantschel, Rix et al. 2008), (Rix, 
Hantschel et al. 2007). In order to monitor the impact of these tyrosine kinase 
inhibitors on the integrity and composition of the Bcr-Abl complex, we treated 
K562 cells with dasatinib and nilotinib for 3 hours at concentrations 
approximately 10 times higher than their respective IC50 values for Bcr-Abl. 
Under these conditions, no Bcr-Abl autophosphorylation or tyrosine 
phosphorylation of other proteins in K562 cell lysates was detectable by 
immunoblotting, suggesting effective suppression of Bcr-Abl kinase activity and 
Bcr-Abl dependent signal transduction (data not shown). In contrast, cell 
viability, total cell numbers and protein content was not decreased after 3 hours 
of inhibitor treatment when compared to mock-treated control cells (data not 
shown). We immunoprecipitated Bcr-Abl complexes from mock- and drug-
treated cells and analyzed the samples by immunoblotting against the Bcr-Abl 
interactors (Figure 3.18A). In addition, we performed relative quantification by 
mass spectrometry using iTRAQ labelling (Ross, Huang et al. 2004) in 
cooperation with the lab of Karl Mechtler at the IMP in Vienna. The outline of the 
iTRAQ workflow is shown in Figure 3.18C. While Bcr-Abl immunoprecipitated 
with equal efficiency from mock-, dasatinib- and nilotinib-treated K562 cells, a 
strong decrease in the interaction of all seven ʻcoreʼ interactors was observed in 
the presence of the drugs (Figure 3.18A). Interaction of Bcr-Abl with c-Cbl, Sts-
1, Shc1 and Crk-I were undetectable upon drug treatment, whereas residual 
binding of Ship2, p85β and Grb2 to Bcr-Abl could be detected in the presence of 
both drugs (Figure 3.18A). In line with these results, interaction of all seven 
ʻcoreʼ members with Bcr-Abl was significantly reduced by dasatinib using 
relative iTRAQ quantification by mass spectrometry (Figure 3.18B). In another 
iTRAQ experiment we compared mock- and nilotinib-treated samples. Here, 
Crk-I, Sts-1 and Shc-1 showed reduced binding to Bcr-Abl (Figure 3.18B). 
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Interestingly, Crk-I, Sts-1 and Shc-1, which were undetectable in Abl 
immunoprecpitates from drug-treated cells, also showed the strongest reduction 
in binding to Bcr-Abl (>5-fold) in both quantitative mass spectrometry 
experiments (Figure 3.18A,B). Notably, Ship2 showed the mildest reduction 
(2.5-fold) in binding by dasatinib in the mass spectrometry experiment. In line 
with this, residual interaction with Bcr-Abl could be detected by immunoblotting 
(Figure 3.18A,B). 
 
 
Figure 3.18 Nilotinib and dasatinib disrupt and remodel the Bcr-Abl ʻcoreʼ 
complex 
(A) Bcr-Abl protein complexes were immunoprecipitated from mock-, dasatinib- and 
nilotinib-treated K562 cells and immunoblotted against Bcr-Abl and the seven core 
interactors. 
(B) Quantitative mass spectrometry analysis using iTRAQ labelling comparing 
dasatinib- versus mock-treated and nilotinib- versus mock-treated Bcr-Abl 
immunoprecipitates. Numbers indicate the medians of the four fold down-regulation 
ratios. 
(C) Workflow outlining the iTRAQ labelling strategy employed for this study. Bcr-Abl or 
Grb2 protein complexes were immunoprecipitated and eluted with HCl. Eluates were 
reduced, alkylated, digested with trypsin, split in half and labelled with two different 
isobaric tags, each. 
 
In order to analyze changes in protein complex composition of a 
specific Bcr-Abl interactor, we immunoprecipitated Grb2 (Figure 3.18C), probed 
for Bcr-Abl and the selected core interactors and performed relative 
quantification using iTRAQ in the presence and absence of nilotinib. Reduced 
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binding of Bcr-Abl, Ship2 and Shc-1 to Grb-2 was detected by iTRAQ and 
immunoblotting (Figure 3.19A,B).  
 
 
Figure 3.19 Nilotinib disrupts and remodels the Bcr-Abl - Grb2 protein complex 
(A,C). Grb2 protein complexes were immunoprecipitated from mock- and nilotinib-
treated K562 cells and immunoblotted against Grb2, Bcr-Abl, SHIP2, Shc-1 and Sos1. 
(B,D). Quantitative mass spectrometry analysis using iTRAQ labelling comparing 
nilotinib- versus mock-treated Grb2 immunoprecipitates. Each of the two conditions 
was labeled with two different isobaric tags. 
 
 
Interestingly, we detected an increase in binding of Sos1 to Grb-2 by 
both iTRAQ (0.5-fold) and immunoblotting (Figure 3.19C,D). Altogether, this 
shows that the entire Bcr-Abl complex is severely affected by the drug 
treatment, but at the same time that individual interactions are affected 
differentially, so that one can still detect a post-drug protein complex. In order to 
confirm that the Bcr-Abl ʻcoreʼ complex per se is the target of tyrosine kinase 
inhibitors such as dasatinib and nilotinib, we immobilized dasatinib on 
sepharose beads with the help of Uwe Rix in the lab, and used the drug beads 
as an affinity reagent for a pull-down experiment from untreated with K562 cells 
or the Bcr-Abl negative lymphoblast cell line U937 (Hantschel, Rix et al. 2007), 
(Rix, Hantschel et al. 2007) (samples provided by Tilmann Bürckstümmer and 
Oliver Hantschel). Bound proteins were analyzed by immunoblotting for Bcr-Abl, 
Ship2, Sts-1, Shc1 and Grb2 (Figure 3.20). From K562 cells, Bcr-Abl and four 
core interactors could be identified by immunoblotting, whereas none of the core 
interactors were identified from U937 cells (Figure 3.20). 
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Figure 3.20 The Bcr-Abl ʻcoreʼ complex is the target of tyrosine kinase inhibitors 
Immobilized dasatinib was incubated with K562 or U937 total cell extracts and bound 
proteins eluted by boiling in SDS sample buffer. The eluates were immunoblotted for 
Bcr-Abl, Ship2, Sts-1, Shc1 and Grb2. 
 
This may indicate that the core interactors may be precipitated along 
with Bcr-Abl and not with another dasatinib target common between K562 and 
U937 cells. 
The increased Sos-1 association with Grb2 upon drug treatment was 
furthermore confirmed by analysis of the same samples by 1D-shotgun LC-
MSMS (data not shown). This result motivated the large-scale 
immunoprecipitation of the remaining six Bcr-Abl interactors Ship2, c-Cbl, p85β, 
Sts-1, Shc1 and Crk-I from mock- and nilotinib-treated K562 cells (Figure 3.21) 
with a two-fold aim; (i) to reciprocally confirm the disruption and remodelling of 
the Bcr-Abl ʻcoreʼ complex by nilotinib action following 1D-shotgun LC-MSMS 
analysis of all remaining 12 samples and (ii) to seek for more effects such as 
the increased Grb2-Sos-1 interaction, observed upon immunoprecipitation of 
Grb2 (Figure 3.19A-D). 
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Figure 3.21 Disruption of the Bcr-Abl ʻcoreʼ complex network is confirmed by 
reciprocal immunoprecipitation in the presence of the tyrosine kinase inhibitor 
nilotinib 
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Protein complexes of Bcr-Abl and each of its seven ʻcoreʼ complex members were 
purified from mock- (A) and nilotinib-treated (B) K562 cells by large-scale 
immunoprecipitations using antibodies coupled to sepharose beads.  
(A,B) Bound proteins were identified by 1D-shotgun LC-MSMS analysis and statistically 
analyzed as describe before. The eight proteins used as bait in the large-scale 
immunoprecipitations are shown as diamond-shapes and all identified interactors as 
ellipses. In (A and B), complexed Bcr-Abl ʻcoreʼ complex members are highlighted by 
red and yellow halos. Baits with three or more edges are shown in red, bait proteins 
with two or one edge amongst each other are shown in orange. Interactors with three, 
two or one edge(s) to the Bcr-Abl ʻcoreʼ complex components are shown in light blue, 
turquoise and dark green, respectively. The figures were generated using Cytoscape 
and modified using Illustrator. 
 
Large-scale immunoprecipitation of Bcr-Abl and all of its seven ʻcoreʼ 
interactors from untreated K562 cells followed by 1D-shotgun mass 
spectrometry and network analysis confirms, that the core interactors are 
strongly inter-connected amongst each other and that Grb2, Ship2, Shc1 and 
Sts-1 cluster around Bcr-Abl (Figure 3.21A, large red halo). As observed before, 
amongst these, Sts-1 has a lower degree of connections to Bcr-Abl, here only 
two edges to Bcr-Abl and Grb2, while Bcr-Abl, Grb2, Ship2 and Shc1 form a 3-
core (Figure 3.21A, large red halo). c-Cbl, Crk-I and p85β are connected 
amongst each other, however, edges to Bcr-Abl as well as Grb2, Ship2 and 
Shc1 were not observed (Figure 3.21A, small red halo). This shows that the gel-
based large-scale immunoprecipitation/TAP approach to protein complex and 
signalling network mapping was superior to this medium-scale 
immunoprecipitation 1D-shotgun-MSMS approach. Many proteins (nodes) and 
protein-protein connections (edges) observed in the Bcr-Abl large-scale 
immunoprecipitation experiments as well as in the TAP network are missing 
from this analysis, which might be a consequence of the reduced amounts of 
starting material in these reciprocal immunoprecipitations as well as a 
shortcoming of gel-free 1D-shotgun-MSMS detection (Figure 3.7). Many 
proteins identified in these experiments, but not in the initial TAP experiments, 
however, might be proteins brought down by the individual antibodies 
unspecifically.  
Despite of these technical differences, however, large-scale 
immunoprecipitation of Bcr-Abl and its seven interactors from nilotinib-treated 
K562 cells independently confirm that the Bcr-Abl ʻcoreʼ complex is profoundly 
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disrupted and remodelled by the action of tyrosine kinase inhibitors. c-Cbl, 
p85β, Sts-1, Shc1 and Crk-I lose their edges to Bcr-Abl and amongst each 
other, while Bcr-Abl, Ship2 and Grb2 remain associated in the ʻpost-drugʼ 
complex. This is in line with the observed residual interaction of Ship2 and Grb2 
with Bcr-Abl upon dasatinib and nilotinib treatment observed by immunoblotting 
and iTRAQ analysis before (Figure 3.18). 
Overall, these experiments suggest the conclusion that Bcr-Abl tyrosine 
kinase inhibitors are targeting the Bcr-Abl ʻcoreʼ complex leading to its re-
modeling rather than ʻjustʼ binding to the Bcr-Abl kinase domain. 
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4 DISCUSSION  
4.1 General conclusions 
In order to study the composition of endogenous Bcr-Abl protein 
complexes we have performed two independent, but connected lines of 
experiments that lead to the characterization of what we would like to call the 
Bcr-Abl ʻcoreʼ complex in CML cells. In order to start out with the identification of 
the native endogenous Bcr-Abl complex we precisely mapped the epitope of the 
24-21 Abl antibody within the C-terminal FABD of Bcr-Abl/c-Abl to exclude 
disturbance of protein interactor binding by the antibody, prepared an antibody 
resin and performed a comprehensive triplicate set of large-scale IPs (Figure 
3.1,Figure 3.2). In parallel we constructed cell lines expressing wildtype Abl and 
the activated form Abl PP and performed duplicate TAP purifications with each 
in order to profile endogenous interactors of c-Abl (167 proteins) (Figure 4.1). In 
addition, profiling of crude K562 cell lysate for the most abundant proteins in 
K562 cells (K562 ʻcore proteomeʼ, 708 proteins) allowed us to determine 
significant interactors out of the 427 proteins identified in the large-scale IPs 
(Figure 4.1). Statistical analysis of these data-sets lead to a concise list of 18 
candidate interactor proteins for which the semi-quantitative parameter 
ʻsequence coverageʼ by mass spectrometry was compatible with their 
association being stoichiometric in nature (Figure 3.2, Figure 3.3 black bars, 
Figure 4.1). While the identity of the individual components is statistically certain 
(high peptide counts, three experimental repeats), the stoichiometry itself is less 
certain, because of the fact that not all peptides in a protein have equal chances 
to be detected by the mass spectrometer due to their different physico-chemical 
properties. Therefore, we determined the protein interaction network of nine of 
the candidates (excluding Bcr-Abl as bait) using a TAP-LC-MSMS approach to 
enable a statistical analysis of the resulting protein network topology (Figure 
3.7, Figure 4.1) and found eight proteins (Ship2, c-Cbl, p85, Sts-1, Shc1, Grb2, 
Crk-I and Bcr-Abl) significantly clustering around Bcr-Abl in a highly inter-
connected sub-network (Figures 3.7, 3.8 and 3.9).  
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Figure 4.1 Workflow diagram and key findings of the presented study 
The dataset of the purification of endogenous Bcr-Abl/c-Abl complexes from K562 cells 
and the K562 'core proteome' identified 18 candidate interactors compatible with high 
stoichiometric interactions. TAP purifications of c-Abl and nine selected interactor 
candidates were performed and ensuing network analysis suggested a highly 
interconnected Bcr-Abl core complex (sub-network). Quantification of total cellular copy 
numbers and quantitative analysis of the Bcr-Abl core complex composition in the 
presence of tyrosine kinase inhibitors was performed. A domain-domain interaction 
model of the Bcr-Abl core complex was built. 
 
TAP and other two-step affinity purification strategies have proven a 
robust technology for the characterization of protein complexes (Gavin, Bosche 
et al. 2002; Gavin and Superti-Furga 2003; Rigaut, Shevchenko et al. 1999) and 
are known to reliably identify rather sturdy protein-protein interactions of either 
high affinity and/or favourable kinetic parameters (e.g. low koff rates) (Gingras, 
Gstaiger et al. 2007; Kocher and Superti-Furga 2007). Therefore, many 
interactions that had been described in the literature, of which some are critical 
for Bcr-Abl function, may have evaded detection by TAP as they may be less 
sturdy, less stoichiometric or confined to other particular cells or conditions. The 
Src family kinase hematopoietic cell kinase (Hck), for instance, has been shown 
to be activated upon formation of complexes with Bcr-Abl and to be the effector 
for the activation of the Jak-Stat pathway by Bcr-Abl (Klejman, Schreiner et al. 
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2002), but has not been identified as a part of our network around the 
stoichiometric interactors of Bcr-Abl (Figure 3.7). A large group of Bcr-Abl 
interactors described in the literature are likely to include Bcr-Abl substrate 
proteins that are ʻjustʼ phosphorylated by Bcr-Abl without engaging in an 
interaction intimate enough to survive two affinity purification steps, such as the 
Jak and Stat proteins (Ilaria and Van Etten 1996) (Figure 4.5, Figure 4.6). In this 
study, we have therefore focused on the seven ʻcoreʼ interactors of Bcr-Abl that 
are thought to form a signalling scaffold that links the Bcr-Abl ʻcoreʼ complex to 
different signal transduction pathways and that is embedded within a wider 
signal transduction network, including major downstream transcriptional targets, 
such as Stat5 or c-Myc (Ren 2005) (Figure 4.5,Figure 4.6). 
 
4.2 A limited set of seven stoichiometric interactors associates with 
Bcr-Abl in a ʻcoreʼ complex 
The significant identification of 18 candidate Bcr-Abl protein interactors 
at high sequence coverage similar to that of Bcr-Abl itself, following purification 
of endogenous Bcr-Abl protein complexes from K562 cells, suggested a 
stoichiometric level of interaction with Bcr-Abl. Eight of these proteins were 
hypothesized to represent modules related to the AP2 adaptor protein complex, 
exerting cellular housekeeping functions and presumably forming different sub-
networks more loosely connected to Bcr-Abl. Out of the remaining 10 candidate 
proteins, eight (c-Cbl, Cbl-B, p85α/β, p52Shc1, p62Shc1, Grb2, Crk-I) were 
well-described bona fide interactors of Bcr-Abl, while Ship2 is of unknown 
function in Bcr-Abl signaling and Sts-1 represents a novel interactor of Bcr-Abl. 
Following TAP purifications with 9 representative proteins (Figure 3.6), we 
obtained a protein-protein interaction network consisting of 91 nodes connected 
by 157 edges in total. Rewardingly, within the centre of the network, the seven 
proteins (Ship2, c-Cbl, p85, Sts-1, Shc1, Grb2 and Crk-I) clustered around Bcr-
Abl and were significantly more inter-connected with each other than with any 
other of the about hundred proteins in the analysis by a total of 29 edges. 
Accordingly, within themselves these eight proteins formed a 4-core sub-
network and, without Sts-1, even a 5-core, where each of the eight or seven 
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proteins has at least 4- or 5 connections to each of the other proteins, 
respectively. Strikingly, neither 4- nor 5-cores were found in 105 randomly 
simulated control networks, underlining the significance of the 4- and 5-core 
protein cluster (Figure 3.7,Figure 3.8). This inter-connection becomes nicely 
apparent from a different representation of the reciprocal TAP matrix displaying 
the proteins co-occurring in each of the TAP purifications as ʻbuilding blocksʼ of 
the complex (Figure 4.2). 
 
 
Figure 4.2 Redundant reciprocal recovery of Bcr-Abl complex components 
Representation of the reciprocal co-occurrence within the nine TAP purifications 
(Figure 3.5) visualizes (i) the performance of the individual TAP purifications, (ii) points 
out putative sub-complexes and (iii) identifies Eps15 and AP2µ1 as members of an 
associated protein complex. Bait proteins are shown in dark red, proteins reciprocally 
and bi-directionally or only uni-directionally identified are shown in red and light red, 
respectively. 
 
Besides the overall high level of co-occurrence, it is obvious that the 
individual TAP purifications yielded different results. While only two interactors 
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were found in the Ship2-TAP, the Crk-I TAP purification, being the smallest bait, 
identified basically the entire candidate Bcr-Abl ʻcoreʼ complex (except Shc1). 
Furthermore, these results suggest the possibility of sub-complexes within the 
Bcr-Abl ʻcoreʼ complex, such as a complex involving Bcr-Abl, Crk-I and Sts-1, 
and clearly position Eps15 and AP2µ1 within a more loosely associated protein 
complex (Figure 3.10). The clustering in Figure 4.3 takes an underlying model 
into account, where each of the seven candidates might be able to directly 
interact with Bcr-Abl. Besides differences in the performance of the individual 
bait proteins in the purifications, these results might point out possible 
architectural characteristics of the complex, such as the strength of individual 
protein-protein interactions or a sub-module architecture. For instance, Bcr-Abl 
and the known protein pair Ship2/Shc1 were co-purified in four out of nine cases 
(Wisniewski, Strife et al. 1999), while for the Ship2-TAP we have to assume that 
Bcr-Abl was not identified for technical reasons related to the size of the bait. 
Both c-Cbl and p85β TAP purifications identified the same set of proteins, Bcr-
Abl, Crk-I, p85β, Ship2, Shc1 and c-Cbl. Only the bait Crk-I identifies the 
components Eps15 and AP2µ1, while when these were used as baits, Crk-I 
was always identified. All interactions observed bi-directionally (red blocks) 
provide the building blocks for an eight component multi-protein complex around 
Bcr-Abl (Figure 4.2). 
Overall, the results obtained by this two-pronged approach presented 
above (see section 4.1) offer convincing evidence for the existence of an eight-
component Bcr-Abl multi-protein complex of high stoichiometry. Such a 
complex, taking Bcr-Abl tetramerization into account, is calculated to exceed 2.5 
megadalton molecular weight. However, all attempts to confirm the size of the 
intact complex by sucrose density gradients (section 3.7.2), gel filtration (section 
3.7.3) or native gel electrophoresis (data not shown), even when combined with 
chemical cross-linking (data not shown), were frustrated by the failure to yield 
homogenous results. This is likely to reflect the general difficulty to measure 
protein assemblies in solution that are close to the size limits of these 
technologies, as well as the relatively low affinity by which the mainly SH2/SH3 
domain dependent interactions of this particular complex appear to depend on 
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(Figure 4.3). Nevertheless, we continued to characterize this eight component 
Bcr-Abl complex in further detail with respect to (i) the functional relevance of 
the seven interactors (siRNA perturbation, see section 4.5.2), (ii) their domain-
domain interaction architecture (see section 4.6) and (iii) their quantitative 
contribution to the complex. We were able to knock down protein expression of 
each of the eight complex components by siRNA efficiently, however, only 
knock-down of Bcr-Abl itself had an effect on the proliferation and viability of 
K562 cells whereas knock-down of the individual ʻcoreʼ complex components 
had no effect (Figure 3.17). While protein knockdown of the individual complex 
components did not seem to affect Bcr-Abl activity, targeted inhibition of Bcr-Abl 
had a severe effect not only on the activity of Bcr-Abl but also on the 
composition of the complex. We could show that the action of tyrosine kinase 
inhibitors such as dasatinib and nilotinib severely disrupts the complex integrity 
and that it leads to a remodelled post-drug composition of the complex (Figure 
3.18, Figure 3.19 and section 4.5). Taking known binary protein-protein 
interactions and binding preferences of individual protein-protein interaction 
domains into account, we built domain-domain interaction models for the 
untreated and drug-treated Bcr-Abl complex that are in line with our 
experimental observations (Figure 4.3). In the future, it could be interesting to 
assess if and how the composition of the complex is affected upon siRNA 
knockdown of each of its individual components. 
Finally, we were able to quantify the absolute cellular protein copy 
number of each of the eight protein complex components as well as the 
interaction stoichiometry within the complex (Figure 3.12,Figure 3.13). We found 
Bcr-Abl to be expressed at about 300,000 protein copies per cell and all of its 
seven ʻcoreʼ interactors within one order of magnitude (Figure 3.12). The 
quantification of 25,000 Crk-I copies per cell, however, appears too low to be in 
line with our semi-quantitative MS data and could be due to detection ambiguity 
problems. Furthermore, the overall interaction stoichiometry measured from one 
Abl immunoprecipitation yielded unexpected results. While only Ship2 seemed 
to interact with Bcr-Abl at a stoichiometry of around 1:1, all the other 
components were found at a ratio of 0.4:1 or lower (Figure 3.13). These results 
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are in clear contradiction to the abundance of these interactors in our MS 
analysis, which indicated significant stoichiometric interaction of the seven 
components with Bcr-Abl. Given the expression of these seven proteins at total 
cellular copy numbers within one order of magnitude, this would have implied 
that the majority of the cellular copies is associated with Bcr-Abl, which may be 
considered unlikely. By measuring the degree of co-depletion of each of the 
seven interactors following immunoprecipitation of Bcr-Abl complexes, we could 
confirm that this is indeed not the case and that at most, 30% of total cellular 
protein (Sts-1) are Bcr-Abl associated. This inconsistency could be due to errors 
in (i) the quantification of total cellular protein copy numbers or (ii) the 
interaction stoichiometry. Furthermore, the semi-quantitative MS data might be 
misleading as different proteins display different detection efficiency depending 
on their physico-chemical properties (Ong and Mann 2005). 
Rewardingly, however, we were able to confirm the disruption and 
remodelling of the eight-component Bcr-Abl machine observed by 
immunoprecipitation and immunoblotting (i) by iTRAQ relative quantification 
(Figure 3.18,Figure 3.19) and (ii) reciprocal immunoprecipitation of each 
interactor from mock- and nilotinib-treated cells followed by 1D-shotgun-MSMS 
and network analysis (Figure 3.21) (see section 4.5). 
 
4.3 Discovery of Sts-1 as a novel stoichiometric interactor of Bcr-Abl 
Sts-1 (suppressor of T-cell receptor signaling 1) (TULA-2), is an SH3 
domain containing protein that is ubiquitously expressed, whereas expression of 
its homolog Sts-2 (TULA) is restricted to lymphocytes (Wattenhofer, Shibuya et 
al. 2001). Both, Sts-1 and Sts-2 possess an N-terminal ubiquitin-association 
(UBA) domain, an SH3 domain and a C-terminal region highly similar to the 
phosphoglycerate mutase (PGM) enzyme family. Sts-1 was initially identified as 
an interactor of Jak2 (Carpino, Kobayashi et al. 2002) although the role in Jak2 
signaling could not be confirmed. The paralogues Sts-1 and Sts-2 differ in their 
biological properties, such as the distinct binding properties of their UBA 
domains (Hoeller, Crosetto et al. 2006) or the reduced phosphatase activity of 
Sts-2 despite the conservation of crucial catalytic residues (Chen, Jakoncic et 
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al. 2009). These differences point towards different target profiles of the two 
proteins and only Sts-1/2-/- double knockout mice show a phenotype in their T-
cells (Carpino, Turner et al. 2004). Sts proteins were found to control the levels 
of Zap-70 phosphorylation and thereby to be involved in regulation of signaling 
downstream of the TCR (Carpino, Turner et al. 2004; Mikhailik, Ford et al. 
2007). Sts proteins bind c-Cbl via their SH3 domain and mono-ubiquitin via their 
UBA domain and consequently negatively regulate the ubiquitin ligase c-Cbl, a 
critical attenuator of receptor tyrosine kinase signaling, resulting in an inhibitory 
effect on receptor endocytosis (EGFR, PDGFR) (Kowanetz, Crosetto et al. 
2004). The crystal structure of the PGM domain was solved and showed that it 
possesses tyrosine phosphatase activity (Mikhailik, Ford et al. 2007). Recently, 
also the structure of the Sts-2 PGM domain was solved and showed that Sts-2 
might function as an acid-dependent phosphatase (Chen, Jakoncic et al. 2009). 
Furthermore, while Sts-2 utilized its UBA- and SH3 domains for mono-ubiquitin 
and c-Cbl binding in order to achieve this effect, Sts-1 was shown to differ in 
this regard, as it used its tyrosine phosphatase activity to dephosphorylate the 
EGFR and to attenuate its signaling without an obvious implication of its UBA 
domain (Raguz, Wagner et al. 2007). Phosphorylation of c-Cbl can be mediated 
by Src, Fyn, Yes, Syk and Abl and overexpression of Sts-1 was shown to 
dephosphorylate endogenous c-Cbl potently (Raguz, Wagner et al. 2007). In 
line with this, Sts-1 was also described as a negative regulator of Syk, a protein 
tyrosine kinase with a key role in lymphoid signalling, and the effect was shown 
to require an intact PGM domain (Agrawal, Carpino et al. 2008). 
To date, Sts-1 was mentioned twice in the context of Bcr-Abl. A gene 
expression screening of adult patients with acute lymphoblastic leukemia (ALL) 
followed by network analysis of gene expression data between Bcr-Abl-positive 
patient subgroups revealed Sts-1 to be overexpressed in p185Bcr-Abl-positive 
ALL relative to p210Bcr-Abl-positive ALL (Juric, Lacayo et al. 2007). Shortly 
thereafter, Sts-1 was identified in a chemical proteomics approach (Bantscheff, 
Eberhard et al. 2007), which suggested that Grb2, Shc1, Ship2 as well as the 
adaptor protein Sts-1 are in a complex with the drug target Bcr-Abl (Figure 3.9).  
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Sts-1 is a hitherto not described interactor of Bcr-Abl and, supported 
by the evidence presented above, may be a novel regulator or antagonist of 
Bcr-Abl action. 
 
4.4 The role of the phosphatases Sts-1 and Ship2 within the Bcr-Abl 
ʻcoreʼ complex 
The prominent identification of the 5-inositol phosphatase Ship2 and 
the protein tyrosine phosphatase Sts-1 as a novel Bcr-Abl interactor were 
interesting as both proteins have been described as negative regulators in 
different signal transduction pathways (Taylor, Wong et al. 2000), (Mikhailik, 
Ford et al. 2007). Ship2 was shown to exert a crucial anti-proliferative function 
by causing protein kinase B (PKB/Akt) inactivation and cell cycle arrest in 
glioblastoma cells (Taylor, Wong et al. 2000). Like PTEN, Ship2 regulates the 
levels of the PI3K product PIP3 (PtdIns(3,4,5)P3), but, unlike PTEN, not the 
levels of PIP2 (PtdIns(3,4)P2). Ship2 was a prime target in drug discovery as it 
was suggested to be a negative regulator of insulin signalling, however, the 
mechanism could not be elucidated to date (Sleeman, Wortley et al. 2005; 
Vinciguerra and Foti 2006). Ship2 is tyrosine phosphorylated in K562 cells 
(Goss, Lee, Moritz, Nardone, Spek, Macneill et al. 2006; Mishra, Suresh et al. 
2006; Salomon, Ficarro et al. 2003) (Figure 3.17B) and it is reduced upon TKI 
treatment (data not shown). However, it was shown that tyrosine 
phosphorylation of Ship2 upon growth factor stimulation did not influence its 
phosphatase activity (Taylor, Wong et al. 2000). It is therefore not clear, 
whether Bcr-Abl activity influences Ship2 activity and if the PI3K-PKB pathway 
is affected. Foci of Bcr-Abl protein complexes with Grb2, c-Cbl and CrkL (which 
is not part of our complex) have been shown to localize in proximity to the 
membrane in primary CML cells (Patel, Marley et al. 2006). Localization of Bcr-
Abl complexes to the cell membrane would support a membrane-proximal 
interaction of Ship2 with its substrate even in complex with Bcr-Abl. 
Furthermore, the observed association with the AP2 adaptor protein complex 
supports the membrane-proximal location of Bcr-Abl complexes (Figure 3.10). 
The presence of the 5-inositol phosphatase, Ship2, in complex with adaptor 
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proteins like Grb2 and Bcr-Abl represents similarity to other AP2 adaptor 
protein-associated complexes between activated receptor tyrosine kinases, 
Grb2 and the 5-inositol-phosphatase synaptojanin (SYNJ1) (Figure 4.4D) 
(Haffner, Takei et al. 1997; Praefcke, Ford et al. 2004). This raises the 
possibility that the Bcr-Abl ʻcoreʼ complex potentially mimics the mode of action 
of activated receptor tyrosine kinase protein complexes in order to exert its 
downstream signalling effects. 
Sts-1 and Ship2 display tumor-suppressor characteristics and it could 
be hypothesized that Bcr-Abl exerts parts of its oncogenic effects by modulating 
Sts-1 and Ship2 activity. I observed an apparent increase in total cellular Sts-1 
protein levels (about 2-fold) upon treatment of K562 cell lysate with nilotinib 
(data not shown), an effect that has not been described. Given the increase in 
protein levels upon inhibition of Bcr-Abl with the specific tyrosine kinase inhibitor 
nilotinib, Bcr-Abl signalling might possibly lead to reduced overall Sts-1 protein 
levels. Oliver Hantschel and Ines Kaupe, in our lab, have already obtained 
preliminary evidence (i) on the ability of Sts-1 to dephosphorylate Bcr-Abl on 
tyrosine residues and (ii) on the dependence on the SH2 domain of Bcr-Abl for 
interaction with Sts-1 on the other hand (unpublished results). Further 
elucidation of the molecular and functional details of this fascinating Sts-1-Bcr-
Abl interaction promises to shed new light on a putative negative regulation of 
Bcr-Abl function and will be the object of future studies. 
 
4.5 The Bcr-Abl multi-protein complex is the therapeutic target of 
tyrosine kinase inhibitors 
Arguably, one of the most interesting findings of our study is the fact 
that not Bcr-Abl alone, but rather a multi-component Bcr-Abl ʻcoreʼ complex is 
the target of tyrosine kinase inhibitors, which consequently alter the integrity of 
this complex. This became apparent from the observations that (i) the tyrosine 
kinase inhibitor dasatinib, used as an affinity reagent, binds to Bcr-Abl and the 
four ʻcoreʼ complex members we tested for (Ship2, Sts-1, Shc1 and Grb2) upon 
incubation with K562 cell lysate but not with lysate from Bcr-Abl negative U937 
cells (Figure 3.20); (ii) that the tyrosine kinase inhibitors dasatinib and nilotinib 
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disrupt the complex integrity and lead to loss or severe reduction of all seven 
interactors (Figure 3.3,Figure 3.18) and (iii) that, reciprocally confirmatory, the 
protein complex composition of one of Bcr-Ablʼs prominent interactors, Grb2, is 
altered accordingly (Figure 3.19). Inhibition of Bcr-Abl kinase activity with 
dasatinib or nilotinib led to a severe reduction in the interactions of four (c-Cbl, 
Sts-1,Shc1 and Crk-I) out of seven core interactors with Bcr-Abl, likely to be 
caused by the inhibition of Bcr-Abl tyrosine kinase activity and the resulting loss 
of autophosphorylation sites on tyrosine residues. As a consequence, SH2- and 
PTB-domain mediated interactions were abolished, whereas interactions that 
are independent of tyrosine phosphorylation, such as SH3-domain mediated 
interactions, could be maintained (Figure 4.3). Furthermore, as tyrosine 
phosphorylation may also allosterically change domain conformations or 
intramolecular interactions, protein-protein interactions may remodel in the 
presence of tyrosine kinase inhibitors. Indeed, we observed that certain 
interactions (Ship2, p85β and Grb2) were only reduced, but not completely 
abolished (Figure 3.3, Figure 3.18, Figure 3.19) and that few interactions, 
exemplified by the Grb2-Sos1 interaction, are even enhanced in the presence of 
drug (Figure 3.19). Therefore, we propose a ʻpost drug complexʼ that may be 
assembled differently, as residually bound Bcr-Abl interactors may have 
switched their molecular interaction mode and that may still contain some 
enzymatic activity (e.g. Ship2 5-inositol phosphatase activity). These insights 
led us to a novel post-genomic view of a drug-target. 
 
4.5.1 A novel post-genomic view of a drug-target 
The small molecule tyrosine kinase inhibitor imatinib served as a 
paradigmatic case for modern targeted cancer therapy at hands of Bcr-Abl in 
CML (Druker 2008). As for imatinib and Bcr-Abl, drug targets in general are 
typically regarded as single proteins or even protein fragments. This traditional 
view is based on the fact that high-throughput screening of large compound 
libraries - that is still the most commonly used approach to identify lead 
compounds in drug discovery - mainly assay binding or inhibition of proteins or 
protein fragments (Bleicher, Bohm et al. 2003; Brown and Superti-Furga 2003). 
4 Discussion 
 
 114 
In line with this, also the action of drugs in a cellular context is commonly 
envisaged as the interaction of the drug with a single or very limited number of 
cellular proteins. In stark strong contrast to this reductionist view, modern post-
genomic technologies, in particular large-scale interaction proteomics and 
drug/chemical proteomics approaches have dramatically changed our view of 
the organization of the human proteome and drug action. Proteins very rarely 
act in isolation, but are organized as part of large multi-protein 
complexes/molecular machines that may dynamically change their spatial and 
temporal organization (Bouwmeester, Bauch et al. 2004; Gavin, Aloy et al. 
2006; Kuriyan and Eisenberg 2007). Along this line, unbiased proteomics 
approaches for drug targets have shown that even drugs that were considered 
highly specific often interact with a much larger number of previously 
unidentified target proteins that themselves are also even part of larger protein 
complexes (Bantscheff, Eberhard et al. 2007; Daub 2005; Rix, Hantschel et al. 
2007). In line with this, pharmacogenomic and microarray profiling studies 
suggest that dozens, if not hundreds of gene products affect the efficacy of 
drugs in individuals (Evans and McLeod 2003; Hantschel, Gstoettenbauer et al. 
2008). Furthermore, drugs often have undesired side effects by impinging on 
different pathways that, in turn, may be shared by different diseases (Yildirim, 
Goh et al. 2007), (Campillos, Kuhn et al. 2008). These insights have changed 
our view of drug action. Instead of considering the alteration of the activity of a 
single protein by a drug, in a more post-genomic view, ʻdrugʼ action may have 
pleiotropic effects on a number of different proteins leading to a perturbation of 
molecular networks at different levels, including changes in gene expression, 
metabolite levels and turn-over, protein-protein interactions and post-
translational modifications. 
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4.5.2 Oncogene addiction but not ʻoncogene protein complexʼ 
addiction 
Apart from the role as stoichiometric interactors of Bcr-Abl, we have 
also tried to address their functional relevance by reducing protein levels using 
siRNAs. We were able to knock-down the protein expression of each of the core 
interactors by at least 75% in K562 cells, but unexpectedly were unable to 
detect changes in the viability or proliferation rate, whereas K562 cells rapidly 
stopped proliferating and underwent apoptosis when Bcr-Abl protein levels were 
reduced using an Abl or Bcr-Abl breakpoint-specific siRNA (data not shown). 
Although drug action clearly seems to target the entire protein complex rather 
than just inhibiting Bcr-Abl, removal of the complex components alone, had no 
effect on Bcr-Abl action. It is not clear to us why none of the individual 
knockdown experiments had an effect on K562 cell proliferation. For the p85α 
subunit of PI3K, for instance, a clear functional relationship between binding to 
fusion tyrosine kinases (FTK) such as Bcr-Abl, as part of a protein network 
involving proteins like Shc, c-Cbl and Gab2, and constitutive activation of the 
p110 catalytic subunit of PI3K and its downstream effector Akt kinase has been 
shown (Ren, Bolton et al. 2005). Here, point mutations of the domains critical 
for the protein-protein interaction with the FTK, the N- and C-terminal SH2 and 
the SH3 domains of p85α, disrupted phosphotyrosine and proline-rich motif 
binding and, as a consequence, abrogated interaction with Bcr-Abl, Shc, c-Cbl 
and Gab2, whereas binding to the catalytic subunit of PI3K remained intact, and 
resulted in reduced activation of PI3K and Akt (Ren, Bolton et al. 2005). Both 
siRNA knockdown of p85α, p85β and simultaneous knockdown of both subunits 
had no effect on the viability of K562 cells (Figure 3.17 and data not shown). On 
one hand, residual protein levels upon knock-down might still be sufficient to 
mediate leukemogenic signalling from Bcr-Abl, on the other hand, this may be in 
line with the severe Bcr-Abl addiction of K562 cells to their oncogene Bcr-Abl 
that may be able to override many different, even severe perturbations in its 
downstream signal transduction network and may uncover unexpected 
redundancy in signalling pathways exerting Bcr-Abl's oncogenicity. 
Furthermore, a recent large-scale effort by the RNAi consortium to map the 
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functional basis of cancer at hands of the identification of the essential genes in 
cancer cells by genome-scale pooled short hairpin RNA (shRNA) screens in 
several cancer cell lines, including K562, by large confirms our data (Luo, 
Cheung et al. 2008). In K562 cells, ABL1 and BCR genes ranked amongst the 
five top-scoring genes out of about 9,500, clearly identifying Bcr-Abl as 
selectively highly required gene in the K562 cell line (Luo, Cheung et al. 2008). 
 
4.6 Towards a domain-domain interaction map of the Bcr-Abl ʻcoreʼ 
complex 
At this point I would like to mention that I am especially grateful for the 
valuable assistance and the insights provided by Oliver Hantschel in the lab 
who has a long-standing background and superior experience in c-Abl/Bcr-Abl 
structure-function analysis as well as the role of the phospho-tyrosine residues 
of these proteins in the regulation of Abl kinase activity as well as their function 
in protein-protein interactions. 
The identification of the stoichiometric interactors of Bcr-Abl by mass 
spectrometry, the ensuing TAP network analysis and the insights from the 
effects of tyrosine kinase inhibitors on the integrity of the complex enabled the 
attempt to build putative Bcr-Abl ʻcoreʼ complex domain-domain interaction 
models based on the domain composition and the tyrosine phosphorylation 
sites of Bcr-Abl and its interactors available from the literature. As all proteins 
included in the analysis, except for Crk-I, are tyrosine-phosphorylated in K562 
cells (Liang, Hajivandi et al. 2006; Steen, Fernandez et al. 2003) (Superti-Furga 
laboratory, unpublished results) and as most contain SH2 domains (7x), SH3 
domains (5x) and/or PxxP motifs (4x), there is a very large number of 
theoretically possible combinations for these eight proteins in a domain-domain 
interaction model. However, the number of possible combinations can be 
reduced by taking information on the molecular interaction mode of known 
binary protein-protein interaction pairs and binding preferences for SH2- and 
SH3 domains into account (Mayer 2001; Pawson 1994; Pawson, Gish et al. 
2001). In the models presented below, for simplicity reasons, formation of Bcr-
Abl tetramers via its N-terminal coiled-coil domain is not considered (Figure 
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4.3). The SH2 domain of Grb2 bound to pTyr-177 in Bcr-Abl (Pendergast, 
Quilliam et al. 1993), as well as the PTB domain interaction of Shc-1 with a C-
terminal tyrosine phosphorylation site in SHIP-2 were built to form the innermost 
interactions with Bcr-Abl (Tauchi, Boswell et al. 1994; Wisniewski, Strife et al. 
1999) (Figure 4.3A,B,C). In addition to its interaction via Shc-1, a PxxP motif in 
Ship2 was also shown to bind the Bcr-Abl SH3 domain (Wisniewski, Strife et al. 
1999). c-Cbl and p85 may interact by one of their PxxP motifs with the C-
terminal SH3 domain of Grb2 (Gaston, Johnson et al. 2004; Skorski, Kanakaraj 
et al. 1995)(Figure 4.3 A,B,C). Alternatively, interactions of the Cbl TKB (SH2-
like) domain or one of the p85 SH2 domains with one of the numerous tyrosine-
phosphorylated residues of Bcr-Abl can be envisaged (Figure 4.3A,B,C). Crk-I 
may also interact with its SH2- or SH3-domain either directly with Bcr-Abl or 
with one of the other core interactors (Sattler and Salgia 1998) (Uemura, Salgia 
et al. 1997)(Figure 4.3A,B,C). Finally, Sts-1 may interact with its SH3-domain 
directly with Bcr-Abl, e.g. binding to one of the proline-rich motifs in the last 
exon region downstream of the kinase domain (Figure 4.3A), or the Abl SH2 
domain may bind to a tyrosine-phosphorylated residue in Sts-1 (Figure 4.3D,E). 
In an alternative model, Sts-1 may be indirectly associated with Bcr-Abl by 
using its SH3 domain to bind the PxxP motif in c-Cbl (Figure 4.3B). The lower k-
core for Sts-1 in the Bcr-Abl core network may be indicative for this indirect 
interaction mode but also suggests the formation of an alternative complex with 
Bcr-Abl that is lacking other core interactors, besides Ship2, which might be 
involved in this alternative complex (Figure 4.3D,E)(Figure 3.5). 
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Figure 4.3 Domain-domain interaction model of the Bcr-Abl ʻcoreʼ complex in the 
absence and presence of nilotinib or dasatinib 
Schematic representation of possible domain interactions within the Bcr-Abl core 
complex. Tyrosine phosphorylation sites are indicated. Different scenarios are shown. 
(A) p85 bound to the C-terminal SH3 domain of Grb2. c-Cbl interacting with unknown 
phosphotyrosine on Bcr-Abl with its TKB (SH2-like) domain. 
(B) Alternatively to (A), Sts-1 may interact with the PxxP motif of c-Cbl via its SH3 
domain. 
(C) c-Cbl bound to the C-terminal SH3 domain of Grb2. p85 interacting with unknown 
phosphotyrosine on Bcr-Abl with one of its SH2 domains. In addition, an alternative 
binding of the Grb2 SH2 domain to a phosphotyrosine residue in Shc-1 is shown. Sts-1 
may not be involved in these complexes (ʻ5-coreʼ) 
(D,E) Potential alternative Bcr-Abl complexes with dominant contribution of Sts-1 that 
may bind the Bcr-Abl SH2 domain. Ship2 may be involved in these complexes (D). 
(F) Bcr-Abl complex in the presence of nilotinib or dasatinib. Note the absence of 
tyrosine-phosphorylated residues. Residual interactions of Bcr-Abl with Ship2, Grb2 
and p85 are mediated by SH3 domain-PxxP motif interactions. 
 
As we have observed the complete loss of the interactions of Bcr-Abl 
with c-Cbl, Sts-1, Shc1 and Crk-I upon drug treatment, it is likely that these 
interactions are mainly phosphotyrosine-SH2 domain dependent. In contrast, 
Ship2, p85β and Grb2 still show residual interaction with Bcr-Abl in the 
presence of the drugs. As under these conditions, Bcr-Abl is not tyrosine-
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phosphorylated anymore, the remaining interactions must be SH2 domain-
independent. For Ship2, the interaction with Bcr-Abl via Shc-1 is lost and may 
only be maintained by interaction with the Bcr-Abl SH3 domain. Also for Grb2 
and p85, SH3 domains binding to proline-rich motifs may mediate residual 
binding, replacing SH2 domains binding to phosphotyrosine residues (Figure 
4.3F). 
 
4.7 A novel link between Bcr-Abl and the AP2 adaptor protein 
complex 
Within the 2-core AP2 complex that we found associated to the Bcr-
Abl ʻcoreʼ complex (Figure 3.7), AP2α1, AP2α2, AP2β1, AP2µ1 and Eps15 
even formed a 3-core complex (Figure 3.10). While only AP2µ1 is directly linked 
to Bcr-Abl, Crk-I has three edges to AP2α1, Eps15 and AP2µ1 and Shc1 has 
four edges to AP2α1, AP2α2, AP2β1 and AP2µ1, hereby hypothesized as the 
interface to the Bcr-Abl ʻcoreʼ complex. The interactions between Eps15 and 
AP2α1 (Benmerah, Gagnon et al. 1995; Benmerah, Lamaze et al. 1998) and 
between Stonin-2 and Eps15 (Martina, Bonangelino et al. 2001; Rumpf, Simon 
et al. 2008) are known (Figure 4.4A). Also interactions between Eps15 and the 
N-terminal SH3 domain c-Crk (Schumacher, Knudsen et al. 1995) as well as the 
binding of Shc1 to AP2α have been reported in the literature (Sakaguchi, 
Okabayashi et al. 2001), which corroborates our model (Figure 4.4A). In this 
model, we show only Bcr-Abl, Shc1 and Crk-I and omit the other components of 
the Bcr-Abl complex for graphical simplicity. The AP2 complex may be recruited 
by binding the signature FDMKPF within the collagen homology region of Shc1 
(Sakaguchi, Okabayashi et al. 2001).  
The AP2 complex brings along Eps15, which is simultaneously bound 
to the α-adaptin appendages of either AP2α or β. This interaction might be 
mediated via DPF-repeats in Eps15 (Iannolo, Salcini et al. 1997; Praefcke, Ford 
et al. 2004). Eps15, in turn, uses its proline-rich motif (PALPPK) to bind the N-
terminal SH3 domain of c-Crk (here Crk-I) (Schumacher, Knudsen et al. 1995). 
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Figure 4.4 Domain-domain interaction model of the Bcr-Abl ʻcoreʼ complex and 
its associated AP2 adaptor protein complex 
(A) Domain-domain interaction model of the accessory AP2-complex with its 
connections to Crk-I and Shc1 within the Bcr-Abl core complex. Only one domain-
structure is shown representative for AP2α and AP2β for simplicity. The other Bcr-Abl 
complex components are omitted for simplicity. 
(B) Cartoon of an AP2 adaptor complex, consisting of AP2α, AP2β, AP2µ and 
AP2σ. The appendages of AP2α and AP2β are the major protein interaction hubs. 
(C) Structure of the AP2 adaptor core in complex with dileucine peptide of CD4 
(orthogonal views) in ribbon surface representation. 
(D) Proteomic analysis of AP2α-appendage interactions by GST-AP2α-appendage 
pulldown and MS-analysis. Also shown are proteins interacting with the two other 
interaction hubs in clathrin-mediated endocytosis, Clathrin and PtdIns(4,5)P2. (B, D) 
taken from (Praefcke, Ford et al. 2004), (C) taken from (Kelly, McCoy et al. 2008) 
 
Finally, the EH (Eps15 homology) domain of Eps15 interacts with two 
NPF motifs (only one shown for simplicity) within the proline-rich domain of 
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4.4A). It is known that, within the AP2-complex, the adaptin-appendage regions 
(ʻearʼ) act as the primary hubs for protein protein interaction (Praefcke, Ford et 
al. 2004) (Figure 4.4B). Accordingly, within our network, using AP2µ1 as a bait, 
AP2α1, AP2α2 and AP2β1 are recovered in an interconnected network with 
AP2µ2, Shc1 and Crk-I. Just recently, the structure of the AP2 complex has 
been solved in complex with the endocytic dileucine motif of the ligand CD4 
(Figure 4.4C) (Kelly, McCoy et al. 2008). Acidic dileucine motifs ([ED]xxxL[LI]) 
and the YxxΦ motif are the two major recognition motifs of endocytic cargo 
ligands of AP2 (Kelly, McCoy et al. 2008; Owen and Evans 1998). Furthermore, 
a proteomic analysis of AP2α-appendage interactions furthermore confirms 
many of the proteins that we identify in our network, such as Eps15, Necap2 
and Stonin-2 (Figure 4.4D). The requirement for the interaction between Eps15 
and the AP2-complex in receptor-mediated endocytosis has been shown and 
therefore the Bcr-Abl ʻcoreʼ complex seems linked to this process (Benmerah, 
Lamaze et al. 1998). However, direct interactions between any of the 
components of the AP2 components and Bcr-Abl directly have not been 
described to date. Phosphorylation of proteins involved in receptor-mediated 
endocytosis by Bcr-Abl could have effects on the activity of these proteins as 
well as the composition of endocytic protein complexes and consequently lead 
to altered rates of endocytosis of certain receptors. This process could 
contribute to the oncogenic properties of Bcr-Abl expressing cells, such as 
K562. 
 
4.8 Putative cellular redistribution of signaling components upon 
therapeutic disruption of the Bcr-Abl ʻcoreʼ complex 
The observation that the Bcr-Abl ʻcoreʼ complex is remodelled by the 
action of tyrosine kinase inhibitors, where binding of most of the interactors to 
Bcr-Abl was disrupted (Figure 3.18), raised the question whether the 
dissociated signalling molecules might redistribute to other signalling 
complexes, thereby altering the activity of the associated signalling pathways. 
While screening for this effect, we indeed found an increased association of 
Sos-1 with Grb2 upon tyrosine kinase inhibitor treatment (Figure 3.19). This 
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effect, however, rather than being the consequence of a redistribution of Grb2 
molecules from Bcr-Abl protein complexes into Sos-1 protein complexes, might 
be due to the loss of tyrosine phosphorylation within the Grb2 SH3 domain upon 
TKI treatment. It was shown that phosphorylation of Grb2 by Bcr-Abl reduces its 
SH3-dependent binding to Sos-1 in vivo, but not its SH2-dependent binding to 
Bcr-Abl (Li, Couvillon et al. 2001). Tyrosine 209 in the C-terminal SH3 domain of 
Grb2 was shown to by phosphorylated and phosphorylated Y209 abolished the 
binding of the C-terminal SH3 domain of Grb2 to a proline-rich Sos-1 peptide in 
vitro (Li, Couvillon et al. 2001). Expression of a Y209F mutant lead to increased 
Grb2-mediated activation of Ras and Erk (Li, Couvillon et al. 2001; Pendergast, 
Quilliam et al. 1993). However, as significant amounts of Grb2 are lost from Bcr-
Abl complexes, it might still be of relevance that these molecules become 
available to redistribute into complexes with Sos-1 so that both mechanisms 
actually contribute to the observed effect. Interestingly it was shown that 
reduction of Bcr-Abl activity by imatinib treatment leads to a growth factor-
dependent compensatory increase in activity of the important Bcr-Abl effector 
p42/44 mitogen-activated protein kinase (MAPK) and that, concordantly, 
combined treatment with MAPK inhibitors lead to an increased elimination of 
CML progenitors by imatinib (Chu, Holtz et al. 2004). 
Taken together, these observations raise the possibility of a 'gain-of-
function' role for kinase inhibitors, where, as opposed to a simple 'loss-of-
function', the molecular mode-of-action of nilotinib and dasatinib can be 
described as a ʻsystem perturbationʼ that leads to a dynamic remodelling of the 
protein-protein interaction space. This may represent a new paradigm for the 
characterization of drug targets in the post-genomic era, but needs further 
experimental support beyond the Bcr-Abl core complex. 
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4.9 Towards an enlarged physical, functional and quantitative 
network of Bcr-Abl signaling 
The TAP-MS approach with the nine selected baits proteins confirmed 
numerous previously identified interactors of most bait proteins through 
unbiased protein identification by mass spectrometry, in particular of the 
intensively studied SH2-containing adaptor proteins Shc1, Grb2 and Crk-I. In 
addition, the approach resulted in the identification of a large number of novel 
protein-protein interactions, taking the human protein reference database 
(HPRD) and the IntAct database as a reference (Figure 3.6) (Hermjakob, 
Montecchi-Palazzi et al. 2004; Mishra, Suresh et al. 2006). The IntAct database 
was screened for human experimentally observed physical associations. Out of 
a total of 161 identified binary protein interactions for the nine bait proteins 
(including reciprocal pairs), 53 were known (annotated in the HPRD and/or 
IntAct databases) while 108 novel interactions were observed (Figure 3.6). 
None of the eight interactors found for Sts-1 was previously annotated, and only 
one (AP2β1) out of 13 interactors found for AP2µ1 was known. For Ship2, four 
interactions were novel in addition to the known interactor Shc1. A large number 
of novel interactions were found for the well-described small adaptor proteins 
Shc1 (11 known/16 new), Grb2 (10 known/22 new) and Crk-I (17 known/21 
new). This dataset significantly increases the existing protein-protein 
interactions of the bait proteins and will be a valuable resource for the scientific 
community. 
The data contained in the Bcr-Abl protein-protein interaction network 
presented here (Figure 3.7) contains only interactors associated with the seven 
Bcr-Abl ʻcoreʼ complex members as well as with Eps15 and AP2µ1, that were 
identified as candidates from initial large-scale immunoprecipitations of Bcr-
Abl/c-Abl protein complexes followed by TAP purifications using these proteins 
as bait. It is within the long-term interest of the lab to generate a comprehensive 
large-scale protein-protein interaction network around Bcr-Abl in K562 cells by 
using more bait proteins in order to reconcile the vast amounts of fragmented 
knowledge on Bcr-Abl signalling in a unified picture. During this study, known 
interactors and putative or known pathway components were already generated 
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as additional ʻentry pointʼ proteins for ensuing TAP-MS analysis, such as 
Paxillin, Dok2, Fes, Hck, Shp2, Fak, Myc, Nck, Crk-II, PKCδ or PSTPIP1 of 
which the TAP purifications for Dok2 and Crk-II were already performed and 
further entry points, such as Stat1, Stat5, PTP1B, PTPN11 (Shp2), Src, Yes and 
Fyn are planned (Cong, Spencer et al. 2000; Frank and Varticovski 1996; Hu, 
Liu et al. 2004; Kin, Shibuya et al. 2001; LaMontagne, Flint et al. 1998; 
LaMontagne, Hannon et al. 1998; Shuai, Halpern et al. 1996; Smith, Katz et al. 
1999; Tauchi, Feng et al. 1994). The extension of the present network will 
create a more precise picture of the protein-protein interaction network more 
remote from Bcr-Abl and be a valuable data-set to identify components that 
could be exploited pharmocalogically. Furthermore, functional studies such as 
siRNA knockdown of its components as well as large-scale relative 
quantification by mass spectrometry of all network nodes in the presence of 
TKIs might add important information about candidate effector proteins. 
In an attempt to simulate such an enlarged protein-protein interaction 
network, Jacques Colinge complemented our present network (Figure 3.7) with 
all protein-protein interactions annotated in the HPRD database for each of the 
91 nodes. This resulted in a hybrid model network consisting of 1130 nodes and 
2574 edges (Figure 4.5). Again, 103 random simulations of a network of this 
size yielded no k-core > 3, corroborating the significance of the Bcr-Abl ʻcoreʼ 
complex. However, this model network suffers from the severe limitation that 
many protein-protein interactions, that might have no relevance in K562 cells, 
were added. Many of these proteins might not be expressed in K562 cells and 
many of the interactions might occur only in different cell types or represent 
ʻfalse positiveʼ interactions from Y2H (yeast-two-hybrid) studies. Accordingly, in 
this model, Bcr-Abl is part of an 8-core with numerous additional members (red 
nodes). 
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Figure 4.5 The Bcr-Abl ʻcoreʼ complex and its signaling network enlarged by all 
HPRD - interactions 
The Bcr-Abl protein-protein interaction network experimentally observed by TAP-LC-
MSMS (Figure 3.7) computationally complemented with all interactions stored in the 
human protein reference database (HPRD). The network contains 1130 nodes and 
2574 edges. 103 randomizations of the network give no k-core with k > 3 and hence 
support the significance of the Bcr-Abl core complex. However, within this network, the 
Bcr-Abl ʻcoreʼ complex is an 8-core with numerous additional members. Furthermore, 
more disjoint 9-core sub-complexes (white nodes) are found. 
 
Furthermore, more disjoint 9-core sub-complexes (white nodes) are 
found. Therefore, the network model has to be treated with caution, as it 
suggests the existence of a much bigger Bcr-Abl ʻcoreʼ complex (Figure 4.5). 
However, this representation can serve as an example for the ʻfocusʼ that the 
Bcr-Abl network generated in this study generates by highlighting only the 91 
nodes of the network (Figure 3.7) amongst all connected HPRD annotations 
(Figure 4.6). 
ASCC2
LAMP1
RIBC2
RTDR1
16106
KLK2
KIAA0408
EHD2
LY9
MEGF10
TNPO2
IKZF1
MED4
GAK
FURIN
DAPP1
KLK3
TGM1
CRMP1
KIAA1377
NECAP1
SURB7
GBP2
RRP12
SERPINA5
PRKAR2A
ARL15TRIM25
TBKBP1 TANK
TCEA2
MAPK9
APPL1
TRAF5
BIRC3
CCDC33
CDC37
ZNF205
CDK9
TNFRSF13B
FBXO28
EDARADDCD27KIAA1267
EDAR
TRAF3IP2
DTNB
IRF4
GSTP1
TRAIP
CDCA3
ACTN4
SOX9
SLAMF1
MPZL1
DVL2
KIR2DL5A
FXR2
GORASP2
TNFRSF1A
PIN1
TNFRSF17
SAPS1ANKHD1
SAPS2
HSP90AA1
DARS
LZTS2
IL15RA
TNFSF4
09835
CCDC130
ZBTB25
FLNA
ALPL
FAM120B
TNFSF9
NUDT18
AZI2
FAM107A
TBK1
HSP90AB1
TNFRSF14
BAHD1
WDR65
MALT1
ZBTB43
TCEB3B
ERN1
FATE1
QARS
LARS
RARS
EEF1E1
EPRS
02915
RBMX
IARS MARS
BCL10
RAD23A
RIPK3
TRIM37
RFX3
SPG21
SIAH2
BANP
NRIP1
AVIL
PRKCZ
NTRK2
PSMC6
ACACA
XPO1
MAPK8
CAT
DPPA4
ITGB3
YWHAB
CDH5
YWHAQ
DAB2
PPM1A
IGF1R
CREBBP
DAB1
CAV1
RETMPL
PIK3CA
PTPN11
MAP4K5
PLSCR1
CD40
MDM2
NGFR
TTBK2
LILRB4 DOK4
CEACAM1
IL4R
CSF2RB
APP
CDKN1B
DDR1
MYO1D
LAIR1
AP2M1
RHOU
NECAP2
TNFRSF11A
GNAQ
HD
BMP2K
EDC4
SEMG2
ATF7IP
SEMG1
PILRB
IL3
SIRPA
DRAP1
CCKBR
ZFAND6
SOCS3
CRY1
DOCK3
KRT74
WEE1
IFNGR1
TREML1
MBPEPHB3
C20orf32
CHGB
KRT13
POLR2A
BAT3
YWHAE
GRIN2D
CSNK2A2
DNAJA2
PRLR
KLRC1
GRIN2B
DDEFL1
13911
MAP3K4
EPHA3
PILRA
USP7
KIAA0802
PNMA1
ARHGEF2
TIAF1
SMARCA4
RNF41
DOCK7
PPP2CB
KCTD20
MAP3K14
11075
NIF3L1
CHUK
RELA
IKBKG
ANKRD28
IKBKB
SIGLEC11
CTNNB1
LEPR
NFKBIA
SELE
CD33
C6orf25
TGOLN2
NRAS
BDKRB2
STAT1
DDR2
ZUBR1
SP1
ALK
LRP1
IL6ST
SIGLEC12
SLAMF6
ATXN1
TRAF6
PRKCH
HNRPU
CXCR4
CALCOCO2
MRAS
LIFR
MVP
DCX
APLP2
GABRB1
RASD2
TICAM1
USP9X
PRPF40A
HSPA1A
PPP2R1A
CDC42
YWHAZ
EEF1A1
TRIM21
MARK4
YWHAH
GARS
KARS
SCYE1
SRRM1
THRA
PTBP1
EEF1D
YBX1
MAP3K7
SFRS2
GRIN1
STATIP1
CCT5
ILF3
FUSIP1
RXRA
SFRS4CDKN2B
SF1
TXNDC9
PRMT1
SNAPAP
ELP4
NIPSNAP3A
PLP2
CSTF2
MRPL42
NDUFB9
BARD1
PDGFB
FGF2
BMP1
SPARC
FBLN1
PDGFA
VWA1
CTGF
FBLN2
ATN1
LAMA1
ELP3
MAN2A2
FGFBP1
GRN
DCP1A
KRT7
GFI1BCNP
13702
DICER1
NCF4
EIF2C2
ADRA1A
DCP2
PPP1R2
EIF2C1 PRKAA1
PPP1R9B
CSNK2A1
PRKAA2
RASGRP3
LMNB1
PPP1R9A
DSC1
DDX20
RPS6KB1
MEP1B
TIAM1
CDKN2A
PKP2
PPP2R5A
NTRK3
MAPKAPK2
FCGR3ACDK2
STAT3 CD81
AGTR2
BCL3
DOK1
SHCBP1
CCNA2
BRE
PRKDC
GPX1
PPP1CA
PTPN2
PRKCD
HNRPK
KRT16
USP9Y
MAPK15
IL2
C1QBP
TPR
PLD2
PAK1
BRCA1
PRKACAIL2RG
RAF1
CHAT
LMNB2
TAGLN
TCHP
RAN
DDB1
RFX1
APBB1
C3
CABLES2
ST5
DDB2
JUN
YTHDC1
TP53
ADRA2A
FSCN1
GABRA1
OPRD1
GNB2L1
ADAM9
NFE2L2
ADRBK1 ITGB2
ITGB7
PPP2R5C
GAP43
PPM2C
HABP4
RUNX2
SFN
CD44
MAPT RGS16
GJA1
TP73
PPP2CA
SHD
ADD2
GRM5
KCNJ4
GNA13
SDC4
EIF2S1
ESRRA
ADD1AFAP1
SIVA1ACTB
PLSCR3 PEBP1DRD2
ADCY7
GSK3A
EP300
PDPK1 CD34PPARA
KLF5GNAZ
CDCP1
ACTA2
KCNJ1
AKT3
15112
RIPK4
PSCD1 PLCB1
PBX2
PRELP
NID1
JUP
DSP
DSG2
PKP3
COL13A1
PKP1
ITGA2
MLLT4
NUAK1
HSPG2
USP4
PNMA2
TTR
ECM1
TROVE2
COL4A3
FBN1
NID2
FGF7
ITGB1
PRKCI
MYBBP1A
IKBKAP
SPI1
CYFIP1
CYFIP2
TAC3
SEC23A FBXW7
FUS
NFKB2
C11orf79
REL
FBXW11
IKBKE
PPP6C
SKP1ACUL1
TTRAP
TNFRSF1B
SPATA2
USP53
NGFRAP1
CYLD
MIZF
UBQLN4
CD3D
RIPK2
MAP4K2
IPO11
TNFRSF19
USP2
MAST2
SETD5
SPHK1
RIPK1
TNFRSF4
THAP7
MAP3K8HIVEP3
TRPT1
ZBTB16
RGS14
C16orf48
ITPK1
CHMP2B
TRPC4AP
TNFRSF9
PEG3
TNFRSF8
SOX30
CASP8AP2
TRADD
FADDMAP3K7IP2
PKN1
AASDHPPT
TRIM31
LNX1
DLG7
TNFAIP3
TRAF1
MAP3K7IP1
TAOK3
PSMF1
MAP3K5
TNFRSF18
TNIK
AFF4
UBXD5
TRAF3
LTBR
TNFRSF25
TNFSF14
TRAF2
DIABLO
14016 BIRC2
ZNF646
ABLIM1
KRR1
TNFRSF12A
CFLAR
CASP8
APEX2
FBF1
TNF
NR2C2
MAP3K7IP3
FCHO2
AP1G1
PACS1
ARF1
KIF13A
ARF5
SPG20 SYT7
EPN2
AP3D1
DEK
HRB
HRBL
TIRAP
TOE1
NUMBL
NAGPA
RIT1
SMAD9
SYT3ELF3
SNAP29
RAB11FIP2
CLTC
AMPH
U2AF2
SMAD2
PPIB
TNFRSF10A
PICALM
10369
STAM
GNB1
HGS
KRT35
SYNJ1
KRT36STAMBP
ITSN1
DDX6
DNM1 JAK3
PIP5K2ATLR8
TLR9
EPN1PIP5K1B
PIP5K2C
BMX
PIP5K1A
NUMB
CCNB1
AP2A1
GHR
SOCS7
PIK3CGGAB3
WASF3
KHDRBS1
SOCS1
REPS1
BIN1
MYO1C BUB1
AP2A2 EPS15
PREI3
WASF2
TUBG1
SHBG
NEDD4
TGFBR1
SOCS6
UBB
BTK
IFNAR1
ARHGAP1
ARRB1
IBTK
REPS2
CDC2
TGFBR2
ARAF
PIK3AP1
RNF11
ERAS
CD22
CD3E
IL2RB
FCGR2A
MS4A2
SIGLEC7
TEC
SH2D1A
TXK
ATP6V1E1
FGFR3
CTTNBP2
CHD3ANKZF1
CAPZA1
FER
ACTR2
ACTR3
ALOX5
PACSIN1
SNAG1
PRAM1
PKD2
HAX1
CD2
YES1
WTIP
NPHS2
RAB4A
CTTN
MAP3K3
JUB
14720
GTF2H1
RRASPTPN1
LIME1
CD2AP
WASF1
ARHGAP8
PCCB
11589
CTNND1
PCCA
FAM125A
E2F2
FXYD6
FGD1
16364
TJP1
WIPF1
DIAPH2
SNTA1
BAIAP2
RIT2
SH2B1
OCRL
DAG1
GRB7
VAV2
NCKIPSD
WASL
FES
RHOQ
FLNC
FCGR2B
CTNND2SDC3
PPP2R3B
EPHB1
RAP1B
NEU3
SGCA MYLK
ACTG1
DMRTB1
ABI3
CCL5
RANBP9
SELL
ITGA2B
ROBO1
PLEC1
FANCC
NCSTN
SPTBN2
CABLES1
SPTB
ZDHHC16
RIN1
SHEROS1
PAK2
TERT
CDK5
RBM19
UTRN
CALM1
PTPRS
ZFP2
TEX10
TGFB1I1
STX16
MYCBP2
PSG9
PTPRM
PKD1
SMAD5
LPXN
PTPRD
CSH1
NPHP1
CGA
ARIH2
TIE1
PDGFRA
PRKCE
PRKD1
SPRY2
FRS3
PRKCA
UBASH3A
RB1
STAT5B
INSR
PIK3CB
CRK
SHC1
BCR
PDGFRB
PECAM1
IRS1
SIT1
NGFB
CRKL
LCK GAB1
ESR1
NTRK1
RAP1GAP
CD247
ITGA6
CAD
ABL2
ADRB2
FGR
BCR-ABL
KRT18
JAK1
IRS2
STAT5A
CSF3R
PIK3R2
IRS4
FGFR1
PRKCB1
ATM
CTLA4
PIK3CD
STS-1
MAPK1
EPS8
ITGB4
CSK
CBL
PAG1
MAP4K1
JAK2
PXN
NEDD9
PTK2B
PIK3C2B
MME
CORO1CPIK3R3
KIT
INPP5D
FLT1
CD72
FLT4
PTPN6
MUC1
LTK
TUBA1B
SLC9A2
EPHB2
PTPN18
GRAP2
FLT3
LAT2ARHGEF7SKAP2
TUBFYN
MAPK3
RASA1
YWHAG
12257
INPPL1
NCK1
GRB2
VAV3
SHB
EPHB6
PLCG2
FCER1G
PACSIN3
SYK
EPOR
PLCG1GAB2
EGFR
LAT
ITK
SH2B2HRA SYN1
CBLC
AXL
PIK3R1
EPHA2
VAV1
CSF1R
CBLB
DDEF1
GRAP
KDR
ERBB2
BLNK
CD19
LCP2
PTK2
MST1R
PSTPIP2
HCK
SOS1SH3KBP1
WAS
ZAP70
FRS2
MET
RAPGEF1LYN
SOS2
BRAF
DOCK1
PTPN22
FGFR2
SRC SH3GL2
ABI1
PTPN12
SORBS1
PPAP2B
ITGB5
SLA2
ADAM15
SH3GL3FYB
TEK
MAPK4
BCAR1
SH3BP1
SMURF2
CNOT8
CNOT1
CNOT2
CNOT4
CNOT6MPHOSPH6
CLPP
CNOT3
HOMER1SH3GLB1
NDEL1
CDH2
MPP6
CCR5
CENTG1
TRAT1
DNM3
IL13
MCCC2
CD7
IL1RAP
TLR2
INPP4A
DYNLL1
WBP11
CHRM4
PSEN1
DNM2
CLPX
SYP
DYNC1H1
TSHR
ANXA2
CHRNA7
SPRY1
PFN1
VIL2
EIF3S6IP
SHANK1
BAT1
ABP1
IL7RCSF2RA
IL1R1
TYRO3
ANK3
SH3BP2
NOTCH1
UBE2D2
UBE2G2
CENTD2
BLKPSTPIP1
RAD52
ABI2
CASP9
RAD51
TNS1
PTPRH
PTPRF SH2D3A
EFS SH2D3C
PPP1R15A
CSPG4
KCNA2
EIF5B
UBE2L3
GSN
PTPRA
CAPN1
F2RL1
OSTF1
SKAP1
SLA
CDKL2
ACTA1
RAD9A
UBE2G1
ITCH
SCN5A
SPTA1
DOK3
SORBS2
EVL
ENAH
VASP
CASP3
XRCC6
TRIP6
NPHS1
ARPC3
VPS11
TUBA4A
HSPA5
MAPK14
NPM1
PTPRC
SORBS3
EGF
CALD1
BAT2
NCK2
USP8
SH2B3
CD5
ERBB3
MTA1
SHANK2TYK2
SNX9HIST2H4A
SHC3
KIRREL
TOM1L1
ADAM12
ADA
RRAS2
SHKBP1
RALGPS1
MAPK12
TP73L
KIAA0157
C6orf21AKT1 MERTK
CD28
FASLG
PDE6G RAPSNMED28 PDZK1
DCTN1
PTPRE
MTA3
BCL2A1
PRKAR1A EPS8L2
TNK2
DRD3
PAK4
PNRC1
LRRK1
RASSF1
PRNP
EPS8L1
USP6NL
DRD4SYNJ2
ADRB1
CD4
LAX1
KHDRBS2
NUP85
ELK1
RAC1
SHC2 HNRPC
DTX1
CHRND
MAP2
RPS6KA1
13115
GPRASP1
POM121
DPPA2
NMI
SMURF1
C14orf1
TBC1D5
KCNJ11
ATP6V1G1
KITLG
THAP1
NUP54
FAM46C
ACVR1
SMAD4
TSSK2
MEA1
TERF2IP
MLH1
GNA12
TLR6
PIP5K1C
AP2B1
SH3BP5
TLR4RALBP1
PRKCQ
CMTM3
ARID3A
GTF2I
EWSR1
BTLA
FAS
ARRB2
SYT1
SYT2
EPS15L1
ARF6
SMAD1
RRN3
HIP1
IL8RB
IRAK1
LDLRAP1
AP1M2
STON2
LAPTM5
AP2S1
AP1S1
AP1B1
STAM2
ADRA1B
GNG2
SNAP91
PIP5K2B
IL4
RALY
AAK1
MYD88
TFG
AQP4
C16orf14
M6PR10616
DNAJC6
BUB1B
CLINT1
AP1M1
4 Discussion 
 
 126 
 
Figure 4.6 The Bcr-Abl ʻcoreʼ complex and its signaling network within an 
enlarged network of HPRD - interactions 
The Bcr-Abl protein-protein interaction network experimentally observed by TAP-LC-
MSMS (Figure 3.7) computationally complemented with all interactions stored in the 
human protein reference database (HPRD). Only the 91 nodes present in the Bcr-Abl 
ʻcoreʼ network are highlighted, all other nodes are shown in grey. 
 
From this simulation it becomes obvious that our Bcr-Abl network 
contains protein-protein interaction hubs such as Traf2, Btk and PRKCD (PKCδ) 
that could represent interesting pharmacological targets for alternative or 
combination CML therapy and it remains to be determined if these exist in K562 
cells (Calderwood, Venkatesan et al. 2007) (Figure 4.6). These data in 
conjunction with recently generated human drug target networks might help to 
select candidate targets and might even allow to assess known compounds 
targeting these candidates for synergistic effects with TKIs in CML (Goh, Cusick 
et al. 2007; Yildirim, Goh et al. 2007). Brutonʼs tyrosine kinase (Btk) has already 
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been shown to be a major target of dasatinib and it might contribute to the 
potent effect of dasatinib on the inhibition of Bcr-Abl signaling (Hantschel, Rix et 
al. 2007). However, it was shown that it is not an essential target for Bcr-Abl-
mediated transformation of lymphoid or myeloid cells (MacPartlin, Smith et al. 
2008). Interestingly, synergistic effects of the anti-cancer drugs arsenic trioxide 
(ATO) and the proteasome inhibitor bortezomib on K562 cells showed that 
cotreatment synergistically induced apoptosis in K562 cells and that they 
synergistically induced proteolytic activation of protein kinase C delta 
(PKCδ), while the effect was reversed by the PKCδ specific inhibitor rottlerin 
(Yan, Wang et al. 2007). Finally, Traf2 is a mediator of antiapoptotic signaling 
and might therefore also represent an attractive co-target (Natoli, Costanzo et 
al. 1998). These examples provide evidence that hub proteins within the Bcr-Abl 
signaling network might represent attractive alternative pharmacological targets. 
However, this hypothetical approach is overshadowed by the lack of functional 
consequence of knockdowns of the seven individual ʻcoreʼ interactors (Figure 
3.17), that this network is built on, and might at best give insights on potential 
target combinations to overcome the obvious signaling redundancy in Bcr-Abl-
ʻaddictedʼ cells. A recent genome-scale pooled shRNA screen of 12 cancer cell 
lines for essential cancer genes, including K562, identified four genes, PTPN1, 
NF1, SMARCB1 and SMARCE1 to be required for the response of CML cells to 
imatinib treatment (Luo, Cheung et al. 2008). Out of these, we find PTPN1, a 
negative regulator of Bcr-Abl signaling (Koyama, Koschmieder et al. 2006; 
LaMontagne, Flint et al. 1998), present in our simulated enlarged hybrid 
network (Figure 4.5) but not with the Bcr-Abl ʻcoreʼ complex network (Figure 3.7, 
Figure 4.6). 
Clearly, the presented network displays a focus on the interactions in 
the closest proximity to Bcr-Abl in K562 cells and may represent a starting point 
resource for further Bcr-Abl signaling studies in K562 cells. 
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4.10 Future perspectives 
The protein-protein interaction network around the Bcr-Abl ʻcoreʼ 
complex presented in this study represents a concise overview of the Bcr-Abl-
proximal connection points to cellular signaling in K562 cells and a valuable 
resource of Bcr-Abl signaling (Figure 3.7). A large-scale extension of this 
signaling network, however, will be crucial for a refined picture of the more 
remote protein-protein interaction network around Bcr-Abl. The comprehensive 
functional analysis of these Bcr-Abl signaling networks and their components 
hold the potential to identify the crucial signal transduction pathways involved in 
Bcr-Abl mediated transformation. One of the major remaining challenges will 
then be the identification of key proteins within these pathways that are suitable 
for pharmacological targeting in synergy with Bcr-Abl, in order to tackle 
resistance complications associated with tyrosine kinase inhibitor therapy) 
(Azam, Latek et al. 2003; Cowan-Jacob, Fendrich et al. 2007; Daub, Specht et 
al. 2004; Druker 2006; Mohi, Boulton et al. 2004). 
 The identification of an eight component multi-protein complex around 
Bcr-Abl and the observation of its sensitivity to tyrosine kinase inhibitors led to 
the understanding that not just the polypeptide Bcr-Abl but also its ʻfirst shellʼ of 
stoichiometric protein interactors is affected by the action of the drugs. This new 
concept, however, poses numerous novel challenges. Further experimental 
approaches are required to elucidate and refine our current models of the 
interaction architecture within this complex, the interaction stoichiometry as well 
as the overall size and macromolecular structure of the complex as an entity. 
Furthermore, while for some components, such as Grb2, the molecular 
interaction mode and the link to downstream signaling pathways are well 
described (Pendergast, Quilliam et al. 1993), the functional role of many of its 
individual components as a part of the complex, such as Ship2 and Sts-1, still 
remains elusive (Bantscheff, Eberhard et al. 2007). We were challenged by the 
fact that none of the siRNA perturbations of these complex components 
affected the fitness of K562 cells and it seems that ʻoncogene addictionʼ of this 
model cell line is strictly limited to its oncogene, not to the oncogene protein 
complex. It will be rewarding to explore alternative targets that could be 
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harnessed to overcome Bcr-Abl ʻaddictionʼ and resistance to current tyrosine 
kinase inhibitors. 
 Finally, it remains to be shown, if this complex can also be identified in 
other Bcr-Abl positive model cell lines, in primary and patient cells and whether 
its composition is static or dynamic in nature with a differential composition 
between different patients and disease stages. 
 
4.11 Final conclusions 
Our study enables a novel view of the tyrosine kinase Bcr-Abl as the 
cognate target of tyrosine kinase inhibitors representing the current front-line 
therapy for chronic myelogenous leukemia. A two-pronged approach featuring 
the purification of endogenous complexes of Bcr-Abl from K562 cells and TAP-
LC-MSMS analysis of its candidate stoichiometric interactors resulted in the 
quantitative identification of a highly significant and interconnected eight-
component Bcr-Abl ʻcoreʼ complex that is embedded in an interaction network of 
90 proteins and links Bcr-Abl to different key signaling pathways. Furthermore, 
the network analysis reveals a new link to the endocytic AP2 adaptor protein 
complex. The components Bcr-Abl, Ship2, c-Cbl, p85, Shc1, Grb2, Crk-I and the 
novel Bcr-Abl interactor Sts-1 assemble into around 200,000 to 300,000 
stoichiometric complexes per K562 cell. Quantitative proteomics analysis 
uncovered that tyrosine kinase inhibitors dramatically disrupt and remodel this 
complex, changing the view of the paradigmatic drug target Bcr-Abl as a single 
polypeptide to a multi-protein macromolecular machine. These data and the 
associated paradigm shift underline the importance of the functional 
understanding of drug targets for the elucidation of drug action in a proteomic 
and cellular context. 
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